




The Dissertation Committee for Sanchita Bhadra
certifies that this is the approved version of the following dissertation:
Host Resistance and Viral Transcription as
Determinants of MMTV Tumorigenesis
Committee:
Jaquelin P. Dudley, Supervisor





Host Resistance and Viral Transcription as
Determinants of MMTV Tumorigenesis
by
Sanchita Bhadra, B. S.; M. S.
Dissertation
Presented to the Faculty of the Graduate School of
The University of Texas at Austin
in Partial Fulfillment
of the Requirements
for the Degree of
Doctor of Philosophy




My development as a person and a scientist has been influenced by many
people. I would like to acknowledge them here, offer thanks for their help and for
what I have learnt from them.
I sincerely thank my advisor, Professor Jaquelin Dudley, for her advice and
encouragement, which significantly contributed to the success of my research work.
Her drive and enthusiasm have been inspiring. I also wish to thank Professors Henry
Bose, Philip Tucker, Martin Poenie, Tanya Paull, Shelley Payne and Paul Gottlieb
for graciously consenting to serve on my dissertation committee and providing me
with helpful corrections and constructive comments. Also, I would like to thank my
teachers at the University of Delhi who initiated me to the area of Microbiology.
I would especially like to acknowledge Mary Lozano for her contribution
towards my research. My work would not have been possible without Mary’s
enthusiasm and painstaking work in mice breeding, maintenance, and experiments.
Her ever-present smile and diligence are infectious.
I would also like to thank all my colleagues in the Dudley laboratory – Dr.
Farah Mustafa, Dr. Jennifer Mertz, Dr. Jin Seo, Dr. Dana Broussard, Dr. Quan Zhu,
Dr. Keqin Gregg, Dr. Melissa Simper, and Urmila Maitra – and the members of the
Payne laboratory. All of them contributed in creating an amiable environment that
v
was not only educative but also fun.
A note of profound gratitude is due to my family. I would not be here today
without the selfless efforts of my mother and my brother, Sujoy, who encouraged
my early inclination towards science and literature, and supported and guided me
over the years while giving me a lot of freedom in taking my own decisions. Finally,
I would like to thank my husband, Jayanta, who motivated me with his dogged
determination and supported me with his love and affection through the countless
frustrations. I could not thank you all enough.
SANCHITA BHADRA
The University of Texas at Austin
August 2005
vi
Host Resistance and Viral Transcription as
Determinants of MMTV Tumorigenesis
Publication No.
Sanchita Bhadra, Ph.D.
The University of Texas at Austin, 2005
Supervisor: Jaquelin P. Dudley
Mouse mammary tumor virus (MMTV) is an oncogenic retrovirus that
causes mammary tumors in susceptible mice within 6 to 9 months of infection.
Type B leukemogenic virus (TBLV) is a variant of MMTV that induces thymic
lymphomas in mice, instead of mammary tumors, with a shorter latency. Exogenous
MMTV has a complicated life cycle involving milk-borne virus transmission and
tissue type and differentiation-specific regulation of viral transcription. Most inbred
mouse strains also harbor endogenous MMTV proviruses (Mtvs) in their germline
that are inherited according to Mendelian rules and are usually not associated with
vii
mammary tumorigenesis.
This thesis reports studies on the intricate relationship of MMTV with
its host by demonstrating that the outcome of MMTV infection is influenced
by both the composition of viral transcriptional elements and by host genetics.
This is the first demonstration that the absence of negative regulation of viral
transcription and presence of a T-cell specific enhancer in lymphoid cells converts
a mammotropic MMTV to a lymphotropic virus. Interestingly, the endogenous
Mtv loci in the BALB/cJ mouse genome are required for susceptibility to infection
and tumorigenesis by both MMTV and TBLV. A BALB/cJ congenic mouse strain
lacking endogenousMtvs (BALB/Mtv-null) is highly resistant to both MMTV
and TBLV. The resistance is not mediated by the production of MMTV-specific
neutralizing antibodies in the BALB/Mtv-null strain. However, cell-mediated
immune response directed against MMTV-infected cells might contribute towards
the tumor resistance phenotype. The BALB/Mtv-null mice also are resistant to
oral infection with the bacterial pathogenVibrio choleraecompared to BALB/cJ
mice, and this resistance toV. choleraecorrelates with the absence of endogenous
Mtvs. Thus, the BALB/Mtv-null mice demonstrate a novel mode of resistance to
multiple pathogens that appears to be linked to expression of MMTV genes. These
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Mammary tumors were first described in wild mice in 1854 [89]. In
1918, Lathrop and Loeb demonstrated a genetic influence on the development
of mouse mammary cancer [239]. Subsequently, a non-chromosomal influence
on the etiology of mammary tumors in mice was detected [210]. Sixteen years
later, Bittner associated this non-chromosomal influence to nursing on females from
high-tumor incidence strains [44] and, alternately, elucidated the role of inherited
susceptibility, and hormones on the development of spontaneous mammary tumors
in mice [45]. A transmissible milk influence was characterized as a high molecular
weight colloid and suggested to be a virus in 1942 [447]. Subsequently, spherical
virus-like particles with a dense central core were observed in the mammary
carcinomas that developed in high-tumor-incidence mouse strains [346]. In the
following year, virus-like particles purified from the milk of a high-tumor incidence
mouse strain were shown to induce mammary carcinomas upon inoculation into a
low-tumor-incidence mouse strain [168].
Several studies established that all tumors from high-tumor-incidence mouse
1
strains contained two kinds of virus-like particles, intracytoplasmic particles
characterized by a concentric double membrane (type A) and extracellular particles
characterized by an eccentrically placed nucleoid (type B) [37]. The type-
A particles were proposed to transform into B-type particles following passage
through the cell membrane [37]. B-type particles purified from milk and mammary
tumor tissue were demonstrated to have a nucleoprotein composition containing
RNA [257, 258]. The particles were ether-sensitive and contained radially oriented
outer membrane spines [257]. In 1963, Moore proposed that these virus-like
particles represented Bittner’s milk agent [301]. He also suggested that the
milk agent could become heritable. Subsequently, reverse transcriptase (RT), the
hallmark DNA polymerase of retroviruses, was detected in the milk-borne mouse
mammary tumor virus (MMTV) [391, 392, 396]. Thus, MMTV was the first
identified mammalian retrovirus [448].
1.2 Classification
MMTV belongs to the virus familyRetroviridae whose members are
enveloped, spherical RNA viruses that undergo reverse transcription during their
replication cycle [63]. This family is comprised of two subfamilies – (i)
Orthoretrovirinae which includes six genera [Alpharetrovirus, Betaretrovirus,
Gammaretrovirus, Deltaretrovirus, Epsilonretrovirus, and Lentivirus] and (ii)
Spumaretrovirinae, which has a single genusSpumavirus. MMTV is currently
assigned to the genusBetaretrovirusin the subfamilyOrthoretrovirinae[63].
2
1.3 MMTV virion morphology
MMTV virions have capsids with an average diameter ranging from 130
to 140 nm and icosahedral symmetry [58, 384]. The eccentrically positioned
nucleocapsid core [37] is irregularly sized and shaped and is often angular [58].
The dimeric viral genome is comprised of non-segmented, plus-sense, single-
stranded RNA (2% by weight) [63, 114]. Proteins and carbohydrates constitute
approximately 60% and 3% of the virion weight, respectively, [63] and lipids
derived from host cell membranes constitute up to 35% of the virion by weight
[63].
The viral membrane displays approximately 400 prominent glycoprotein
spikes that project radially from the viral membrane surface [58]. The spikes are
spaced approximately 12 nm apart and each spike is surrounded by 5 or 6 immediate
neighbors and assume the symmetry of the underlying capsid [58, 353, 384]. The 8
nm long glycoprotein spikes [58] have two distinguishable components – (i) knobs
at the distal ends measuring 54.4 ± 10.3Å in diameter and composed of three
subunits 15 to 25̊A in diameter [384], and (ii) thin stalks that connect the knobs to
the viral membrane [384].
1.4 MMTV genome organization
The 70 S MMTV genome [114] is composed of two identical genomic RNA
molecules joined by non-covalent interactions at the dimer linkage sequence (DLS)
near the 5’-end of the genome and facilitated by multiple interactions throughout the
3
genome [448]. According to the loop-loop kissing complex model, dimerization is
initiated by symmetrical intermolecular bonds to form a kissing-loop complex that
is subsequently stabilized by formation of an extended duplex [330].
The 35 S monomeric RNA is 8600 nt long with a 15 nt direct repeat (R) at
each end. The 5’-end of the genomic RNA has a methylated nucleotide cap with a
type 1 sequence of m7G5ppp5’GmpNp while the 3’-end is polyadenylated. The R
region at the 5’-end is sequentially followed by the 110 nt unique region (U5), the
primer binding site (PBS), three out-of-phase, overlapping reading frames encoding
thegag (group-specific antigen),pro (protease), andpol (reverse transcriptase and
integrase) genes, an overlapping reading frame encoding theenvand rem genes,
and the approximately 1200 nt long unique region (U3) that encodes the C-terminal
end of the envelope (Env) protein and the out-of-phase, overlapping superantigen
(sag) gene [209, 300, 448] (Figure 1.2).
Two -1 ribosomal frameshift events during genomic RNA translation allow
uninterrupted readthrough fromgagto pol genes, leading to the production of three
polyprotein precursors Pr77Gag, Pr110Gag−Pro, and Pr160Gag−Pro−Pol (Figure 1.1)
[209, 300]. Translation of Env, regulator of export of MMTV mRNAs (Rem) and
Sag requires the synthesis of spliced, subgenomic mRNAs. Therefore, the naked
MMTV genomic RNA is not infectious. The genomic RNA presumably harbors
one or more encapsidation sequences termedψ or E that allow the packaging of

























Figure 1.1. Structure of MMTV genomic and subgenomic RNAs.
The full-length genomic RNA encodes the Gag, Pro and Pol proteins while thenv, rem andsag
coding sequences are interrupted by introns (depicted as dashed V-shaped lines) that are spliced out
to generate subgenomic mRNAs.
1.5 MMTV proteins
The 35 S genomic RNA encodes the non-glycosylated structural polyprotein
precursors Pr77Gag, Pr110Gag−Pro, and Pr160Gag−Pro−Pol (Figure 1.2) [90, 99, 111,
398]. These large polyprotein precursors are proteolytically processed by the viral
protease to yield the proteins found in mature virions. Cellular proteases might also
participate in the maturation of viral polyproteins [284].
Two singly-spliced 24 S and 14 S subgenomic mRNAs encode the viral Env
glycoprotein and the 36 kDa Sag protein, respectively [101, 111, 398, 400], while a
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novel doubly-spliced mRNA encodes the Rem protein (Figure 1.2) [J. Mertzet. al.,
manuscript submitted].
1.5.1 Group-specific antigen (Gag)
MMTV Gag is cotranslationally directed to the pericentriolar region via
its cytoplasmic targeting-retention signal (CTRS) [82, 367] in a microtubule-
dependent process through interaction with the dynein/dynactin motor complex
[402]. The domain structure of MMTV Pr77Gag polyprotein is defined as: NH2-
MA(p10)-pp21-p3-p8-n-CA(p27)-NC(p14)-COOH, where ’n’ represents 17 amino
acids present in the viral sequence, but not found as a cleavage product among
purified virion proteins [99, 195, 275, 399]. The three domains – matrix or
membrane associated (MA), capsid (CA), and nucleocapsid (NC) – are common
to all retroviruses.
The mature, 10 kDa MA protein is the most hydrophobic Gag protein [272]
and harbors an N-terminal glycine residue with an amide-bonded myristoyl group
that is essential for virus assembly and budding [195, 395]. MA proteins of
some retroviruses do not undergo myristoylation, but are subject to acetylation and
phosphorylation [448]. Some MA proteins also have stretches of basic amino acid
residues [448]. MA allows the membrane targeting of viral cores and may also
interact with Env during budding [67, 448].
The 27 kDa CA protein [195, 395] is the major structural virion protein that
forms the shell around the viral ribonucleoprotein [272]. MMTV CA contains a
hydrophobic domain and exists in phosphorylated and non-phosphorylated forms
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[272, 323, 385]. Phosphorylation occurs in the Pr77Gag polyprotein, which upon
cleavage generates phosphorylated p27 as well as the phosphorylated core protein
pp21 [195, 352, 395]. MMTV MA, pp21, p3-p8-n, and CA possess weak
interaction potentials, which together form a significant secondary force during Gag
self-association [480].
The 14 kDa, highly basic NC protein [195, 395] is responsible for genomic
RNA binding and dimerization by interacting with the RNA packaging sequence
[448, 480] via its two zinc-coordinating Cys-X2-Cys-X4-His-X4-Cys motifs [38,
188, 195, 225]. NC proteins stabilize the RNA genome in mature virions, stimulate
reverse transcription by promoting complementary RNA annealing, facilitate viral
DNA elongation by reducing RT pauses at stable stem-loop sites, and also stabilize
the viral DNA after reverse transcription [448]. NC also provides the major force for
Gag multimerization via its interaction or I domain rich in basic residues [448, 480].
1.5.2 Deoxyuridine triphosphatase (dUTPase or DU)
The dUTPase catalyzes the hydrolysis of deoxyuridine triphosphate (dUTP)
to deoxyuridine monophosphate (dUMP) and pyrophosphate, thus increasing the
fidelity of reverse transcription by preventing the incorporation of dUMP into DNA
and also providing a pool of dUMP, the precursor of thymidine nucleotides [36,
448]. The MMTV dUTPase is atransframe 30 kDa protein, p30, generated from
the Gag-Pro junction by proteolytic processing of the Gag-Pro polyprotein [194].
The N-terminal 95 amino acids of p30 are produced from the C-terminus of NC
while the following 154 amino acids, that display dUTPase homology, are derived
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from the 5’-end of thepro open reading frame (ORF) [194].
The MMTV dUTPase forms enzymatically active trimers that might directly
associate with the viral RNA through the NC domain [36]. This NC domain-
mediated anchoring might compensate for the low specific activity of the MMTV
dUTPase [36, 230]. Furthermore, location of the MMTVdutgene in thepro region
would generate higher amounts of the enzyme compared to non-primate lentiviruses
that harbor thedut gene in thepol region [36, 230]. In addition to its enzymatic
activity, the abundant MMTV p30 protein could also play a structural role in the
virion [36, 230].
1.5.3 Protease (Pro/PR)
PR belongs to the aspartic proteinase enzyme family that is characterized by
two aspartic acid residues, each placed in the highly conserved motif Asp-Thr/Ser-
Gly, which coordinates a water molecule used to hydrolyze the target peptide
bond [448]. Retroviral PR contains a single Asp-Thr-Gly motif thus, requiring
dimerization for activity [285, 448]. PR gets packaged into the MMTV virion as
part of the Gag-Pro and Gag-Pro-Pol polyprotein precursors. A drop in the virion
pH might lead to the activation of PR, which is maximally active between pH 4 to 6
[285, 448]. PR undergoes autocatalytic cleavage and performs ordered processing
from the N-terminus towards the C-terminus of Gag, Gag-Pro, and Gag-Pro-Pol
polyprotein precursors [285, 448]. Ordered processing of the virion polyproteins is
an essential step in the viral life cycle as it is intimately linked to virion assembly,
budding and maturation [448].
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1.5.4 Reverse transcriptase (RT)
MMTV RT displays 3 enzymatic activities – RNA and DNA-dependent
DNA polymerase activities using RNA or DNA primers and RNase H (RNA-DNA
hybrid: ribonucleotide-hydrolase) activity. Each activity requires divalent cations
with a preference for Mg2+ ions [108, 421]. MMTV RT uses tRNALys3 that is
hydrogen-bonded to the viral genome for priming of minus-strand DNA synthesis
[340]. The RNase H activity of RT cleaves phosphodiester bonds in the RNA strand
of a RNA-DNA hybrid producing 3’-OH and 5’-PO4 groups [108]. RT lacks 3’-5’
proofreading exonuclease activity, allowing nucleotide misincorporation. Thus, RT
plays a significant role in generating retroviral diversity, rapid viral evolution, and
adaptation to the environment [448].
MMTV RT is a transframe protein containing at its N-terminus 27 amino
acids derived from the C-terminus of PR, while the remaining amino acids are
derived from thepol gene [124, 421]. The DNA polymerase domain is located
at the N-terminus, whereas the RNase H domain is located towards the C-terminus
[448]. MMTV RT is enzymatically active as a 66 kDa monomer with a pH optimum
of 7.5 for the DNA polymerase activity [421]. RT is a slower enzyme compared to
cellular DNA polymerases and is not highly processive.
1.5.5 Integrase (IN)
The retroviral IN protein catalyzes viral DNA insertion into host cell
DNA. IN is encoded within the 3’-terminal portion of thepol gene immediately
downstream from RT sequences and, in the same uninterrupted reading frame.
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Proteolytic cleavage from the C-terminus of the Gag-Pro-Pol polyprotein generates
active IN [448]. Virion incorporation is determined by Gag-Gag interactions within
these precursors.
Retroviral integrases range in size from 280 to 450 amino acids in length
[448]. A highly conserved zinc-finger-like HHCC (H-X(3−7)-H-X(23−32)-C-X2-C)
motif is found near the N-terminus followed by a conserved DD35E (D-X(39−58)-D-
X35-E) motif – a universal feature of integrases and transposases [448]. The DD35E
domain functions as the catalytic core of the enzyme while the C-terminal variable
domain functions in DNA binding [448].
A tetrameric integrase complex bound to viral DNA ends provides the
minimal requirements for concerted integration of both viral long terminal repeats
(LTRs) [131]. The inverted repeat sequences at the ends of viral DNA containing
the CA/TG dinucleotide pair positioned 2 bp from the ends of the linear precursor
are crucial for recognition of viral DNA ends by integrase [448]. Integrase also
promotes reverse transcription by direct physical interaction with the nucleoprotein-
RT complex [467].
1.5.6 Regulator of export of M MTV mRNAs (Rem)
MMTV encodes a protein (Rem) of 301 amino acids, which regulates the
nuclear export of unspliced viral mRNAs to the cytoplasm for translation [J. Mertz
et. al., manuscript submitted]. The Rem protein consists of the Env leader peptide
(98 amino acids), 162 amino acids from the Env surface protein (SU or gp52) and 41
amino acids from the transmembrane protein (TM or gp36). Rem is expressed from
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a novel doubly spliced mRNA (Figure 1.1). Software analysis predicted several
protein motifs, including sites for glycosylation, myristoylation, amidation, and
protein kinase C phosphorylation. Rem also contains two functional, overlapping
nuclear localization signals (NLSs), a putative leucine-rich nuclear export signal
(NES) as well as an arginine-rich motif (ARM), which is an RNA-binding domain
found in human immunodeficiency virus (HIV) regulator of virion expression
(Rev)-related proteins [133, 268]. Rem overexpression partially restores Gag
expression from a Rem-deficient MMTV mutant deficient ingagmRNA export.
The 33 kDa Rem protein is unique because it is two to three times larger
than Rev (13 kDa) and other Rev-like RNA export proteins, including human T-
cell leukemia virus (HTLV)-1 Rex (27 kDa) [191, 327] and human endogenous
retrovirus (HERV)-K Rec (14 kDa) [264, 253, 477] proteins. The extensive C-
terminal region of Rem contains few predicted motifs and may function as a
negative regulator. Rem binds a Rem-responsive element that encompasses the 3’
end of theenvand the U3 region [J. Mertzet. al., manuscript submitted].
Rem is primarily detected in nuclei within the nucleolus. MMTV Env
leader peptide was also reported to localize to the nucleoli of MMTV-derived T-cell
lymphomas where it colocalized with the nucleolar protein B23 [196]. Association
with B23 has been previously reported for other auxiliary nucleolar retroviral
proteins, such as Rev and Rex [196].
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1.5.7 Envelope (Env)
MMTV Env is translated in the order N-SU-TM-C [399] from a 24 S
[111], 3.6 kb mRNA that splices out thegag, pro, and pol genes (Figure 1.1)
[266, 398]. The 5’ splice site for the subgenomic RNA is located approximately
288 nt downstream from the 5’-end of the viral RNA at the U3/R border of the 5’
LTR [130]. Theenvgene terminates within the LTR and its 3’-end overlaps the
5’-end of thesaggene [189].
The non-glycosylated Env precursor, p67Env, is synthesized on the rough
endoplasmic reticulum as a type I transmembrane protein [100]. The signal peptide
(98 amino acids) is cleaved between Gly and Glu within the sequence Thr-Gly-
Glu-Ser-Tyr to generate the p61Env precursor. The precursor is subsequently
glycosylated to produce the gPr73Env protein [100, 189], which contains five
asparagine (N)-linked oligosaccharides rich in fucose, mannose, galactose, N-
acetyl glucosamine, and N-acetyl neuraminic acid [15, 100, 472]. Glycosylation of
gPr73Env is essential for proper maturation and cell surface localization of mature
Env proteins [140]. The gPr73Env is then trafficked to thetrans-Golgi where it
is proteolytically processed by cellular proteases like furin [448] and subjected to
secondary glycosylation followed by transport to the cell surface [88]. Although a
minor population of gPr73Env is found at the cell surface, proteolytically processed
Env is critical for the membrane fusion event required for viral entry [448].
Proteolytic processing of gPr73Env occurs by removal of the dipeptide Lys-Arg
at the sequence Ile-Arg-Ala-Lys-Arg-Phe-Val-Ala and generates the surface (SU)
gp52Env and transmembrane (TM) gp36Env proteins [98, 189]. Two of the N-linked
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oligosaccharides are located on the 25.5 kDa TM protein, while 3 are located on the
41 kDa SU protein [189, 360].
The TM protein functions as the membrane anchor via its hydrophobic
domain (amino acids 523 through 548) and also complexes with the N-terminal Gag
protein p10 [353, 448]. TM also allows Env trimerization shortly after translation
in the ER [448] to form the 230 kDa envelope spike [353, 384].
The SU protein serves as the anti-receptor for binding the cell surface
receptor. Several other functions have also been attributed to MMTV SU, including
(i) Sag presentation to T cells, resulting in stimulation of T-cell proliferation
and interleukin 2 (IL2) production [160], (ii) enhancing the sensitivity of
mouse mammary epithelium towards prolactin (PRL) by increasing the synthesis
and membrane recruitment of PRL receptors [48, 49], (iii) facilitating viral
infection by activating B cells via interactions with the surface toll-like receptor
4 (TLR4) [359], and (iv) initiation of mammary tumorigenesis mediated by the
immunoreceptor tyrosine-based activation motif (ITAM), which triggers early
hallmarks of transformation [219].
1.5.8 Superantigen (Sag)
An open reading frame within the MMTV U3 region encodes a 37 kDa
protein that functions as a superantigen (Sag) [273]. Sag presentation induces
CD4+ T cells to produce cytokines like IL2, IL4 and interferon (IFN)γ [320]
followed by clonal, apoptotic deletion of these CD4+ T cells [1, 39, 80, 109,
129, 205, 333, 452]. While strong Sags like that encoded byMtv7 induce
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proliferation of cognate T-cells prior to clonal deletion, weak Sags like C3H
Sag and GR Sag fail to induce proliferation of reactive T cells or expression
of IL2 receptors (IL2R) [320]. Activated CD8+ T cells bearing Sag-specific
TCR Vβ chains also produce IFNγ following Sag stimulation, but Sag-bearing
target cells are not lysed [190]. The endogenousMtv-encoded Sags have been
extensively studied previously as minor lymphocyte-stimulating (Mls) antigens
[117, 127, 143, 349, 463] and have also been associated with both negative and
positive selection of thymocytes [57, 77, 250]. Besides its superantigenic function,
Sag also has been reported to transactivate the MMTV LTR-driven transcription
[441] and to induce transformation [312].
Subgenomic MMTVsagmRNAs [442, 459] have been described from 4
different promoters (i) the classical promoter at the U3-R border (P1196 or P1)
[78, 442]; (ii) an internal U3 promoter (P698 or P2) [173]; (iii) a T-cell-specific
phorbol ester-inducible promoter in theenv gene (P7246 or Penv) [120, 293, 316,
481]; and (iv) a second, LTR-proximal promoter (P8498 or Penv2) [14] within the
envgene (Figure 1.2). MMTV strain specific differences may affect the choice of
sagpromoter [470]. A 183-bp segment (Epol) in the pol gene (nt 5499 to 5681)
upregulatessagexpression in mature B cells [365] while an intragenic enhancer
(EproB) (nt 9 to 556 in the 5’ LTR or nt 54 to 991 in the 3’ LTR) stimulates
the expression of MMTV genes, includingsag, in pro-B cells [364, 365]. Sag
expression is reduced by glucocorticoids despite increased transcription from the 5’
LTR [427]. The level ofsagmRNA expression correlates directly with kinetics of
self-reactive T-cell loss [31].
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Stable cell surface expression and presentation of Sag requires association
with major histocompatibility complex (MHC) class II molecules [41, 46, 169].
MHC class II I-E molecules present Sag more efficiently than the MHC class II
I-A molecules. The I-A allotypes show a hierarchy of Sag-presentation efficiency,
which in turn determines the magnitude of the T-cell response and the extent of
help provided to infected B cells [166, 187]. Some MMTV Sags (GR, C3H, SIM,
Mtv1, 6, and 9) require class II I-E for presentation while others (Mtv7, SW) can
be presented by both class II I-E and I-A molecules. A diverse repertoire of MHC
class II-peptide complexes is also critical for recognition of MMTV Sag by T cells
[166], and the amount of cell surface class II limits Sag presentation [254].
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Figure 1.2. Structure of MMTV genome and transcripts.
The mature 47 kDa Sag [354, 54] is a type II transmembrane [227, 229]
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glycoprotein [54, 233]. The N-terminus of Sag has a short, non-essential
cytoplasmic tail followed by a transmembrane region [227] of 22 amino acid
residues, and a large extracellular portion containing six consensus N-linked
glycosylation sites [39, 54, 81, 227, 229, 462], at least one of which must
be glycosylated for effective Sag presentation at the cell surface [280]. The
extracellular region also includes an MHC class II peptide binding motif (CIIPBM)
[200]. The C-terminal region of Sag interacts directly with the hypervariable region
4 (HV4) outside the peptide binding groove [147, 261] and the complementarity
determining regions 1 and 2 (CDR1 and 2) of the T-cell receptor (TCR) Vβ
chain [2, 30, 39, 349, 466, 478]; the TCR Vα chain has minor indirect effects on
this interaction [439, 449, 464]. The TCR Vβ specificity of Sag is determined
by the highly variable 30 to 40 amino acid residues at the C-terminus of Sag
[30, 39, 55, 349, 478].
Sag is synthesized in the ER as a 45 kDa glycoprotein containing N-
asparagine-linked oligomannosyl carbohydrates with a half-life of 1.5 to 2 hr
[233, 462]. During transit through the Golgi complex Sag is modified by the
addition of complex-type glycans and proteolyzed at three possible positions by the
endoprotease furin and also the endosomal protease cathepsin L [97, 296, 336, 462].
Proteolytic processing is essential for Sag presentation at the cell surface where
the 18.5 kDa C-terminal proteolytic fragment remains non-covalently associated
with the N-terminal proteolytic fragment that is required for superantigen function
[238, 461]. Some reports indicate that Sag associates with MHC class II molecules
within the ER and Golgi during biosynthesis, analogous to the invariant chain (Ii)
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[199, 462]. Others suggest that Ii prevents Sag-MHC class II association in the ER
such that Sag traffics directly via the cellular exocytic machinery to the cell surface
where it is efficiently bound and presented by MHC class II-peptide complexes
[169]. In the absence of MHC class II, Sag is shed in the culture medium and can
undergo paracrine transfer to MHC class II+ cells independent of cell-cell contact
[96, 363].
Sag-mediated immune modulation is required for milk-borne transmission
of MMTV [3, 379] and may enhance the tumorigenicity of transformed cells
through the production of cytokines that support tumor growth [436]. T-cell-
mediated immune responses to Sag could also break tolerance and augment immune
responses against tumors expressing MMTV Sag [390] while deletion of Sag-
reactive T cells can modulate the susceptibility or resistance to infectious and
autoimmune diseases [167, 240, 255, 277, 419].
1.6 MMTV replication cycle
The MMTV replication cycle involves a number of stages (Figure 1.3).
1.6.1 Adsorption and cell entry
Retroviral adsorption is facilitated by Env-mediated recognition of a
cell surface receptor (Figure 1.3, step 1). A cellular receptor for MMTV,
designated as MTVR-1, was localized to mouse chromosome 16 [192] while a
second ubiquitously expressed candidate receptor, MTVR, was mapped on mouse




































Figure 1.3. MMTV replication cycle.
that contains a hydrophobic domain, a putative N-linked glycosylation site, three O-
linked glycosylation sites, and six putative myristoylation sites. Human homologs
of the mtvr gene have also been described [414]. Most recently, phenotypic
screening of the T31 mouse/hamster radiation hybrid panel mapped the transferrin
receptor 1 (TfR1) (gene locus on chromosome 16) as the MMTV cell-entry receptor
[380]. TfR1 is a type II, single membrane-spanning glycoprotein that is the major
means of iron uptake by most cells. Upon ligand binding, TfR1 traffics to the
early acidic endosome, where it releases iron, recycles back to the cell surface,
and releases transferrin. In addition to transferrin, peptides binding to TfR1 also
trigger its endocytosis and traffic into acidic endosomes. Thus, a proposed pathway
for MMTV cell entry involves binding to TfR1 at the cell surface followed by
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endocytosis via clathrin-coated pits and traffic to acidic endosomes where the low
pH would trigger membrane fusion releasing the nucleocapsid into the cytosol
(Figure 1.3, steps 2 and 3) [361, 380]. This model is supported by blocks to MMTV
infection after treatment of cells with lysomotropic alkalinizing agents [47].
Similar to HIV, following cell entry, the MMTV virion cores might use
cytoplasmic dynein and the microtubule network to migrate towards the nucleus
and accumulate in the perinuclear region to facilitate access to the host DNA [279].
1.6.2 Reverse transcription
Viral RNA genome is reverse transcribed (Figure 1.3, step 4) by RT to
generate a blunt-end, colinear DNA duplex that contains long terminal repeats
(LTRs) composed of U3, R, and U5 regions [448]. Two template switches or
strand-transfer reactions during reverse transcription generate the LTRs [448]. All
the components, except deoxyribonucleotides, required for reverse transcription
are present within the virion, and reverse transcription is activated upon entry
of the virion core into the cell cytoplasm. Reverse transcription occurs in a
ribonucleoprotein complex that includes NC, which enhances RT processivity and
template switching [448]. Most retroviruses complete reverse transcription in the
cytoplasm; however, some viruses, e.g., avian leukemia virus (ALV), complete
reverse transcription following nuclear translocation.
Minus-strand DNA synthesis initiates at the 3’-OH group of a partially
unwound tRNA base-paired to the PBS near the 5’-end of the genomic RNA
(Figure 1.4, step 1) [448]. DNA synthesis proceeds to the 5’-end of the genomic
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RNA to generate the minus-strand strong-stop DNA (-sssDNA) (Figure 1.4).
Following RNase H-mediated degradation of the RNA strand in the RNA:-sssDNA
duplex (Figure 1.4, step 2), the R sequences at the 5’- and 3’-ends of the viral
RNA mediate the first strand transfer of -sssDNA by annealing to the inter- or
intramolecular 3’-end of one of the RNAs in the diploid genome (Figure 1.4, step
3). Minus-strand DNA synthesis then continues to the 5’-end of the genomic RNA
(Figure 1.4, step 4) accompanied by RNase H digestion of the template RNA,
leaving a short polypurine tract (PPT) containing RNA intact (Figure 1.4, step
5). Some viruses may generate additional plus-strand primers from the viral RNA
genome.
The PPT RNA primes plus-strand DNA synthesis which halts after a portion
of the primer tRNA is reverse transcribed, yielding the plus-strand strong-stop
DNA (+sssDNA) (Figure 1.4, step 6). RNase H degrades the primer tRNA
exposing the +sssDNA copy of the PBS (Figure 1.4, step 7) that anneals to
the complementary PBS on the intramolecular minus-strand DNA completing the
second strand transfer (Figure 1.4, step 8). Proviral synthesis is then completed with
the plus and minus strands of DNA serving as templates for the complementary
strand (Figure 1.4, step 9). The ends of unintegrated viral DNA are defined by the
sites where RNase H removes the plus- and minus-strand primers. These cleavages






















































































































































































































































































































































































































































































The dimeric nature of the retroviral genome increases the probability of
successful reverse transcription while also allowing a high recombination rate
[448]. Recombination occurs during reverse transcription according to 2 models -
(i) a copy choice model where genetic recombination occurs during intermolecular
minus-strand synthesis, and (ii) strand displacement-assimilation model where
discontinuous plus-strand synthesis displaces the 5’ end of an adjacent nascent plus-
strand which can then undergo intermolecular base pairing with the minus-strand
DNA and allow recombinant plus-strand synthesis.
1.6.3 Nuclear translocation
Most oncoretroviruses, including MMTV, depend on actively dividing cells
for their replication as they gain access to the nucleus during mitosis, when the
nuclear membrane is disassembled [448]. The preintegration complex (PIC) is
unable to pass through the nuclear pores (Figure 1.3, step 5). HIV, and other
lentiviruses, also enter the nucleus during mitosis, but may enter the nucleus during
interphase by active transport through the nuclear pore. The viral proteins required
for nuclear translocation and integration remain associated with the virions and their
replication intermediates.
1.6.4 Proviral integration
A linear DNA copy of the viral genome (provirus) is integrated into host
chromosomal DNA (Figure 1.3, step 6) by joining a precise site in the viral DNA to
non-homologous sites in the host DNA [265]. The process begins by IN-mediated
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cleavage of the 3’-termini of the viral DNA within the viral nucleoprotein PIC.
This cleavage eliminates the terminal 2 bases from each 3’-end [109] resulting in
recessed 3’-OH groups that provide the proviral attachment sites to the host DNA,
and thus define the ends of the integrated provirus. Following 3’-end processing, the
PIC translocates to the nucleus [448]. This step precedes the 3’-end processing for
viruses that complete reverse transcription in the nucleus. Binding of the host DNA
by the viral PIC is followed by an integrase-catalyzed transesterification reaction
in which the 3’-OH groups at the viral DNA ends attack the phosphodiester bonds
on opposite strands of the target DNA, at positions staggered by 6 bases in the 5’
direction for MMTV IN [109, 265]. Gap-filling DNA synthesis by viral RT or host
DNA polymeraseβ or δ extends from the host 3’-OH groups flanking the host-viral
DNA junctions [123, 448]. Removal of the 5’ dinucleotide overhangs, perhaps by
host flap endonuclease I [123], followed by ligation completes proviral integration
and duplicates a 6 bp target site sequence flanking the integrated MMTV provirus
[109, 265, 448]. The integrated provirus is replicated along with the host-cell DNA,
allowing transmission as an integral element of the host genome [448].
Although specific target sequences are not required for integration, large-
scale surveys of murine leukemia virus (MuLV) and HIV integration have
revealed a strong bias towards transcriptionally active regions of the genome while
avian sarcoma-leukosis virus (ASLV) lacks a similar preference for active genes
[468]. Highly bent regions of nucleosomal DNA and nuclear matrix-associated
chromosomal locations are also strongly preferred as integration sites [448, 468].
The tethering model of integration proposes that host DNA binding proteins interact
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with the viral PIC and influence the target site selection [468]. For instance, barrier-
to-autointegration factor (BAF) and high mobility group (HMG) chromosomal
protein A1 associate with the viral PIC and inhibit autointegration while promoting
intermolecular strand transfers [123]. Host DNA binding proteins may also occlude
potential target sites [448].
1.6.5 Viral transcription
Retroviral transcription, mediated by the host-cell RNA polymerase II,
occurs from the integrated provirus (Figure 1.3, step 7) and is influenced by
chromosomal position effects [134, 434, 448]. As previously mentioned (Section
1.5.8), four different MMTV promoters have been described (Figure 1.2) [14, 78,
120, 173, 293, 316, 442, 481]. Penv2 has elements homologous with promoters of
B-cell specific genes like immunoglobulin (Ig) heavy chain, Ii, and MHC class II
[14]. Expression ofsagmRNA has been reported from all 4 promoters while all
other known MMTV genes and the genomic RNA are mainly transcribed from P1196
(the standard LTR promoter).
Standard LTR transcription starts at the U3/R boundary (Figure 1.2) and
directs tissue-specific transcription in epithelial cells of lungs, kidney, mammary,
salivary and prostate glands and also in Leydig and lymphoid cells [79, 448]. The
primary transcripts of the proviral DNA are capped at the 5’-end (methylated GDP
attached to the first encoded nucleotide by a 5’-5’ linkage), polyadenylated at
the 3’-end (50 to 200 noncoding A residues), methylated at several specific sites
internally, and in some instances, spliced to generate subgenomic mRNAs [448].
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Transcription from P1196 terminates at various positions outside the viral template,
and 3’-end processing of retroviral RNAs is generated by post-transcriptional
endonuclease digestion at the R/U5 border followed by polyadenylation. The
sequence AGUAAA in the MMTV U3 region regulates 3’-end processing and
polyadenylation [448]. Under most circumstances transcription initiates only from
the 5’ LTR. This dominance might be due to promoter occlusion as the elongating
transcription complexes that originate in the 5’ LTR could disrupt or prevent the











































Figure 1.5. Regulatory elements in the MMTV LTR.
The P1196 TATA sequence, TATAAAA, is located from -41 to -23 bp
upstream of the transcription start site. A basal promoter element located at +2 to
+10 from the transcription start site binds the initiation site-binding protein (ISBP)
and is required for optimum transcription from the MMTV LTR [344]. Spacing
between the TATA box and the ISBP site is important for MMTV promoter function
and selection of the transcription start site [132].
Steroid hormones, e.g., glucocorticoids, androgens, and progesterone
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enhance MMTV LTR-driven transcription and increase protein production [68, 93,
172, 337, 370, 371, 374, 397, 435, 479]. The hormone responsive element (HRE)
located upstream of the transcription start site (-190 to -80) within the LTR (Figure
1.5) provides transcriptional responsiveness to glucocorticoids [204, 267, 343, 387]
and also other steroid hormones like androgens, progestins, and mineralocorticoids
[69, 70, 180] leading to a dramatic increase in MMTV expression during lactation
[299]. The hexanucleotide half-site 5’-TGTTCT-3’ and its direct and partial
inverted repeats serve as glucocorticoid receptor (GR) binding elements (GREs)
[18, 387]. There are 4 GREs within the MMTV HRE, which also bind other
hormone receptors that recruit distinct sets of coactivators to the MMTV promoter
to upregulate transcription [141, 249, 338].
Hormone induction repositions the 6 nucleosomes (A-F) in a sequence-
specific manner on the MMTV LTR and provides differential access to sequence-
specific DNA binding proteins, including the octamer transcription factor (Oct-
1/OTF-1), nuclear factor 1 (NF1)/CCAAT transcription factor (CTF), and the TATA
binding protein (TBP) [9, 10, 87, 223, 368, 428]. Nucleosomes A and B represent
the HRE, and binding sites for transcription factors, NF1, Oct-1, and TBP [223].
Oct-1 binds to a region of two 10 bp direct repeats between the positions -60
and -38 immediately upstream of the TATA box (Figure 1.5) and stimulates both
basal transcription and hormone induction of transcription from the standard LTR
promoter [62, 222, 426]. NF1 binds to the MMTV promoter between -82 to
+12 of the transcription start site [87] and is required for glucocorticoid-induced
transcription from the MMTV promoter [292].
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Hormone induction from the LTR promoter is a bimodal process involving
chromatin presetting mediated by weak binding of NF1 and Oct-1 that induces
translational re-positioning of the nucleosomes, allowing GR binding and increased
basal transcription [183]. Hormone-activated GR binding then triggers a
more distinct translational positioning of nucleosomes by recruiting chromatin
remodelling and histone modifying complexes that allow a tighter binding of NF1
and Oct1 and transcriptional induction [34, 106]. Strong NF1 binding stabilizes
an open nucleosomal conformation to allow efficient binding of more receptor
molecules [106]. Prolonged glucocorticoid exposure dephosphorylates histone H1
and inactivates the MMTV promoter [244].
Two regions fp1 (position -139 to -146 from the transcription start site)
and fp2 (position -157 to -164 from the transcription start site) show B-cell-
specific binding to the heterodimeric Ets factor, GA-binding protein (GABP),
which synergizes with the steroid receptor mediated transcriptional upregulation
of the MMTV LTR [19]. Ear3/COUP, an orphan member of the steroid/thyroid
hormone receptor superfamily of transcription factors, transactivates RNA synthesis
by binding to the +102 to +135 region downstream of the transcription start site in
the MMTV LTR [215].
The MMTV LTR contains a negative regulatory element (NRE) (Figure 1.5)
composed of 3 regions – distal (d) NRE ( -645 to -471), junctional (j) NRE (-471
to -365), and proximal (p) NRE (-365 to -264) – which controls tissue-specific
expression of MMTV [52, 199, 242, 294, 483]. The transcriptional repressors,
special AT-rich-sequence binding protein 1 (SATB1) and the homeodomain protein
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CCAAT displacement protein (CDP), bind to the MMTV NRE (Figure 1.5) and
repress MMTV transcription in lymphoid cells and the undifferentiated mammary
gland, respectively [251, 482, 483, 484]. SATB1 is most abundant in thymus, but
it also is expressed in a number of tissues that are semipermissive or nonpermissive
for MMTV expression [483]. CDP is expressed in most undifferentiated tissues,
yet during differentiation, CDP expression is greatly diminished, thus relieving
the repression [483]. The transcription factor Ku recruits DNA-dependent
protein kinase in a sequence specific manner to the MMTV NRE (Figure 1.5)
resulting in repression of glucocorticoid-induced MMTV transcription [152]. The
transcriptional enhancer factor 1 (TEF-1) binds to the pNRE (Figure 1.5) and
downmodulates basal and glucocorticoid dependent transcription from the MMTV
LTR [263]. MMTV transcription is also inhibited by transforming growth factor-
beta (TGFβ), which may be an upstream effector of CDP [71, 291]. The pNRE
harbors two GREs [141, 338]
The MMTV LTR harbors a bipartite mammary gland-specific enhancer
(MGE) (Figure 1.5) comprised of the BanII element (located between -1075 to
-978 or -1078 to -1052 upstream of the transcription start site) and the mammary-
specific enhancer of MMTV (MEM) element (-938 to -862 upstream of the
transcription start site) [170, 245, 474]. The MGE increases basal and hormone-
induced transcription from the MMTV LTR and directs high level expression in
the mammary glands of transgenic mice [299, 474]. The BanII element interacts
with a multifactor complex containing the mammary gland specific nuclear factor
mp4, mp5/AP-2, F3/NF1, and F12 [245, 282]. The MEM element has binding sites
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for mammary specific factors, mp4 and Fp1 complex, and ubiquitous factors like
signal transducer and activator of transcription 5 (Stat5) or mammary gland factor
(MGF), which is activated in response to prolactin [351]. The MEM element also
binds mammary cell activating factor (MAF) or Ets, NF-1, AP-2 and F5 complex
[171, 351, 458]. The MGE contains prolactin responsive elements, interacts with
a factor that binds to the core sequence ACAAAG [181, 295], and overlaps the
transcription enhancer for B-cell/myeloid progenitors [366]. Both enhancers share
specific functional regions that include the NFI and MAF binding sites [366].
Othercis-acting transcriptional elements in MMTV include a 13 bp tannic
acid response element in the LTR located downstream of the transcription start site
that binds Sµbp-2, a DNA helicase domain containing protein, which negatively
regulates transcription from the MMTV LTR [433]. Forkhead transcription factor
family member Forkhead box A (FoxA) binds to the MMTV LTR at the positions
-232/-221, -57/-46 and -45/-34 [197] and mediates chromatin changes that allow
increased basal transcription while decreasing GR-induced transcription.
MMTV also contains transcription regulatory elements outside the LTR. The
MMTV envgene contains a 411 bp (nt 6801 to 7212) activation-dependent, helper
T-lymphocyte-specific transcriptional activator termed MMTVenv transcriptional
activator (META) [293].
1.6.6 Viral translation
Viral proteins are translated from genomic as well as singly and doubly-
spliced subgenomic RNAs on free and membrane-bound ribosomes (Figure 1.3,
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step 8). Two -1 ribosomal frameshift events are required for complete translation
of the genomic MMTV RNA leading to the expression of MMTV Gag-Pro and
Gag-Pro-Pol precursors. The dUTPase/Pro coding sequence begins about 16 nt
upstream of the Gag termination codon in the -1 reading frame, while the Pol
reading frame begins 13 nt upstream of the Pro termination codon [209]. Ribosomal
frameshifting occurs when ribosomes traverse a 7-nt sequence termed the shift site
[72]. The shift site sequence, host tRNAs, and G-C-rich RNA pseudoknots located
6 to 8 bases downstream of the shift site are critical for determining the efficiency
of frameshifting [72, 209]. Thegag-pro junction specified by the NC stop codon
is the first frameshift site where 23% of the ribosomes shift their reading frame
to generate the Gag-Pro polyprotein, while 8% of these ribosomes undergo the
second frameshift at thepro-pol junction to generate the Gag-Pro-Pol polyprotein
[209, 300]. The lower frequency of ribosomal frameshifting at thepro-pol junction
provides a mechanism to regulate the concentration ofgag-encoded structural
proteins andpol-encoded enzymes. The three polyproteins Pr77Gag, Pr110Gag−Pro,
and Pr160Gag−Pro−Pol are synthesized in the approximate ratio of 30:10:1.
1.6.7 Virion assembly and structure
The MMTV polyproteins Pr77Gag, Pr110Gag−Pro, and a smaller proportion
of Pr160Gag−Pro−Pol encapsidate the dimeric viral genomic RNA into a coiled,
rope-like structure [302]. This ribonucleoprotein complex forms a spherical
immature nucleocapsid core termed intracytoplasmic A particle (IAP) measuring
80 nm in diameter (Figure 1.3, step 9 and Figure 1.6) [283, 303, 480]. Packaging
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of the dimeric RNA genome may occur by the RNA switch mechanism wherein
NC-bindingψ or E (for encapsidation) sites are sequestered by base-pairing in the
monomeric RNA and become exposed following RNA dimerization [110, 448].
Identity of theψ sequence in the MMTV genome is unknown.
The polyproteins in the IAPs are stabilized by disulfide bonds and are
arranged radially with their N-termini near the surface and the C-termini located
in the interior [409]. IAPs assemble in virus factories near the nucleus and the
plasma membrane [149]. Envelopment occurs by budding through regions of the
plasma membrane or the ER that have been modified by the insertion of viral Env
proteins (Figure 1.3, steps 10 and 11) with the exclusion of some normal cellular
membrane proteins [149, 406, 480]. Gag molecules in the IAPs interact with the
TM in the viral membranes via the hydrophobic MA domain [275]. Virion assembly
is proposed to be both concentration-driven (based on Gag-Gag interactions) and
template-driven (based on envelope/MA and the NC/RNA interactions) [35].
MMTV assembly and budding process interacts with the ubiquitination
system as determined from the presence of monoubiquitinated p3-p8 and
diubiquitinated NC in MMTV virions [329]. During or shortly after particle
budding, the Gag polyprotein is cleaved by the viral protease into mature structural
proteins [149, 409]. Cleavage of Gag results in a dramatic structural rearrangement,
termed maturation (Figure 1.3, step 12 and Figure 1.6), which is necessary for
infectivity. The mature virions also contain cellular constituents, e.g., ribosomes,
the primer tRNA associated with the PBS of the viral RNA, and low levels of
cellular mRNAs and 5 S ribosomal RNA [149, 340, 448]. Virions also contain
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some DNA that might be the early products of reverse transcription [448].
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Figure 1.6. MMTV virion structure.
1.6.8 Virion release
Fully assembled MMTV IAPs bud from both the plasma and endosomal
membranes (Figure 1.3) and preferentially exit at sites of cell-to-cell contact
[150, 303]. Viral infection often induces cell-to-cell contact sites termed
virological or infectious synapses that resemble immunological synapses by their
high concentrations of adhesion molecules and polarization of the microtubule
organization center toward the synapse [303]. These synapses form, at least in
part, because Env proteins on the infected cell surface crosslink with their receptors
on the target cells [303]. Particles budding at cell-to-cell contact sites are often
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elongated and undergo simultaneous endocytosis into the adjacent cell [150, 303].
Retroviral release can also occur directionally in polarized cells [303].
Recent studies have revealed that retroviruses bud by Gag late (L) domain-
mediated recruitment of cellular factors involved in the multivesicular bodies
(MVB) sorting pathway [303]. Candidate L domains in MMTV Gag include
a PSAP sequence in CA and two YXXL motifs in MA and pp21 [329].
Ubiquitination commonly serves as the signal for sorting proteins into MVB
vesicles [303]. Membrane distortion during virus budding is achieved through the
combined interactions of viral and cellular proteins and, possibly, also specialized
lipids [303]. Ubiquitination also plays a role in the release of enveloped viruses.
Although Gag proteins of several retroviruses including MMTV are ubiquitinated,
its precise role in viral release is not known [303].
1.7 MMTV Transmission
MMTV is an oncogenic retrovirus that causes mammary carcinomas in mice
after a long latency (6 to 9 months) [1, 379]. MMTV is transmitted exogenously
through milk of infected female mice to the progeny during the first 2 weeks of
life [302], or may be inherited in the germline as stably integrated endogenous
proviruses (Mtvs) [231].
1.7.1 Endogenous MMTVs (Mtvs)
Most laboratory mouse strains harbor between 2 to 8 endogenous MMTV
proviruses (Mtvs) in their germline that follow the Mendelian rules of inheritance
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Figure 1.7. MMTV life cycle.
[231]. A majority of the endogenous proviruses are defective for replication
and mammary tumorigenesis due to mutations [231]. However, most of these
proviruses encode functional Sag that induces intrathymic or peripheral deletion
of Sag-reactive T cells altering the mouse T-cell repertoire [31, 388]. Proteins
encoded by endogenousMtvs may also serve as self-antigens to generate partial
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tolerance against MMTV [4]. Thus, the presence of endogenousMtv might
potentially aid infection by exogenous MMTV. Conversely, it has been proposed
that Sag-expressing endogenousMtvs have been maintained in most mouse strains
for protection against infection by virulent exogenous MMTVs encoding Sags with
similar T-cell reactivities [157, 158, 184].
1.7.2 Exogenous MMTVs
The life cycle of exogenous MMTV is intricately linked with the immune
system [4]. While some milk-borne MMTV particles are digested in the stomach
[42], other virions enter the Peyer’s patches in the small intestine (Figure 1.7,
steps 1 and 2) through M cells in the overlying follicle-associated epithelium
[176, 218]. Short gastric veins emptying in the superior hilus of the spleen may
also serve as portals of MMTV entry [381]. Initial infection is restricted to the
Peyer’s patches where viral DNA is detectable within 4 days of birth [218]. This
infection (until 17 days post-partum) is independent of Sag function and depends on
viral reverse transcription and the developmentally regulated proliferation of target
cells [186, 345] which primarily include small, resting naive B cells and immature
dendritic cells (DCs) (Figure 1.7, step 3) [40, 184, 185, 440]. MMTV can also
activate DCs and B cells via the TLR4 [64, 136] and trigger the production of
the immunosuppressive cytokine IL10 from B cells, which is stimulated by DCs
and macrophages in a TLR4-dependent manner [213]. This immune suppression
is critical for the maintenance of infection since in the absence of a functional
TLR4, wild type MMTV is eliminated by a cytotoxic T-lymphocyte (CTL) response
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directed against Gag epitopes [213]. MMTV infection also results in rapid CD40-
CD40L interaction followed by downregulation of both molecules within 24 hr of
infection, allowing a balance between virus propagation and host defenses [405].
Antigen presenting cells (APCs) express the MMTV-encoded Sag at their
cell surface in association with MHC class II molecules [1, 4, 41] and initiate a
helper T-cell response by priming Sag-reactive CD4+ T lymphocytes (Figure 1.7,
step 4) [1, 4, 11, 201, 281, 348]. DCs are important Sag presenters in the thymic
and splenic environments [135] and play an essential role during T-cell priming [29,
256]. Activated B cells upregulate surface MHC class II expression and also present
passively acquired Sag [298]. While conventional peptide antigens are recognized
on average by 1 in 105 T cells, 5 to 35% of the total mouse T-cell repertoire may
be activated by MMTV Sag to undergo rapid proliferation and/or release cytokines
(Figure 1.7, step 5) [4, 12]. Sag-mediated stimulation of T-helper cells is essential
for virus propagation since most inbred mouse strains are potentially tolerant to
MMTV proteins encoded by endogenousMtvs in their genome [256].
Helper-T cells initiate extra-follicular and follicular activation of virus-
infected B cells that proliferate vigorously and differentiate into antibody-producing
plasma cells (Figure 1.7, step 6) [13, 137, 185, 256]. The antibody response
is unable to clear the virus in susceptible mice. MMTV infection also results
in IFNα and β production, which limits the early infectious phases and results
in longer latency of mammary tumorigenesis. Higher levels of interferon may
inhibit the progression of pre-neoplastic lesions [33]. The Sag-mediated immune
response results in viral amplification (Figure 1.7) in the absence of reverse
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transcription [186] and generates a reservoir of infected and susceptible B and
T cells. These lymphoid cells spread the infection from the Peyer’s patches to
the mesenteric lymph nodes and later to the peripheral lymphoid organs, gut
mucosa and epithelial cells of the thymus and the exocrine glands, including
the mammary glands in a Sag-dependent manner (Figure 1.7, steps 7 and 8)
[137, 138, 164, 184, 218, 274, 318, 345]. Sag also attracts lymphocytes into the
draining lymph nodes to enhance the efficiency of viral amplification and spread
[278].
Sag activity and MMTV-infected lymphocytes are also required for virus
spread within the mammary gland [164]. Disruption of T-B cellular interactions
in T- or B-cell knockout mice (Sag transgenic mice [157, 158], nude mice [431],
µMT-/- [40]) or mice lacking co-stimulatory molecules (CD40L-/- [76], CTLA4Ig
transgenic mice [73], CD28-/- [331]) reduces or abolishes the Sag-mediated
immune response as well as viral spread and transmission. In later stages of chronic
MMTV infection, peripheral Sag-mediated T-cell response is reduced since most
of the Sag-reactive T cells are gradually deleted following activation (Figure 1.7)
[1, 31, 91, 118, 216]. Anergy is maintained in the residual Sag-reactive T-cell
population by Sag-specific natural regulatory CD4+ CD25+ T cells that escape
deletion [262, 334]. CD4+ T cell-Sag interaction also disrupts B- and CD8+ T-
lymphocyte homeostasis [356].
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1.8 Mechanism of tumorigenesis
MMTV is a non-acutely transforming retrovirus that induces tumors by the
stochastic process of insertional mutagenesis. Proviral insertion in the vicinity
of a cellular oncogene disrupts the normal organization of the locus and also
introduces strong promoter and enhancer elements into the locus that could alter the
oncogene expression by several mechanisms [448]. (i) Promoter insertion occurs
when a provirus integrates upstream of an oncogene in the same transcriptional
orientation. The promoter and enhancer elements in the proviral LTRs may
direct increased or developmentally inappropriate levels of oncogene expression
[448]. (ii) In enhancer insertion, proviruses inserted upstream of target genes
in the opposite transcriptional orientation or downstream from target genes in
either orientation can increase gene expression by placing the gene under the
influence of strong enhancers within the retroviral LTR [448]. The BanII and
MEM elements of the MMTV MGE mediate transcriptional activation of provirus-
proximal oncogenes [170]. (iii) During read-through transcription, proviruses
integrated within genes may initiate transcripts at the LTR promoter that extend into
cellular sequences. Translation of such hybrid transcripts can lead to the expression
of altered proteins [448]. (iv) Inactivation of cellular regulatory elements may occur
after proviral insertions. Cellular gene expression may be altered by destroying
cellular regulatory elements like silencers, pause sites, or polyadenylation signals
or lead to altered methylation patterns at the locus [448]. Proviral insertional
mutagenesis could also result in the inactivation of tumor suppressor genes [448].
Members of thewnt (wingless-related MMTV integration site),fgf (fibrob-
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last growth factor), andnotchgene families among others [66, 326] are common
integration sites (CISs) of exogenous MMTV proviruses [86, 128, 305] (Table 1.1)
in mammary tumors. Thewnt genes are a family of 19 or more genes related to
theDrosophilasegmented polarity gene,wingless (wg)[66]. Thewntgenes encode
cysteine-rich secreted glycoproteins that bind to cell surface receptors. Receptor
binding initiates signaling cascades implicated in patterning during embryogenesis
and stem cell self-renewal for maintenance of mature tissues [206]. Thefgf g ne
family includes 22 members that encode secreted proteins involved in various
biological processes, including angiogenesis, mitogenesis, cellular differentiation,
cell migration and tissue-injury repair [207]. The four members of thenotchgene
family encode cell surface receptors, which when activated by membrane-bound
ligands, influence developmental cell-fate choices in a variety of cellular lineages
[214]. Several other potential oncogenes have been identified by directing their
expression from the MMTV LTR in transgenic mice (Table 1.2).
The choice of oncogene target and the efficiency of tumor induction is
influenced by multiple factors [342] like oncogene cooperativity [448] (Tables 1.1
and 1.2), mouse genetic background [270] and hormonal status [84].
MMTV-encoded proteins may also have a direct role in the tumorigenesis
process as suggested by the oncogenic activity of Sag in certain mammary epithelial
cell lines [312] and the influence of thegag gene on the efficiency of mammary
tumor induction by different strains of MMTV [198]. MMTV Env recently was
reported to have a transforming activity dependent on the immunoreceptor tyrosine-

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.9 MMTV-associated non-mammary tumors
MMTV has been associated with the induction of non-mammary tumors,
primarily of lymphoid origin. Exogenous MMTV proviruses have been detected in
T-cell tumors from mouse strains harboring milk-borne MMTV (GR and DBA/2)
as well as in strains that lack demonstrable milk-transmitted virus (BALB/cJ and
C57BL/6) [94, 112, 113, 241, 289]. However, T-cell tumors often fail to produce
MMTV virions although viral RNA and proteins are detectable [112]. MMTV
proviruses cloned from these T-cell tumors [for example, type B leukemogenic virus
(TBLV), MA, and DL-8] harbor varying deletions within the U3 region of the LTR
[27, 112, 113, 199, 237, 241, 290, 473]. These deletions remove the 3’-end of the
saggene as well as the NREs in the MMTV LTR; in some cases part of the HRE is
lost [27, 199, 237, 241, 290]. Some lymphoma-associated MMTV proviruses also
acquire T-cell specific enhancers that may duplicate or triplicate the HRE in the U3
region [27, 286, 473].
Milk-borne MMTV infection has also been associated with the induction
of kidney adenocarcinomas in the BALB/cf/Cd mouse strain (a 70% incidence)
[457]. Newly integrated MMTV proviruses cloned from these tumors harbor a
unique alteration in their LTR U3 region. Starting at the position -333 relative to
the transcription start site, 113 bp of the original MMTV LTR have been replaced
with a 90 bp unrelated DNA sequence. The deletion and substitution also result
in truncation of the NREs and thesag gene. In rare cases, MMTV has been
reported to induce Leydig cell testicular tumors [355]. MMTV may induce pituitary
gland tumors as suggested by the detection of amplified MMTV proviruses in a
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pituitary tumor line [355]. Since MMTV is expressed in a variety of epithelial and
lymphoid cell types, transcription levels may determine the frequency of insertional
mutagenesis.
SJL mice develop germinal center (GC)-derived B-cell lymphomas also
called reticulum cell sarcomas (RCS) with>90% incidence within 12 months of
age. EndogenousMtv29-encoded Sag plays a critical role in the growth of these
tumors by stimulating cytokine production from CD4+Vβ16+ T cells [429, 430].
Other immune responses to MMTV have also been implicated in facilitating
polyomavirus-induced tumorigenesis. The presence ofMtv7 in mice of H-
2k background confers susceptibility towards developing polyomavirus-induced
tumors [255].
1.10 Type B leukemogenic virus (TBLV)
1.10.1 History
TBLV is a T-cell tropic variant of MMTV that predominantly induces
thymic lymphomas in mice [26]. This virus was originally described as a highly
leukemogenic virus (DMBA-LV) isolated from a 7,12-dimethylbenz (α)-anthracene
(DMBA)-induced thymic lymphoma in a CFW/D strain mouse [21]. The original
DMBA-LV isolates contained a 10:1 mixture of type B and type C retroviral RNA
while lacking type B-C recombinant genomes [24, 25]. Nucleic acid hybridization
demonstrated a high level of relatedness (90%) between the type B retroviral
genome and the MMTV(C3H) genome [24]. DMBA-LV-induced lymphoma cell
lines and virions released from these cells contained MMTV-related proteins [95].
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High levels of type C retroviral proteins, except Env, were also present in these
samples. Complete neutralization of viral leukemogenicity by a monoclonal
antibody directed against the MMTV Env glycoprotein established the primary role
of the MMTV-related type B retrovirus in the induction of thymic lymphomas [25].
In contrast, antibodies directed against the type C retroviral component of DMBA-
LV failed to neutralize viral leukemogenicity [25]. Subsequent analysis of DMBA-
LV-induced thymic lymphomas revealed the presence of newly integrated MMTV
proviruses, whereas newly integrated type C retroviral proviruses were undetectable
[94].
1.10.2 Comparison of MMTV and TBLV
Heteroduplex mapping and nucleotide sequence analysis revealed that the
major differences between the TBLV and MMTV genomes lie within their LTRs
[27]. TBLV has a deletion of 443 nt and a substitution of 124 nt in the LTR U3
region [27]. This deletion encompasses the NREs [52, 242, 251, 252, 304, 482, 483]
while the substitution contains triplicate 62 bp elements comprised of the 18 bp 5’
flanking sequence apposed to the 44 bp 3’ flanking sequence of the deleted region
[27] (Figure 1.8). This triplication functions as a T-cell specific enhancer [286].
The TBLV enhancer contains a novel assembly of transcription factor
binding sites, combining sites commonly found in MuLV enhancers (c-Myb,
GR and Runx1) and in the HIV-1 enhancer (NF-κB) [287]. GR- and c-Myb-
binding sites are critical for the TBLV enhancer function in CD4+ T cells but
not in CD4+CD8+ T cells, the majorin vivo targets of TBLV oncogenesis.
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Two unidentified multi-protein complexes, NFA and NFB, and the transcriptional
coactivator Aly are also critical for the TBLV T-cell enhancer function. Three
other TBLV enhancer-binding proteins, HMG1, HMG2, and hnRNPA1/A2, were
identified by mass spectrometry [287]. The role of these proteins on enhancer





















Figure 1.8. Comparison of MMTV and TBLV LTRs.
MMTV and TBLV LTRs (1326 bp and 1007 bp, respectively) are divided into U3, R, and U5
regions. The transcriptional start sites at the U3/R border (1195 bp and 876 bp downstream from
the beginning of MMTV and TBLV LTRs, respectively) are denoted by the arrows. The NRE in
the U3 region of the MMTV LTR is shown as a white box. The 5’ 18 bp and the 3’ 44 bp NRE
flanking sequences that constitute the triplicate T-cell enhancer in the TBLV LTR are depicted by
red and blue boxes, respectively. The Sag protein (320 amino acids) encoded within the U3 region
of the MMTV LTR is shown as a green bar above the LTR. The C-terminal hatched box represents
the polymorphic 30 amino acid residues that determine the specificity of TCR Vβ chain recognition.
The transmembrane (TM) region and the CIIPBM are shown as black and blue boxes, respectively.
The three proteolytic processing sites are denoted by triangles below the Sag protein. The NRE
deletion and T-cell enhancer substitution in the TBLV LTR truncate thesaggene to encode only the
first 165 amino acids of MMTV Sag.
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1.10.3 TBLV Sag
The LTR deletion and substitution also truncate thesag gene [27]
encompassing the U3 region of the TBLV LTR (Figure 1.8). The truncated TBLV
Sag lacks the entire C-terminal region required for interaction with the TCR
[478]. However, TBLV Sag retains the transmembrane region and a portion of
the extracellular domain, including the glycosylation sites and a single proteolytic
processing site [97, 280]. TBLV Sag retains the CIIPBM and the potential to
interact with MHC class II molecules
1.11 Retroviral restriction factors
A number of cellular genes have been identified that actively inhibit
retrovirus replication in their mammalian hosts. Among these are the dominant
Friend virus susceptibility genes,Fv1 andFv4, which provide resistance against
Friend MuLV [43]. Fv4 encodes an endogenous retroviral Env protein that blocks
infection by receptor interference [43].Fv1 encodes a protein that is related to
the capsid-like domain of the MuERV-L family of murine endogenous retroviral
Gag proteins. Fv1 restricts viral infection at a post-entry step, most likely by
interacting with the incoming viral capsid protein and restricting the viral PIC in
the cytoplasm [155]. Many human cell lines express a similar factor termed Ref1
(restriction factor 1) [43, 155] while several primates restrict HIV-1 infection by
encoding a related factor termed Lv1 (lentivirus restriction factor 1) [155].Lv1
encodes TRIM5α which belongs to a family of TRIM proteins named for a cluster
of tripartite sequencemotifs: a RING domain (E3 ubiquitin ligase activity), either
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one or two B boxes (zinc binding sequences), and a coiled-coil domain (likely
involved in homo- and heterodimerization of the TRIM proteins) [155]. TRIM5α
could potentially target the CA protein of the incoming virus for ubiquitination and
degradation. TRIM5α is also involved in the action of Ref1 and possibly Fv1.
Several other retroviral restriction mechanisms also have been reported.
A restriction system that targets retroviruses at an early post-entry step involves
enzymes of the APOBEC (apolipoprotein B mRNA editing catalytic subunit) family
of cytidine deaminases, in particular APOBEC3G, which remove the amino group
from cytosine to form uracil [155]. APOBEC3G is highly specific for single
stranded DNA in which C to U conversions result in G to A mutations. The
proviral DNA presumably is destabilized due to the subsequent action of uracil N-
glycosidases and nucleases such as apurinic/apyramidinic endonuclease 1 (APE1)
[155]. A novel retrovirus resistance gene termed ZAP (zinc fingerantiviral protein)
acts at a late stage of viral infection by blocking the accumulation of viral RNAs
in the cytoplasm. ZAP binds viral RNAs and presumably targets them to the RNA
exosome, a multiprotein complex involved in cellular mRNA turnover [155].
1.11.1 Modes of MMTV resistance
Several mechanisms of resistance to MMTV infection and tumorigenesis
in inbred strains of mice have been described. Increased resistance against
mammary tumorigenesis with advancing age of the host and the mammary gland
was reported in 1966 [116]. In the same year Rileyet al. described a phenomenon
of interference in which infection of a susceptible mouse strain with the lactate
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dehydrogenase elevating virus (LDV) significantly decreased the incidence of
spontaneous mammary carcinomas [369]. Reciprocal interference between MMTV
and MuLV has also been reported [412]. MuLV infection of milk-borne MMTV-
infected BALB/cJ mice resulted in delayed and reduced incidence of MuLV and
MMTV-induced tumorigenesis. Interferon production in response to viral infection
was proposed to play a major role in this reciprocal interference [32].
An unknown recessive resistance gene in the II-TES mouse strain ensures a
low mammary tumor incidence despite the production of high titer, infectious, milk-
borne MMTV [8]. Milk-borne transmission of MMTV in the X/Gf mouse strain
induces mammary carcinomas with declining incidence until the 7th generation
[156]. The cessation of mammary tumorigenesis may be mediated by high levels
of antibodies produced against MMTV. Serum antibody response against MMTV
has been correlated with resistance to MMTV infection and tumorigenesis in three
other instances. In the SWISS and anMtv3+ BALB/cHeA congenic mouse strains,
the non-tumorigenic expression of the endogenous provirusMtv3 protects, at least
partially, against exogenous MMTV infection and tumorigenesis by inducing the
production of MMTV neutralizing antibodies [177, 178]. Sustained production
of virus-neutralizing IgG2a antibodies also provides resistance to MMTV-induced
tumorigenesis in I/LnJ mice despite Sag-mediated viral amplification and mammary
gland infection [165]. Infected mice also shed antibody coated milk-borne virions
that fail to transmit infection to the subsequent generation [350]. The resistance
phenomenon is a recessive trait dependent on the production of IFNγ in response
to viral infection [350].
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Inefficient Sag-cognate T-cell interaction also may produce resistance to
MMTV tumorigenesis [347]. The C57BL/6 strain lacks MHC class II I-E molecules
that are required for efficient cell surface presentation of MMTV(C3H) Sag [407].
Thus, C57BL/6 mice demonstrate reduced and delayed kinetics of Sag-mediated T-
cell deletion and virus production in the mammary gland, resulting in relatively
increased resistance to MMTV(C3H)-induced tumorigenesis compared to MHC
class II I-E+ strains [465].
Strong Sag-mediated immune responses could also result in protection of
mice against mammary tumorigenesis. BALB/c mice infected as neonates with
MMTV(SW) develop a high incidence (65%) of mammary adenocarcinomas within
12 months [335]. However, adult mice infected with MMTV(SW) demonstrate
reduced mammary gland infection and only a 13% tumor incidence with an
average latency of 23 to 24 months. Sag response is inefficient in neonatal mice,
and tolerance induction by clonal deletion is delayed. In contrast, adult mice
demonstrate dramatic local activation and rapid clonal deletion. Thus, although
T-B cellular interaction is required for viral amplification and completion of the
life cycle, a strong local immune response to MMTV(SW) in adult-infected mice
limits mammary gland infection and protects the mice against mammary tumor
development.
A strong immune response also results in resistance against the wild-
type MMTV(C3H) and selection of an immune escape variant, MMTV(HeJ), in
C3H/HeJ mice [213]. Maintenance of the wild-type virus is dependent on TLR4
signaling, which triggers the production of the immunosuppressive cytokine IL10.
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The C3H/HeJ substrain of mice bearing a dominant negative TLR4 mutation
eliminates MMTV(C3H) by a cytotoxic immune response directed against Gag
[213]. The MMTV(HeJ) recombinant also does not efficiently induce tumors in
the C3H/HeJ strain, although it is highly tumorigenic in BALB/cJ mice [198].
Lastly, deletion of cognate T cells by Sags expressed from endogenousMtv
loci can protect mice against infection by tumorigenic exogenous MMTV strains
encoding Sags with similar T-cell reactivities [157, 184]. However, endogenous
Mtvs might potentially aid infection of mice by exogenous MMTV strains by
altering the T-cell repertoire [388] and generating a partial tolerance against
exogenous MMTV proteins [4].
1.12 Comparison ofVibrio choleraeand MMTV pathogeneses
V. choleraeis a motile, Gram-negative, curved rod belonging to the family
Vibrionaceae[362]. These bacteria are natural inhabitants of aquatic ecosystems
and are facultative human pathogens. Infection usually starts by ingestion of food
or water contaminated withV. cholerae. Subsequently the bacteria must pass
through and survive the gastric acid barrier of the stomach, then penetrate the mucus
lining that coats the intestinal epithelia [362]. The surviving bacteria adhere to and
colonize primarily the small intestinal epithelial cells, eventually producing cholera
toxin (CT) and causing diarrhea.
Normal adult mammals (other than humans) are not colonized byV.
cholerae, yet these bacteria colonize the small intestines of several suckling
mammals, including mice, presumably due to immature host immune defenses
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[226]. The majority of cholera symptoms in humans are caused by CT.V. cholerae
strains lacking CT genes have a markedly higher 50% lethal dose (LD50) in suckling
mice, but display no colonization defects.V. choleraestrains that produce CT
induce a highly secretory diarrhea that develops in the absence of inflammation,
while strains that do not produce CT cause milder diarrhea, but the disease is more
inflammatory in nature [386].
CT belongs to the AB5 family of toxins [246]. Five identical 11-kDa
peptides associate in a ring-like structure to form the pentameric B-subunit (55
kDa). The B-subunit binds to the oligosaccharide domain of a membrane glycolipid
receptor, ganglioside GM1, at the cell surface resulting in the association of CT
with lipid rafts. The single A-subunit assembles non-covalently with the B-subunit
and is cleaved into A1- and A2-chains, which remain linked by a disulfide bond and
extensive non-covalent interactions. The toxin is internalized by clathrin-dependent
and -independent mechanisms in different cell types. CT is then transported from
the plasma membrane to the ER by a lipid-sorting pathway. In the ER lumen,
the A1 subunit is activated by thiol-dependent reduction followed by unfolding
and disassembly from the rest of the toxin. The A1 subunit is transported to the
cytosol where its ADP-ribosylating activity targets the host cell G-protein Gsα.
ADP-ribosylated Gsα constitutively activates adenylate cyclase activity, leading to
increased levels of intracellular cyclic adenosine monophosphate (cAMP), which
inhibits active sodium chloride absorption and increases chloride and bicarbonate
secretion. The result is passive water loss, leading to a marked decrease in
intravascular volume, hypotension and hypoperfusion of critical organs and, in
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severe cases, death ensues with a high mortality rate (>20%). Interestingly, cAMP
is also reported to upregulate glucocorticoid-induced expression of MMTV [476].
Like MMTV Sag, CT acts as an immunomodulator that suppresses host
innate immunity and skews the development of an adaptive immune response.
However, CT inhibits the production of tumor necrosis factorα (TNFα) and nitric
oxide (NO) by macrophages, thus inhibiting innate immunity at the earliest steps
of infection. TNFα is a proinflammatory cytokine that induces endothelial cells
to express chemokines and cell adhesion molecules to recruit neutrophils and other
leukocytes to the site of infection. CT also downregulates the production of IL12 by
macrophages and reduces T-cell responsiveness to IL12 by inhibiting the expression
of surface receptor chains IL12Rβ1 and IL12Rβ2. Through suppression of the
major Th1-associated cytokine, CT inhibits the amplification of a cell-mediated
immune response. On the other hand, CT stimulates DC maturation for priming of
a Th2 immune response. The primary role of CT in aV. choleraeinfection may be
modulation of host immune responses.
1.13 Rationale for these studies
MMTV is an oncogenic retrovirus that causes mammary tumors in mice
after a long latency (6 to 9 months) [3, 379]. In contrast, TBLV causes thymic T-cell
lymphomas with a short latency (42 to 60 days) when introduced intrathymically
into neonatal mice [26]. TBLV is a unique virus for study despite sharing a very
high degree of sequence similarity with MMTV, because of its altered tissue and
disease tropism. The cellular oncogene targets of TBLV and MMTV also appear to
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be different. A common integration site of TBLV, termedTblvi1, was mapped to a
53 kb locus on the mouse X chromosome in 20% of primary TBLV-induced tumors
[311]. The c-mycandRorcgenes are common integration sites for TBLV in thymic
T-cell lymphomas, while MMTV frequently targets members ofwnt, fgf, andnotch
gene families among others [60, 66, 358]. Therefore, the factors that control disease
and tumorigenic specificity are key to understanding retroviral pathogenesis.
In vivo studies have been previously performed by intrathymic injection of
neonatal mice with heterogeneous TBLV-containing tissue culture supernatant from
a T-cell lymphoma line, 485-10 [21, 22, 23, 375]. T-cell lymphomas were observed
in these mice at an incidence of approximately 90% [26]. To further understand
the biology of this virus, a tumorigenesis assay in adult mice was developed in
our laboratory by using a cloned TBLV hybrid provirus (HYB-TBLV) created by
replacing a portion of the 3’ LTR of an MMTV clone with the corresponding
region from the TBLV LTR (section 3.1). Lymphomagenicity of HYB-TBLV
demonstrated that the determinants of TBLV lymphotropism lie within the LTR.
Lymphomagenicity of two other T-cell tropic MMTV variants, MA and DL-8,
have been previously studied in adult mice in the context of molecular viral clones
[475]. Similar to TBLV, these variant LTRs also harbor NRE deletions and T-
cell enhancers that truncate thesag gene [286, 473]. Thus, mutant MMTV and
TBLV hybrid proviruses were used to assess the contributions of the truncated
TBLV Sag, NRE deletion and T-cell enhancer acquisition towards the conversion
of mammotropic MMTV to a lymphomagenic virus (section 3.1).
EndogenousMtvs integrated in the germline of most inbred mouse strains
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are known to prevent infection by exogenous MMTV strains bearing Sags of similar
T-cell specificities. The endogenousMtvs can recombine with exogenous MMTV
strains and influence the infection cycle of exogenous MMTVs with disparate
Sag specificities. Therefore, we were motivated to develop a well characterized
inbred mouse strain (termed BALB/Mtv-null) that lacks endogenousMtvs capable
of recombination with engineered exogenous MMTV strains under investigation.
Surprisingly, the endogenousMtv-free BALB/Mtv-null mice were resistant to
MMTV-induced mammary tumorigenesis and TBLV-induced lymphomagenesis.
These mice also were resistant to the cholera toxin-producing strain ofVibrio
cholerae. This novel mouse strain was characterized to identify novel pathogen
restriction pathways. Description of such pathways could elucidate new aspects of
the pathogen replication cycle as well as host-pathogen interactions. Knowledge of
restriction factors would also allow the identification of potential therapeutic targets




BALB/cJ [H-2d, Mtv6, 8, 9] and PERA/Ei (H-2k [446], endogenousMtv-
free [446]) mice were obtained from Jackson Laboratories (Bar Harbor, ME)
while exogenous MMTV(C3H)+ C3H/HeN mice were obtained from Harlan
(Indianapolis, IN). BALB/Mtv-null (H-2d) mice lacking endogenousMtvs were
selected from a BALB/cJ x PERA/Ei cross followed by 10 backcrosses to the
BALB/cJ strain. These mice have been maintained for numerous generations by
standard brother-sister mating. The BALB/Mtv-null strain was backcrossed to
the BALB/cJ strain to derive BALB/cJ x BALB/Mtv-null F1 mice heterozygous
for Mtv6, 8, and 9 endogenous proviral loci (Figure 3.19). BALB/cJ congenic
strains that were homo- or heterozygous for a single endogenousMtv locus
(BALB/Mtv6, BALB/Mtv8, and BALB/Mtv9 mice collectively termed BALB/Mtv-
SP) were derived by backcrossing the BALB/cJ x BALB/Mtv-null F1 (NE1) strain
to the BALB/Mtv-null strain followed by inbreeding of selected NE2 strains (Figure
3.19). Siblings of BALB/Mtv-SP mice from the NE3 generation that lacked
endogenousMtvs were designated as BALB/Mtv-nullSP to indicate the similarity
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of their genetic derivation with the BALB/Mtv-SP mice (Figure 3.19). All mouse
strains were bred and maintained in the Animal Resources Center at the University
of Texas at Austin. Sentinel mice were tested periodically to ensure the absence of
common bacterial and viral pathogens. Some mice were bled under anesthesia at 1
to 3 month intervals from their retro-orbital sinus using heparinized Natelson blood
collecting tubes (Fisher Scientific, Pittsburgh, PA). Mouse breeding, maintenance,
PCR typing, inoculations and bleeding were performed by Mary Lozano.
2.2 Mouse injections and foster nursing
Weanling (4 to 5 week-old) mice were intraperitoneally injected with a
single dose of 2×107 rat XC fibroblast cells or Jurkat human T cells stably
expressing wild-type or mutant MMTV/TBLV hybrid proviruses using a 23 gauge
needle. For some experiments weanling mice were inoculated intraperitoneally
with 5×106 A20 B cells or A20 cells stably transfected with the infectious provirus,
pHYB-MTV [403] (A20/HYB-MTV). Prior to inoculation into mice, the cells were
washed twice with phosphate-buffered saline [PBS] (137 mM NaCl, 3 mM KCl,
8 mM Na2HPO4.7H2O, 2 mM KH2PO4, pH 7.4) and resuspended in 500µl of
PBS. Aliquots of the cells inoculated into mice were analyzed by Western blotting
to verify the expression of MMTV proteins. XC cells stably transfected with
pHYB-MTV (XC/HYB-MTV) were induced for 24 hr before injection into mice by
supplementing the culture medium with 10−6 M dexamethasone (Sigma Chemical
Laboratories, St. Louis, MO).
BALB/cJ and BALB/Mtv-null pups were foster-nursed on exogenous
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MMTV(C3H)+ C3H/HeN females by substituting them for some age-matched
C3H/HeN pups within 24 hr of birth. All injected and foster-nursed females were
bred regularly to stimulate lactogenic hormones.
2.3 Cell lines
Jurkat human T-cell leukemia line (clone E6-1) [456] was obtained from
American Type Culture Collection (ATCC) (Manassas, VA) and maintained in
complete medium containing RPMI medium (Gibco®, Invitrogen Corporation,
Carlsbad, CA) supplemented with 7.5% (v/v) heat-inactivated (30 min at 56°C) fetal
bovine serum (FBS) (Gibco®, Invitrogen Corporation), 2 mM L-glutamine (Gibco®,
Invitrogen Corporation), 50µg/ml gentamicin sulfate (Abbott Laboratories, North
Chicago, IL), 100µg/ml streptomycin (Gibco®, Invitrogen Corporation), and 100
U/ml penicillin (Gibco®, Invitrogen Corporation). The HC11 normal murine
mammary epithelial cell line derived from BALB/c mice [28] were obtained
from Dr. Jeff Rosen (Baylor College of Medicine, Houston, TX). This cell line
was maintained in complete medium containing RPMI supplemented with 10%
(v/v) heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100µg/ml
streptomycin, 50µg/ml gentamicin sulfate, 0.5µg/ml insulin, and 0.5µg/ml
epidermal growth factor (Invitrogen Corporation). XC/HYB-MTV cells are a
rat fibroblast cell line [418] stably transfected with the hybrid proviral clone of
MMTV, pHYB-MTV [403]. The derivation of these stable transfectants has been
described previously [316]. Briefly, XC cells were co-transfected with 5µg of
CsCl-purified pHYB-MTV and 0.05µg of the plasmid, pTR174, expressing the
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hygromycin resistance cassette, using 10µl of DMRIE-C (Invitrogen Corporation).
Transfections were performed in triplicate using six-well plates, and the cells were
selected in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco®, Invitrogen
Corporation) containing 7.5% (v/v) heat-inactivated FBS, 100 U/ml penicillin, 100
µg/ml streptomycin, 2 mM L-glutamine, and 500µg/ml hygromycin B (Invitrogen
Corporation) until discrete colonies were established. The colonies in the three
wells were pooled, expanded, and maintained in DMEM substituted with 5%
(v/v) heat-inactivated FBS, 100 U/ml penicillin, 100µg/ml streptomycin, 50µg/ml
gentamicin sulfate, 2 mM L-glutamine, and 250µg/ml hygromycin B (Invitrogen
Corporation). XC/HYB-MTV cells were treated with 10−6 M dexamethasone for
24 hr to induce MMTV production prior to inoculation into mice. The BALB/c
derived B-cell lymphoma line, A20 [221], (obtained from Dr. Bridget Huber, Tufts
University, Boston, MA) was maintained in RPMI medium supplemented with 10%
(v/v) heat-inactivated FBS, 100 U/ml penicillin 100µg/ml streptomycin, 50µg/ml
gentamicin sulfate, 2 mM L-glutamine and 50µM β-mercaptoethanol. All cell
lines were grown in a humidified incubator maintained at 37°C and 7.5% CO2.
2.4 Plasmid preparation
2.4.1 Large-scale plasmid preparation
Large-scale plasmid preparations were performed by alkaline lysis and
CsCl/ethidium bromide equilibrium centrifugation as described by Sambrooket al.
[383]. Briefly, 500 ml of Luria-Bertani (LB) broth (1% tryptone w/v, 0.5% yeast
extract w/v, 0.5% NaCl w/v, pH 7.4) was inoculated with 20 ml of an overnight
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culture of the bacterial transformant grown in LB broth supplemented with the
appropriate antibiotic. The culture was incubated at 37°C with aeration by shaking
at 250 rpm to density equivalent to an A600 (absorbance at 600 nm) of 1.2. Freshly
prepared chloramphenicol solution in 100% ethanol was added to the culture to a
final concentration of 170µg/ml followed by overnight incubation at 37°C with
aeration (shaking at 250 rpm). Bacteria were collected by centrifugation at 6000
rpm for 10 min at 4°C using the JA-10 rotor in the Avanti®-JE centrifuge (Beckman
Coulter Inc., Fullerton, CA). The bacterial pellet was thoroughly resuspended
in 7 ml solution I (50 mM glucose, 25 mM Tris-HCl, pH 8.0, 10 mM EDTA)
followed by transfer to a 50 ml conical tube. Bacterial lysis was performed by
adding 1 ml lysozyme solution to a final concentration of 2 mg/ml followed by
a 10 min incubation at room temperature. The solution was mixed with 16 ml
of freshly prepared solution II (0.2 N NaOH, 1% w/v SDS) and incubated at room
temperature for 10 min. The lysate was neutralized with 12 ml cold solution III (3 M
potassium acetate solution) followed by thorough mixing and a 10 min incubation
at 4°C. The suspension was centrifuged at 3800 rpm for 30 min at 4°C in the 243
swinging bucket rotor of the IEC Centra CL3R centrifuge (International Equipment
Company, Needham Heights, MA). The supernatant was transferred to a 50 ml
conical tube, and nucleic acids were precipitated after a 20 min incubation with
0.6 volume of isopropanol at room temperature. Precipitated nucleic acids were
recovered by centrifugation at 3800 rpm for 30 min at 25°C in the IEC Centra
CL3R centrifuge. The pellet was washed once with 10 ml of 70% ethanol, air-dried
for 5 min, and resuspended in 3.5 ml of TE 10:10 (10 mM Tris-HCl, pH 7.4 and
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10 mM EDTA, pH 8.0). CsCl (4.6 g) was dissolved into this suspension followed
by the addition of 680µl of ethidium bromide solution [5 mg/ml]. The suspension
was centrifuged at 3800 rpm for 15 min at 4°C in the IEC Centra CL3R centrifuge.
The supernatant was transferred to an OptiSeal™ ultracentrifuge tube (Beckman
Coulter Inc.) and centrifuged at 50,000 rpm for 18 hr at 20°C in the NVT 65.2 near
vertical tube rotor using the L7 centrifuge (Beckman Coulter Inc.). The plasmid
DNA band was transferred to a 15 ml conical tube using a 5 ml syringe and an 18
gauge needle. The ethidium bromide was extracted 3 to 4 times with 2 volumes
of G50 buffer [10 mM Tris-HCl, pH 7.4, 0.1 M NaCl, 2 mM EDTA] saturated n-
butanol. Two volumes of TE 10:10 were added, and the solution was adjusted to
0.2 M NaCl prior to addition of 2 volumes of cold 100% ethanol. After 15 min
incubation at 4°C, the DNA was recovered by centrifugation at 2850 g for 30 min
at 4°C in the IEC Centra CL3R centrifuge. Following a 70% ethanol wash and 5
min of air-drying, the pellet was resuspended in 2 ml of TE 10:10. Contaminating
RNA was removed by incubation with 100µg/ml pancreatic RNase A (Sigma) and
200 units of RNase T1 (Sigma) at 37°C for 30 min. The solution was incubated
with 100µg/ml of proteinase K (Sigma) in the presence of 0.5% SDS for 30 min
at 37°C. Following phenol:chloroform extraction, the solution was dialyzed using a
10,000 molecular weight cut-off (MWCO) Slide-A-Lyzer® dialysis cassette (Pierce,
Rockford, IL) against TE 10:1 with 3 buffer changes. Plasmid DNA was recovered
by ethanol precipitation and resuspended in TE 10:0.1 following a 70% ethanol
wash.
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2.4.2 Small-scale plasmid preparation
Small-scale plasmid preparation was performed according to the alkaline
lysis protocol described by Sambrooket al. [383]. Bacterial cultures were grown
overnight at 37°C by shaking at 250 rpm in 2 ml LB broth supplemented with the
appropriate antibiotic. Bacteria were collected from 1.5 ml of the culture transferred
into a 1.8 ml Eppendorf tube by centrifugation at 13,000 rpm for 2 min at room
temperature in the Sorvall® Biofuge pico centrifuge (Kendro Laboratory Products,
Asheville, NC). The bacterial pellet was resuspended in 250µl of solution I (50
mM glucose, 25 mM Tris-HCl, pH 8.0, 10 mM EDTA) containing 100µg/ml
pancreatic RNase A followed by lysis with 250µl of freshly prepared solution II
(0.2 N NaOH, 1% SDS) and neutralization with 350µl of cold solution III (3 M
potassium acetate solution). The lysate was centrifuged at 13,000 rpm for 10 min at
room temperature. The supernatant was transferred to a 1.8 ml Eppendorf tube and
600µl of isopropanol was added to precipitate the nucleic acids, which were then
recovered by centrifugation at 13,000 rpm for 15 min at room temperature. The
pellet was washed with 70% ethanol, air-dried for 5 min and resuspended in 50µl
of TE 10:0.1.
2.5 Plasmids
pHYB-TBLV. The TBLV molecular clone, pHYB-TBLV, (made by Dr.
Jaquelin Dudley) was constructed by substituting theClaI to SstI region of the
3’ LTR of pHYB-MTV with the corresponding region from the TBLV LTR. The
gel purifiedClaI to SstI fragment of the plasmid pTBLV-LUC [286] containing
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the TBLV enhancer triplication was ligated to a gel-purified fragment of pHYB-
MTV [403] that had been digested completely withSstI and partially withClaI.
After transformation of DH5α cells, the 3’ LTR of the MMTV provirus containing
the TBLV enhancer region was recovered in the plasmid backbone of pHYB-MTV
(pTBLV 3’PRO). pTBLV 3’PRO was digested to completion withClaI and treated
with alkaline phosphatase. The phosphatase-treated fragment was ligated to a
gel-purified 9.2 kb fragment containing the majority of the pHYB-MTV provirus
obtained after complete digestion of pHYB-MTV withSstI and partial digestion
with ClaI. Following transformation of DH5α and screening, a full-length proviral
clone (pHYB-TBLV) was obtained.
The hygromycin resistance cassette within the 1.5 kbXhoI fragment from
pUHD15-1-Hygro (-) (kindly provided by Dr. Paul Bates) was introduced at the
NheI site of both pHYB-TBLV and pHYB-MTV (by Dr. Farah Mustafa).
pHYB-TBLVsagDFS. This plasmid (made by Dr. Farah Mustafa) was
prepared by introducing frameshift mutations at theAvrII and ClaI restriction
enzyme sites in the 3’ LTR of pHYB-TBLV. TheClaI site within the TBLV LTR in
the plasmid pTBLV-LUC was digested, and the ends were repaired using Klenow
DNA polymerase. The resulting linearized plasmid was re-ligated and digested
with AvrII andSstI. The 0.6 kb fragment obtained from this digestion was ligated to
the 16 kb fragment of pHYB-TBLV digested withAvrII and SstI. The resulting
clone was then digested withAvrII, the overhangs were repaired using Klenow
DNA polymerase, and the linearized plasmid was re-ligated to generate the plasmid
pHYB-TBLVsagDFS.
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pTBLVsagDFS-LUC. The 3’ LTR of pHYB-TBLVsagDFS was amplified
by PCR using KlenTaq polymerase (AB Peptides, St. Louis, MO) with the
primers (Table 2.1) TBLVENV8509(+) containing aBglII restriction site and
MMTVLTR1302(-) containing anNheI restriction site. The product was gel
purified using the QIAquick gel extraction kit (Qiagen Inc., Valencia, CA) and
digested withBglII and NheI followed by repair of the overhangs using Klenow
DNA polymerase. This PCR product was ligated to the promoterless firefly
luciferase (LUC) expression construct, p19LUC [444], which had been digested
with HindIII and treated with Klenow DNA polymerase followed by removal of the
5’ phosphate groups with alkaline phosphatase.
pMTVAflE-LUC and pMTVStuE-LUC. The TBLV T-cell enhancer was
amplified by PCR using KlenTaq polymerase from pTBLV-LUC with the primers
(Table 2.1) TBLVENHAlu(+) and TBLVENHAlu(-). The product was gel purified
using the QIAquick gel extraction kit and digested withAluI followed by gel
purification. The pMTVAflE-LUC plasmid was obtained by ligating this PCR
product with the gel purified pMTV-LUC plasmid (previously described as pC3H-
LUC [52, 286]) that had been digested withAflII followed by subsequent treatments
with Klenow DNA polymerase and alkaline phosphatase. The product also was
ligated with the gel purified pMTV-LUC plasmid that had been digested withStuI
and treated with alkaline phosphatase to generate pMTVStuE-LUC.
pMTV∆NRE-LUC. The construction of this plasmid (previously termed
pd6) has been described [286].
pRL-TK. This plasmid (obtained from Promega, Madison, WI) contains the
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herpes simplex virus (HSV) thymidine kinase (TK) promoter upstream of the sea
pansy (Renilla reniformis) luciferase gene.
pHYB-MTVAflE, pHYB-MTVStuE, and pHYB-MTV∆NRE. The AvrII
to SstI fragments of the corresponding LTRs were obtained from pMTVAflE-
LUC, pMTVStuE-LUC, and pMTV∆NRE-LUC. These gel purified fragments
were individually substituted for theAvrII to SstI fragment within the 3’ LTR of
the pHYB-MTV plasmid containing the hygromycin resistance cassette.
All restriction enzymes and Klenow DNA polymerase were purchased
from New England Biolabs (NEB) (Beverly, MA). T4 DNA ligase used for
ligation reactions was purchased from Invitrogen Corporation. Calf intestinal
alkaline phosphatase was obtained from Roche (Basel, Switzerland) and Promega
(Madison, WI). All primers were synthesized by Integrated DNA Technologies
(IDT), Coralville, IA. All selected clones were confirmed by sequencing at the
Institute for Cellular and Molecular Biology (ICMB) DNA sequencing facility at
the University of Texas at Austin.
2.6 Stable transfections
Jurkat/HYB-TBLV and Jurkat/HYB-TBLVsagDFS cell lines (made by
Dr. Farah Mustafa [317]) were obtained by transfecting Jurkat T cells with
2 µg of pHYB-TBLV or pHYB-TBLVsagDFS plasmids (purified by the CsCl
method described in Section 2.4) using Superfect (Qiagen Inc.) according to the
manufacturer’s instructions. The cells were plated in 6-well plates and transfected
in triplicate. Stably transfected cells were selected in 0.2 mg/ml hygromycin B
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(Invitrogen Corporation) in complete medium five days following transfection.
Stably transfected cells arising in the triplicate wells were pooled, expanded and
maintained in complete medium supplemented with 0.2 mg/ml hygromycin B.
Jurkat T cells that stably express HYB-MTV, HYB-MTVAflE, HYB-
MTVStuE, or HYB-MTV∆NRE (termed Jurkat/HYB-MTV, Jurkat/HYB-MTVAflE,
Jurkat/HYB-MTVStuE, and Jurkat/HYB-MTV∆NRE, respectively) were obtained
by electroporation of CsCl-purified plasmid preparations. Jurkat cells (split in a 1:3
ratio one day prior to electroporation) were resuspended in complete medium at
2.5×107 cells/ml. The cell suspension was aliquoted (400µl) into electroporation
cuvettes (BTX Instrument Division, Harvard Apparatus Inc., Holliston, MA) with a
4 mm gap size with 30 to 40µg of purified plasmid DNA. The cells were incubated
with the DNA for 10 min at room temperature and then subjected to electroporation
at 1050µF, 720 ohms, and 260 V using the BTX Electro Cell Manipulator (ECM)
600 (Harvard Apparatus Inc.). Each plasmid was electroporated in triplicate.
Following a 10 min rest at room temperature, the cells were plated in 6 ml of
complete medium in 60 mm Petri dishes. At 48 hr post-transfection, cells from
the triplicate transfections were pooled and plated in a 100 mm Petri dish in 20
ml complete medium supplemented with 250µg/ml hygromycin B and, cultured
for three weeks in the presence of hygromycin B. These cells were subsequently
maintained in hygromycin B-containing complete medium. A portion of the pooled
cell population was used to prepare DNA and analyzed by PCR to confirm the
identity of the proviral integrants. Western blotting and reverse transcription (RT)-
PCR (followed by sequencing) was used to assess the expression of the viral
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proteins and mRNA, respectively.
A20/HYB-MTV stable transfectants were obtained by electroporation of
A20 cells with 20µg of the plasmid pHYB-MTV that contains the MMTV
molecular clone [403] and a hygromycin resistance cassette (provided by Dr.
Farah Mustafa). Electroporation was performed in triplicate using the BTX ECM
600. Twenty four hours prior to electroporation, A20 cells were plated at a
density of 6×105 cells/ml. For electroporation, the cells were washed once with
RPMI medium, and resuspended to 3.8×107 cells/ml in RPMI. DNA purified
by CsCl method was added to 400µl of the cell suspension and placed in a
sterile 4 mm cuvette (BTX Instrument Division, Harvard Apparatus, Inc.). The
cell suspension was incubated at 25°C for 10 min and then electroporated at 280
V, 975 µF, and 72 ohms. Following electroporation, the cells were incubated
on ice for 10 min and then plated in 6 ml complete medium in 60 mm Petri
dishes. At 48 hr post-transfection, cells from the triplicate transfections were
pooled and plated in 20 ml of fresh complete medium supplemented with 400µg/ml
hygromycin B (Invitrogen Corporation) in a 100 mm Petri dish for three weeks.
The concentration of hygromycin B was determined by the survival of A20 cells in
different concentrations of the drug.
2.7 Transient transfections
All plasmids used for transfection were prepared by the CsCl method. Jurkat
T cells (split at a 1:3 ratio one day prior to transfection) were transiently transfected
in triplicate using Superfect (Qiagen) according to the manufacturer’s instructions.
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Six-well plates were plated with 2.5×106 Jurkat cells/well in 2.5 ml complete
medium. The transfection mix/well of the six-well plate was prepared in 75µl
of RPMI by adding 2µg of the LTR-LUC reporter plasmid (pTBLVsagDFS-LUC,
pMTV-LUC, pTBLV-LUC, pMTVAflE-LUC, pMTVStuE-LUC, or pMTV∆NRE-
LUC), 0.1 µg of the co-transfectant pRL-TK, and 10µl of Superfect. The
transfection mix was incubated at room temperature for 10 min and then applied
drop-wise to the well. The six-well plate was swirled to evenly distribute the
transfection mix and incubated at 37°C in 7.5% CO2. The firefly andRenilla
luciferase activities were measured 48 hr post-transfection.
HC11 cells were transfected twice in triplicate with 10µg of the LTR-
LUC plasmids [pMTV-LUC, pTBLV-LUC, pMTVAflE-LUC, pMTVStuE-LUC,
or pMTV∆NRE-LUC] and 2µg of pRL-TK by electroporation using the BTX
ECM 600 electroporator. HC11 cells (split 1:3 one day prior to transfection) were
trypsinized, washed once with RPMI, and resuspended in RPMI at 5×107 cells/ml.
Plasmids were then added to 200µl aliquots of cells placed in 2 mm electroporation
cuvettes. The DNA was mixed with the cells and incubated at room temperature
for 10 min. The cells were then electroporated at 1750µF, 140 V, and 72 ohms.
Following 10 min at room temperature, the cells were plated in 5 ml of complete
medium in 60 mm tissue-culture dishes and incubated at 37°C in 7.5% CO2. At 24
hr post-transfection,10−6 M dexamethasone (DEX) was added to a triplicate set of
transfections, while the other triplicate set was maintained without DEX induction.
All cells were harvested at 48 hr post-transfection and assayed for firefly andRenilla
luciferase activities.
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2.8 Reporter gene assay
Firefly andRenilla luciferase luminescence was measured with the Dual-
Luciferase® Reporter Assay System (Promega) according to the manufacturer’s
instructions. Briefly, cells were washed twice in PBS and lysed in 50µl of
passive lysis buffer by 3 cycles of freezing and thawing. The lysate was clarified
by centrifugation at 13,000 rpm for 1 min at room temperature, and the protein
concentration was measured by the Bradford method [51] using the Bradford
protein assay reagent from Bio-Rad Laboratories (Hercules, CA). Forty micrograms
(20 µl) of the lysates were assayed for the firefly andRenilla luciferase activities
using the TD-20e Luminometer (Turner Designs, Inc., Sunnyvale, CA). The firefly
luciferase activity of each sample was normalized for DNA uptake by dividing by
theRenilla luciferase activity in the same sample. The normalized firefly luciferase
activity in each sample was then re-calculated relative to the normalized firefly
luciferase activity from the wild-type MMTV LTR (assigned a value of 1). The
mean (± standard deviation) derived from the triplicate relative firefly luciferase
activities of each plasmid was plotted.
2.9 Preparation of retrovirus containing culture supernatants
Retrovirus-containing culture supernatants were prepared by growing
Jurkat/HYB-MTV, Jurkat/HYB-TBLV or Jurkat/HYB-TBLVsagDFS cells at a high
density [1-2×107 cells/ml] for 18 hr in complete medium lacking hygromycin B.
The cells were removed by centrifugation at 3800 rpm for 15 min at 4°C in
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the IEC Centra CL3R centrifuge. The retrovirus containing supernatant was
stored at -85°C in aliquots. In some instances, the retroviral supernatant was
further concentrated by centrifugation at 20,000 rpm for 1.5 hr at 4°C in ethanol-
sterilized Ultra-Clear centrifuge tubes using the SW 55 Ti rotor in the L7 centrifuge
(Beckman Coulter Inc.). The supernatant was discarded, and the pellet was
resuspended overnight with shaking at 4°C in complete medium at 1/100th of the
original volume of the culture supernatant. Culture supernatants from 485-10 cells
were obtained from a laboratory stock.
2.10 SDS-PAGE and Western blotting
Cells were washed twice in PBS followed by lysis in 50 to 100µl of
RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% v/v Triton-X100, 1%
v/v sodium deoxycholate, 0.1% SDS) that was supplemented with 50µl/ml β-
mercaptoethanol (Sigma-Aldrich Corporation), 1µl/ml aprotinin (Sigma-Aldrich
Corporation), and 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich
Corporation). The cell lysate was pelleted at 13,000 rpm for 10 min at 4°C, and the
protein concentration in the supernatant (whole cell lysate) was measured using the
Bradford protein assay reagent from Bio-Rad Laboratories [51]. Loading buffer
[6X: 0.35 M Tris-HCl, pH 6.8, 10.28% (w/v) SDS, 30% (v/v) glycerol, 0.6 M
dithiothreitol, 0.012% (w/v) bromophenol blue] was added at a final concentration
of 3X to the whole cell lysate containing 100, 50, or 20µg of protein prior to
boiling for 2 min. For Western blot analysis of virions in the culture supernatants,
3X loading buffer was used for varying volumes of the culture supernatants and
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boiled for 2 min. The proteins were resolved on 8% SDS-PAGE gels according
to the protocol described by Sambrooket al. [383] and transferred at 150 mA to
nitrocellulose membranes (Schleicher and Schuell, Keene, NH) overnight at 4°C in
Western transfer buffer (39 mM glycine, 48 mM Tris base, 1% (w/v) SDS, 20%
(v/v) methanol). The membrane was blocked with TBST [20 mM Tris-HCl, pH
7.6, 137 mM NaCl, 0.05% (v/v) Tween-20] containing 10% (w/v) nonfat milk for 1
hr at room temperature on a rotary shaker. The membrane was then incubated with
the primary antibody [MMTV CA-specific mouse monoclonal antibody (MAb)
[350] or actin-specific goat antiserum diluted 1:50 or 1:500, respectively, in TBST
containing 1% (w/v) nonfat milk] for 1 hr at room temperature on a rotary
shaker. The membrane was then subjected to three washes with TBST (10 min
each) and incubated with horseradish peroxidase (HRP) conjugated secondary
antibody [anti-mouse immunoglobulin G (heavy + light chain), IgG(H+L), or goat
immunoglobulin-specific antibody] (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA), diluted 1:8000 in TBST containing 1% (w/v) nonfat milk, for
1 hr at room temperature on a rotary shaker. The membrane was washed thrice
for 10 min each with TBST, and the antibody bound protein bands were visualized
by Western Lightning enhanced chemiluminescent (ECL) reagent (Perkin Elmer,
Wellesley, MA) according to the manufacturer’s instructions.
The specificity of MMTV-specific mouse antisera was determined by
Western blotting against purified MMTV virions [National Institutes of Health
(NIH), Bethesda, Maryland]. MMTV virions (750µg) were boiled in an equal
volume of 6X loading buffer, separated on a preparative 8% SDS-PAGE gel, and
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the proteins were transferred to a nitrocellulose membrane. The membrane was
blocked with TBST containing 10% (w/v) nonfat milk for 1 hr prior to use in a
Mini-PROTEAN II multiscreen apparatus (Bio-Rad Laboratories). Mouse serum
dilutions [1:20 in 200µl of TBST containing 1% (w/v) nonfat milk] were applied
to the membrane through the channels and incubated for 2 hr at 25°C on a rotary
shaker. As positive controls for the Western analysis, 200µl of a 1:50 dilution
[in TBST containing 1% (w/v) nonfat milk] of MMTV CA- and SU-specific
monoclonal antibodies were also applied to the membrane. The membrane was
washed twice with TBST before release from the multiscreen apparatus. Following
three more washes with TBST, the membrane was incubated with HRP-conjugated
secondary antibody [anti-mouse IgG(H+L)] diluted 1:8000 in TBST containing 1%
(w/v) nonfat milk. Following a 1 hr incubation with shaking at room temperature,
the membrane was washed thrice with TBST, and the antibody-bound protein bands
were visualized using the Western Lightning ECL reagent (Perkin Elmer).
2.11 Flow cytometry
Peripheral blood lymphocyte (PBL) analysis. Mice were bled from their
retro-orbital sinus at three-month intervals. PBLs were isolated from 200µl of
blood that was layered on 500µl of Histopaque mixture containing a 1:1.21 ratio of
Histopaque 1119-1 and Histopaque 1077-1 (Sigma) followed by centrifugation at
1000 g for 20 min at 25°C. The PBLs were washed with cold fluorescence activated
cell sorting (FACS) wash buffer (FWB) containing PBS supplemented with 2.5%
(v/v) heat-inactivated FBS and 0.1% (w/v) sodium azide. Cells were collected by
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centrifugation at 450 g for 10 min at 4°C, and the pellet was resuspended in 30µl of
FWB. The cell suspension was distributed into the required number of aliquots in
alternate wells of a round bottom 96-well tissue culture plate and incubated in the
dark for 30 min on ice with 100µl of the antibody solution containing an optimal
dilution (determined experimentally) of the MAb in FWB. Following antibody
labeling, the cells were washed thrice with 200µl of cold FWB, resuspended in
150µl FWB, and analyzed on the FACSCalibur flow cytometer (Becton Dickinson,
Franklin Lakes, NJ) using CELLQuest software. In some instances, the labeled
cells were washed thrice with 200µl of PBS before fixation in 200µl of 1%
paraformaldehyde in PBS and stored at 4°C until analysis.
For estimating the proportion of Sag-reactive T cells, the PBLs were dually
stained for cell surface markers CD4 and TCR Vβ3, -5, -7, -8, -12 or -14 using
phycoerythrin (PE) conjugated anti-mouse CD4 MAb (RM4-5) and fluorescein
isothiocyanate (FITC)-conjugated anti-mouse TCR Vβ3 (KJ25), Vβ5.1 and 5.2
(MR9-4), Vβ7 (TR310), Vβ8.1 and 8.2 (MR5-2), Vβ12 (MR11-1) or Vβ14 (14-2)
MAbs from PharMingen (San Diego, CA). The percentage of TCR Vβ+ cells in the
gated CD4+ T-cell population was calculated. Multiple animals were analyzed for
each time point. The average percentage (± standard deviation) of CD4+TCR Vβ+
T cells was plotted.
Tumor cell population analysis. Single cell suspensions prepared from
tumor samples were labeled for cell surface markers CD4, CD8α and Thy1.2 using
PE-conjugated MAb against mouse CD4 (RM4-5), CyChrome-conjugated MAb
against mouse CD8α (53-6.7), and FITC-conjugated MAb against mouse Thy1.2
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(53-2.1) from PharMingen. The cells were analyzed on the FACSCalibur Flow
Cytometer using CELLQuest software.
2.12 Genomic DNA preparation
Tissue fragments were incubated in 2 to 3 ml and cell lines were incubated
in 1 ml of lysis buffer (100 mM NaCl, 10 mM Tris-HCl, pH 8.0, 25 mM EDTA,
pH 8.0, 0.5% w/v SDS, 100µg/ml fresh proteinase K) at 55°C for 1 to 2 days.
If the lysates were very viscous, additional proteinase K and lysis buffer were
added during this incubation. The lysates were then extracted once or twice with
phenol/chloroform, and the aqueous phase was collected in a separate tube. DNA
was precipitated using ethanol and the genomic DNA was spooled out into an
Eppendorf tube using a Pasteur pipette. The DNA was washed with 70% ethanol,
resuspended in TE 10:0.1, and stored at 4°C.
2.13 Southern blotting
Southern blotting was performed as described previously [288]. Genomic
DNA (15 µg) was digested overnight with the appropriate restriction enzyme
(HindIII for clonality analysis of lymphomas andPstI for determining the LTR
structure of proviruses in virus-induced tumors) according to the manufacturer’s
(NEB) recommendation. The digested DNA was subjected to electrophoresis
on a 0.8% agarose gel, photographed following ethidium bromide staining, and
then subjected to depurination in 0.125 M HCl for 15 min. After rinsing with
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water the DNA was subjected to denaturation for 30 min in a solution containing
0.5 M NaOH and 1.5 M NaCl followed by neutralization in a solution of 1.5
M NaCl and 0.5 M Tris-HCl, pH 7.0. The DNA was transferred overnight
and subjected to UV crosslinking on a nitrocellulose membrane (HYBOND™-
XL) (Amersham Biosciences, Piscataway, NJ). The membrane was incubated at
42°C in 7 ml of hybridization buffer containing 5X SSPE [0.9 M NaCl, 0.05
M NaH2PO4, 0.05 M EDTA], 50% v/v formamide, 0.5% w/v SDS, 100µg/ml
salmon sperm DNA, 100µg/ml yeast RNA and 5X Denhardt’s solution [1X: 1 g/l
Ficoll, 1 g/l polyvinylpyrrolidone, 1 g/l bovine serum albumin - pentox fraction V].
Radioactively labeled probes were prepared by random priming using hexameric
primers extended by Klenow DNA polymerase using a deoxyribonucleotide
triphosphate (dNTP) mix containing32P-dCTP (Perkin Elmer). Previously
described probes [288] p86T5β and Cγ1.2 were used for assessing the clonality
of T-cell tumors based on TCRβ andγ chain rearrangements, respectively. The
LTR structure of proviruses in virus-induced tumors was determined using labeled
probes prepared from the entire MMTV LTR (released from pMTV-LUC byHindIII
digestion) and the MMTV NRE (theStuI to AflII fragment of the MMTV LTR).
The membranes were incubated overnight at 42°C with 4.8 ml of the hybridization
buffer containing 10 ng/ml of the probe labeled to a specific activity of ca.108
cpm/µg. The membranes were washed five to six times with buffer containing 2X
to 0.1X SSC (20X SSC: 3 M NaCl, 0.3 M sodium citrate) and 0.1% w/v SDS and
subjected to autoradiography.
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2.14 Polymerase chain reaction (PCR)
Genomic DNA (1 µg) isolated from Jurkat/HYB-MTV, Jurkat/HYB-
MTVAflE, Jurkat-HYB-MTVStuE, and Jurkat/HYB-MTV∆NRE was subjected to
PCR analysis using KlenTaq DNA polymerase according to the manufacturer’s
instructions. The following primer (Table 2.1) pairs were used for the PCR analyses
- LTR403(+) with C3HLTR978(-); C3HLTR961(+) with MMTVLTR1302(-); and
C3HLTR727(+) with MMTVLTR1302(-). All primers were synthesized by IDT.
The PCR products were gel purified using the QIAquick gel extraction kit and
verified by sequencing.
The presence and identity of endogenousMtvs in mice was determined by
PCR as described previously [31]. Briefly, genomic DNA was isolated from tail
clips of individual mice according to a previously described protocol [31], and
endogenousMtv sequences were amplified by priming from the variable portion
of the MMTV LTR and/or the DNA sequences flanking the proviruses. Initial PCR
assays were performed using PCR Supermix (Gibco BRL, Gaithersburg, MD) and
was subsequently replaced with JumpStart REDAccuTaq™ LA DNA polymerase
(Sigma-Aldrich Corporation) according to protocols specified by the manufacturer.
2.15 RNA preparation
RNA was prepared according to the guanidine isothiocyanate method
described by Chomczynski and Sacchi [83]. Mouse tissue was homogenized
in the appropriate volume (100 mg tissue/ml) of TRI reagent [2 M guanidine
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Table 2.1.Primers used for cloning, PCR, and RT-PCR analyses.
Primer Sequence
TBLVENV8509(+) 5’ AGCCTTGACCAAGTGCAGTCAGATCTTAACGTG 3’
MMTVLTR1302(-) 5’ GACTAGGCTAGCTGCCGCAGTCGGCCGACCTGAGGG 3’
TBLVENHAlu(+) 5’ AATAGAAAGAGACGCTCAAGCT 3’
TBLVENHAlu(-) 5’ GTCTCACAAGCTTGTTTTAA 3’
LTR403(+) 5’ CCAATAGGTAGATTATTAGTTACT 3’
C3HLTR978(-) 5’ AGGTTGGGCCAATAAAGGCTATTCA 3’
C3HLTR961(+) 5’ CCTTTATTGGCCCAACCTT 3’
C3HLTR727(+) 5’ AAAGTGTTATATAGATCCCTCCC 3’
C3HLTR501(-) 5’ GAGGTTGAGCGTCTCTTTCTATT 3’
C3HLTR501(+) 5’ AATAGAAAGAGACTCTCAACCTC 3’
C3HLTR1074(-) 5’ AACACTCAGAGCTCAGATCAGAACC 3’
TBLVLTR786(-) 5’ CACTCAGAGCTCAGATCAGAAC 3’
gag79(+) 5’ TCATGTGAAAGAGAGTAGTGCAATAGAA 3’
gag461(-) 5’ ATCTGCCTTCTCCTTTTCTTCATATGGTTC 3’
C3H230(+) 5’ CATCACAAGAGCGGAACGGAC 3’
env796(-) 5’ GCTTATCTACTTGAAAGCAGCCT 3’
GAPDH427(+) 5’ CATGTTTGTGATGGGTGTGAACCA 3’
GAPDH983(-) 5’ GTTGCTGTAGCCGTATTCATTGTC 3’
isothiocyanate, 12.5 mM sodium citrate, pH 7.0, 0.25% sarkosyl, 0.05 Mβ-
mercaptoethanol, 0.2 M sodium acetate, pH 5.2, and 50% phenol, pH 7.5, saturated
with diethyl pyrocarbonate (DEPC)-treated water] using a Kinematica Polytron
homogenizer (Brinkmann, Westbury, NY). The homogenate was centrifuged at
2850 g for 20 min at 4°C in the IEC Centra CL3R centrifuge, and the supernatant
was transferred to a 15 ml conical tube. The phase separation reagent, 1-bromo-
3-chloropropane (BCP), (Molecular Research Center, Inc., Cincinnati, OH) was
added to a concentration of 100µl/ml of homogenate. The solution was vigorously
shaken, incubated for 15 min at room temperature, and subjected to centrifugation
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for 30 min at 2850 g (4°C). The aqueous phase was transferred to a fresh 15 ml
conical tube, and RNA was precipitated by adding isopropanol to a concentration
of 0.5 ml/ml of the original volume of TRI reagent. For isolation of RNA from
glycogen-rich tissues, like liver, RNA precipitation was performed with a 1:1
mixture of isopropanol and a salt solution (1.2 M NaCl, 0.8 M sodium citrate)
added to the aqueous phase at the concentration of 0.5 ml/ml of the original volume
of TRI reagent. After 10 min at room temperature, the RNA was collected by
centrifugation at 2850 g for 30 min at 4°C. The RNA pellet was washed once in
70% ethanol, air-dried, resuspended in DEPC-treated water and transferred to an
Eppendorf tube. DNA and low-molecular-weight RNA were removed by high-
salt precipitation of the RNA [332] by adding sodium acetate, pH 5.6, to a final
concentration of 3 M. The RNA was collected by centrifugation at 13,000 rpm
for 15 min at 4°C. The pellet was washed once with 70% ethanol, air-dried,
resuspended in DEPC-treated water and stored at -80°C. For longer periods, the
RNA was stored as an ethanol precipitate by adding 0.3 M sodium acetate and 2.5
volumes of cold 100% ethanol.
To extract RNA from cell lines, cells were disrupted in TRI reagent
(107 cells/ml) by repeated pipetting. The protocol detailed above was used for
purification of the RNA from the lysate. All solutions used for RNA preparation
and manipulation were treated overnight with 0.1% DEPC and autoclaved.
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2.16 Reverse transcription (RT)-PCR
Total RNA (20 µg) isolated from normal or malignant mouse tissue
or cell lines was treated with 3U of amplification grade DNase I (Invitrogen
Corporation) at 37°C for 30 min in the presence of an RNase inhibitor.
DNase I was inactivated using 2.5 mM EDTA and incubation at 68°C for
20 min. The RNA was incubated with 400 U of Moloney murine leukemia
virus (M-MLV) RT (Invitrogen Corporation) and poly-dT17 as primer in 50µl
as recommended by the manufacturer. Reactions without RT were performed
to verify the lack of DNA contamination. The resulting cDNA (5µl) or the
minus-RT reaction was used in a 50µl reaction containing 50 mM Tris-HCl
(pH 9.1), 16 mM ammonium sulphate, 3.5 mM MgCl2, 150 mg/ml BSA, 0.3
mM dNTPs, 100 ng or 20 pMol each of forward and reverse primers, and 2.5
units of KlenTaq. Forty cycles of amplification, including 1 min denaturation
at 94°C, annealing at 55°C for 1 min, and extension at 72°C for 1 min,
were performed in a PTC-100™ Programmable Thermal Controller (MJ Research
Inc., Reno, NV). The following primer (Table 2.1) pairs were used for RT-PCR
analyses of Jurkat/HYB-MTV, Jurkat/HYB-MTVAflE, Jurkat/HYB-MTVStuE,
and Jurkat/HYB-MTV∆NRE cells and tumor RNA - TBLVENV8509(+) with
C3HLTR501(-); C3HLTR501(+) with C3HLTR1074(-); C3HLTR727(+) with
C3HLTR1074(-); C3HLTR501(+) with C3HLTR978(-); TBLVENV8509(+) with
TBLVLTR786(-); and C3HLTR501(+) with TBLVLTR786(-). RT-PCR analysis of
MMTV-infected BALB/Mtv-null tissues was performed using the following primer
(Table 2.1) pairs: all MMTV cDNAs, TBLVENV8509(+) with C3HLTR501(-)
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and C3HLTR501(+) with C3HLTR1074(-); MMTVgag cDNA, gag79(+) with
gag461(-); MMTVenvcDNA, C3H230(+) with env796(-). As a control for RNA
integrity, RT-PCR amplification of glyceraldehyde-3-phosphate dehydrogenase
(gapd) mRNA was performed, as above, with 1µl of cDNA using primers (Table
2.1) GAPDH427(+) and GAPDH983(-). RT-PCR products were analyzed by
electrophoresis on 2% agarose gels. The expected RT-PCR products were purified
using QIAquick gel extraction kit and sequenced. In some instances, the gel-
purified RT-PCR products were cloned into pGEM®-T Easy vector (Promega)
according to the manufacturer’s instructions and then sequenced. All RT-PCR
primers were synthesized by IDT.
For some experiments, restriction fragment length polymorphisms (RFLPs)
were used to differentiate the RT-PCR products amplified from exogenous
MMTV(C3H) versus endogenousMtvs using the primers TBLVENV8509(+) and
C3HLTR501(-) (Table 2.1). RT-PCR products were purified through Micro Bio-
Spin P-30 columns (Bio-Rad Laboratories) and digested withClaI (NEB) for 2
hr at 37°C. An internal plasmid control forClaI digestion was included in each
reaction. The restriction digests were analyzed by electrophoresis on 2% agarose
gels. The expected fragments were gel purified and sequenced.
2.17 Mouse serum preparation
Mice were bled from their retro-orbital sinus and 200µl of non-heparinized
mouse blood was allowed to clot for 4 hr at room temperature. Samples were
incubated overnight at 4°C to allow clot retraction, and the serum was separated
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by centrifugation at 2750 g for 10 min at 4°C.
2.18 ELISA: Enzyme-linked immunosorbent assay
MMTV virion proteins were used to detect MMTV-specific antibodies
in mice sera using a previously described [350] ELISA protocol with some
modifications. All wells of Nunc-Immuno™ 96 Microwell™ Maxisorp ™ plates
(Nalge Nunc International, Rochester, NY) were coated with 10µg/ml of purified
MMTV virions (National Institutes of Health) in 50µl of borate buffered saline
(125 mM NaCl, 167 mM boric acid, pH 8.0) overnight at 4°C. The coating buffer
was then removed, and the wells were washed twice with the wash buffer [0.05%
(v/v) Tween-20 in PBS]. The excess wash buffer was removed by tapping the plates
and the wells were incubated for 2 hr at 37°C in a humid atmosphere with 150µl of
the blocking buffer [0.05% (v/v) Tween-20 and 1% (w/v) bovine serum albumin
(BSA) in PBS]. Two-fold sera dilutions (1:10, 1:20, 1:40, 1:80, 1:160, 1:320,
1:640) were prepared in 30µl of the dilution buffer [0.05% (v/v) Tween-20 and
0.25% (w/v) BSA in PBS] and added in duplicate columns of wells after removal
of the blocking buffer. The positive controls consisted of 30µl each of a 2-fold
dilution series (1:60, 1:120, 1:240, 1:480, 1:960, 1:1920, 1:3840) of the MMTV
CA-specific monoclonal antibody [350] added to duplicate columns of wells. The
last well of each column received 30µl of the dilution buffer alone. The plates
were incubated for 2 hr at room temperature and then washed thrice with the
wash buffer. The HRP-conjugated secondary antibody against mouse IgG(H+L)
(Jackson ImmunoResearch Laboratories, Inc.) (50µl at 1:8000 in dilution buffer)
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was added to each well and incubated for 1 hr at room temperature. The wells
were washed thrice with the wash buffer followed by three washes with PBS. Wells
then received 100µl of the substrate solution [phosphate/citrate buffer, pH 5.0 (50
mM Na2HPO4, 24 mM sodium citrate), 0.01% (w/v) 3,3’,5,5’-tetramethylbenzidine
dihydrochloride (Sigma-Aldrich Corporation), 6% H2O2], and the plates were
incubated in the dark at room temperature for 15 min. The enzyme reaction was
stopped by addition of 25µl of 2 M H2SO4 to each well followed by measurement
of absorbance at 450 nm. The antibody titer was calculated as the reciprocal of the
highest serum dilution that reacted specifically with the MMTV virions.
2.19 Vibrio choleraelethal dose 50 (LD50) assay
V. choleraestrain 0395 colonies were isolated on an L agar [1% (w/v)
tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 1.5% (w/v) agar] plate
supplemented with 67µg/ml streptomycin sulfate. A single colony was inoculated
into 3 ml of L broth containing 67µg/ml streptomycin sulfate and cultured
overnight at 37°C with shaking at 250 rpm. Subcultures (diluted 1:100) were
then established in 3 ml L broth without the antibiotic and allowed to grow to an
A650 of 0.5. This culture was estimated to contain approximately 5×108 colony
forming units (CFU)/ml of bacteria. A 1:10 dilution of the culture in PBS was
used to prepare 1 ml bacterial suspensions in PBS supplemented with 0.02% (w/v)
Evan’s blue dye containing 2×106 and 2×107 CFU/ml of bacteria. A suspension
containing 2×108 CFU/ml of bacteria was prepared by pelleting the bacteria from
the required volume of the original undiluted culture at 13,000 rpm for 2 min. The
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pellet was resuspended in PBS containing 0.02% (w/v) Evan’s blue dye. Each
bacterial suspension was then distributed into 1.8 ml Eppendorf tubes in 50µl
aliquots. BALB/cJ, BALB/Mtv-null and BALB/Mtv-SP pups (5 to 6 days old) were
intragastrically inoculated with 50µl of the bacterial suspension (dose = 105, 106
or 107 CFU) using a 1 ml syringe and a 23 gauge needle covered with a 1 inch long,
sterile intramedic polyethylene tubing after smoothing of the open end. The pups
were observed for 48 hr for death and morbidity. Serial dilutions were prepared
from the 3 bacterial suspensions used for mouse inoculations, and the appropriate
dilutions (100µl) were plated on L agar plates containing 67µg/ml streptomycin
sulphate. The CFU/ml of bacteria was then calculated according to the formula:
CFU/ml =
Number of colonies×Dilution factor × 1000µl
100µl
(2.1)
The LD50 of V. cholerae0395 was calculated as follows:
Table 2.2.Example dataset for LD50 calculation.
Dose N1 × 107 N2 × 106 N3 × 105
Dead/Live pups D7/L7 D6/L6 D5/L5
Total dead pups D1 = D7 + D6 + D5 D2 = D6 + D5 D3 = D5
Total live pups L1 = L7 L2 = L7 + L6 L3 = L7 + L6 + L5










Algorithm for calculating LD50:
1. From table 2.2 let P1 (> 0.5) and P2 (< 0.5) be
the proportions that bracket 0.5 (by inspection).
2. Let∆P = P1 − P2
3. LetδP2 = 0.5− P2
3. LetR = δP2∆P
4. Let (from Table 2.2)Ni × 10j be the lower bracket dose
5. LetS = R + j
6. LetT = antilog(S)
7. LetLD50 = Ni × T
In some cases, small intestines from the pups were recovered at 48 hr post-
inoculation and homogenized in 1 ml of PBS using Dounce homogenizers. A
dilution series was prepared from this homogenate and 100µl of the appropriate
dilutions were plated on L agar supplemented with 67µg/ml of streptomycin




3.1 Conversion of MMTV to a Lymphomagenic Virus
3.1.1 Overview
TBLV is an MMTV variant that causes thymic lymphomas, instead of
mammary tumors, in mice. Unlike the MMTV LTR, the TBLV LTR has a 443
bp deletion that eliminates the NREs and duplicates NRE-flanking sequences to
generate a T-cell enhancer. The deletion and substitution also truncate the TBLV
sag gene. Substituting a portion of the MMTV LTR U3 region in an infectious
MMTV clone (HYB-MTV) with a 438 bp segment (encompassing the deletion and
substitution) of the TBLV LTR produces a recombinant virus that induces thymic
lymphomas instead of mammary tumors in a Sag-independent manner. To evaluate
the role ofcis-acting LTR elements (NREs and the T-cell enhancer) in converting
MMTV to a lymphomagenic virus, mutant HYB-MTV proviruses were constructed
by inserting the TBLV T-cell enhancer in the 3’ LTR either at theStuI site upstream
of the NRE (HYB-MTVStuE) or at theAflII site downstream of the NRE (HYB-
MTVAflE). A third mutant provirus (HYB-MTV∆NRE) lacking the entire NRE
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and the flanking T-cell enhancer sequences in the 3’ LTR was also constructed.
Weanling BALB/cJ mice inoculated with HYB-MTV∆NRE developed a low
frequency of mammary tumors, while HYB-MTVAflE and HYB-MTVStuE had
similar incidences of both mammary tumors and thymic lymphomas. Expression
of the T-cell enhancer in proviruses from HYB-MTVAflE and HYB-MTVStuE-
induced lymphomas was confirmed by RT-PCR. In contrast, Southern analysis of
proviruses integrated in the lymphomas revealed that the NRE was retained in
HYB-MTV AflE proviruses, but deleted from HYB-MTVStuE proviruses. Transient
transfection assays in T cells demonstrated that the T-cell enhancer completely
masked the NRE activity when located downstream of the NRE (HYB-MTVAflE),
yet had only a partial effect when placed upstream of the NRE (MTVStuE LTR).
Thus, conversion of MMTV to a lymphomagenic virus requires two alterations in
the LTR - (i) acquisition of a T-cell specific enhancer and (ii) loss of NRE-mediated
transcriptional repression through either NRE deletion or by masking the NRE
activity via a T-cell enhancer.
3.1.2 TBLV lymphomagenesis is Sag-independent.
Yanagawaet al. [475] demonstrated that the tropism of the MMTV hybrid
provirus, HYB-MTV [403], could be altered by replacement of its 3’ LTR with
that from thymotropic MMTVs, DL-8 and MA. The resulting recombinant viruses,
DL-8 MMTV and MA MMTV, induced thymic lymphomas in 20 and 29% of adult
BALB/cJ mice with average latencies of 26 and 34 weeks, respectively. Although
this study established the critical role of the LTR in determining viral tumorigenesis,
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the contributions of the truncated Sag andcis-acting elements in the LTR relative to
the tissue specificity of tumorigenesis was not determined.
Therefore, TBLV-specific sequences from theClaI to SstI sites in the LTR
(438 bp), encompassing the NRE deletion and T-cell enhancer substitution [27,
286], were used to replace 756 bp from theClaI to SstI region of the pHYB-MTV
3’ LTR. This molecular clone has been called pHYB-TBLV (Figure 3.1) [317].
Frameshift mutations were introduced at theAvrII andClaI sites in the truncatedsag
gene of pHYB-TBLV to generate thesag-frameshift mutant, pHYB-TBLVsagDFS
(Figure 3.1). The frameshift mutations further truncate thesag gene in pHYB-
TBLVsagDFS to encode only the first 17 amino acids of Sag.
The frameshift mutations in pHYB-TBLVsagDFS are located within the
transcriptional regulatory sequences in the 3’ LTR. Therefore, the 3’ LTRs from
pHYB-TBLVsagDFS and pHYB-TBLV were inserted into a promoterless firefly
luciferase (LUC) expression vector [444] and transiently transfected into Jurkat T
cells. The LUC activity from the two LTRs did not differ significantly (Figure
3.2) suggesting that the frameshift mutations did not alter the LTR transcriptional
efficiency.
Subsequently, Jurkat T cells were stably transfected with either wild-
type or mutant hybrid TBLV proviruses (Jurkat/HYB-TBLV and Jurkat/HYB-
TBLVsagDFS). Jurkat T cells were chosen because of their high efficiency of
transfection and because the presence of the TBLV enhancer should induce
high levels of viral expression, thus allowing a high efficiency of infection and
tumorigenesis following inoculation into mice. Transfected cells then were tested
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Truncated TBLV Sag (165 aa)
Truncated TBLV Sag (17 aa)
Mtv1                             MMTV(C3H)
pHYB-MTV
AvrII ClaI  SstI
pHYB-TBLV
pHYB-TBLVsagDFS
AvrII ClaI  SstI
AvrII ClaI  SstI





Mtv1 Sag MMTV(C3H) Sag             (320 aa)
Figure 3.1. Construction of hybrid MMTV-TBLV proviral molecular clones.
The pHYB-MTV plasmid [403] contains a hybrid MMTV provirus whose 5’ half (stippled)
upstream of theEcoR1 site is derived from endogenousMtv1 and the 3’ half (yellow) downstream
of the EcoR1 site is derived from exogenous MMTV(C3H). The approximate positions of viral
genes are shown, and the LTRs are represented by the larger boxes at the ends of the provirus. The
grey boxes within the MMTV LTRs represent the NRE. The Sag proteins are designated by boxes
above the proviral constructs. pHYB-TBLV was constructed by replacing theClaI to SstI region
of the 3’ LTR of pHYB-MTV with the corresponding section (orange box) from the TBLV LTR
that encompasses the NRE deletion and triplicate T-cell enhancer (blue bars) substitution. A mutant
TBLV hybrid provirus, pHYB-TBLVsagDFS, was constructed by introducing frameshift mutations
at theAvrII and ClaI sites in thesagcoding sequence (indicated by arrows). These mutations allow
translation of only 17 amino acids of Sag.
for expression of MMTV capsid protein by Western blotting using MMTV CA-
specific monoclonal antibodies [350]. Comparable levels of Gag protein expression
were detected in the cell lysates (Figure 3.3A) as well as in the concentrated culture
supernatants (Figure 3.3B) from the two transfected cell lines.
The Jurkat/HYB-TBLV or Jurkat/HYB-TBLVsagDFS cells were inoculated
intraperitoneally into weanling BALB/cJ mice. Thymic lymphomas developed in


























Figure 3.2. TBLV and TBLV sagDFS LTRs demonstrate similar transcriptional efficiencies
in transiently transfected Jurkat T cells.
Transcriptional efficiencies of wild-type (TBLV) and mutant (TBLVsagDFS) LTRs in Jurkat T cells
were compared by transient transfection of LTR-driven LUC reporter plasmids. LUC activity is
reported in light units normalized for DNA uptake as measured by co-transfection with theRenilla
luciferase expression plasmid, pRL-TK. LUC activity from the pTBLVsagDFS-LUC plasmid is
depicted relative to that from the pTBLV-LUC plasmid (assigned a value of 100). Standard
deviations from the means of triplicate assays are shown.
months, whereas HYB-TBLVsagDFS-infected mice developed T-cell lymphomas
with a 60% incidence and an average latency of 4.8 (± 0.6) months (Table 3.1)
[317]. Statistical analysis did not reveal any significant difference in the incidence
and latency of tumor induction by the wild-type and Sag-mutant TBLV (P>0.05).
Interestingly, one mouse infected with HYB-TBLVsagDFS developed a mammary
tumor with a latency of 9.5 months (Table 3.1). Since this was the only mammary
tumor observed in the study, the viral origin of the tumor was not determined.
Expression of HYB-TBLV or thesagframeshift mutant virus in these tumors
was confirmed using RT-PCR followed by sequencing (data not shown). RT-
PCR analysis also detected three enhancer elements in the U3 region of viral
RNA expressed in most of these lymphomas, while variants containing one or two
enhancer elements were also present at low levels (Figure 3.4).
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Figure 3.3. Jurkat T cells stably transfected with proviral constructs express viral proteins
and release extracellular virions.
(A) Western blot analysis of whole cell lysates from Jurkat T cells stably transfected with pHYB-
TBLV or pHYB-TBLV sagDFS. Whole cell lysates prepared from untransfected Jurkat cells were
used as a negative control. Each lane was loaded with 100µg of cellular lysate. Viral Gag
expression was detected using MMTV CA-specific antibody (upper panel). Arrows indicate
processed and unprocessed forms of Gag. Fifty micrograms of each cellular lysate was analyzed by
Western blotting using actin-specific antibodies (lower panel) as a control for protein loading. (B)
Extracellular virus production from Jurkat T cells stably transfected with pHYB-TBLV or pHYB-
TBLVsagDFS. Varying amounts of cell culture supernatants from the transfected cells were analyzed
by Western blotting using MMTV CA-specific antibody and compared to culture supernatant
obtained from the TBLV-induced lymphoma, 485-10.
from the TBLV LTR into the 3’ LTR of pHYB-MTV is sufficient to alter MMTV
disease tropism and create a lymphomagenic virus. Furthermore, these results also
established that the truncated TBLV Sag is not essential for the development of
virally-induced thymic lymphomas in the BALB/cJ strain.
3.1.3 TBLV and TBLV sagDFS-induced tumors have similar phenotypes.
To compare the phenotypes of T-cell lymphomas induced by the wild-
type (HYB-TBLV) and the mutated (HYB-TBLVsagDFS) viruses, the tumor
cell populations were labeled for cell surface markers and analyzed using flow
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Table 3.1. Incidence and latency of tumors induced by clonal TBLV proviruses after








































a Jurkat T-cell transfectants (2×107 cells) were injected intraperitoneally into the indicated number
of female (F) and male (M) weanling BALB/cJ mice.
b There was no statistically significant difference (P = 0.08) between the incidence and average
latencies of tumors induced by the wild-type andsagdouble-frameshift mutant viruses. Differences
between wild type and mutant-injected animals were analyzed using the Statistical Package for
Social Sciences (SPSS) (SPSS, Inc., Chicago, IL.). Time to tumor appearance was evaluated using
the Kaplan-Meier survival analysis technique with a log-rank test of significance. This analysis
excluded one HYB-TBLV-induced tumor that appeared at 12 months.
c The mammary tumor incidence was based on the number of female mice injected.
d Only one mammary tumor was observed.
cytometry. Most tumors had a high percentage of Thy1.2+ cells, confirming that the
lymphomas had originated from the host T-cell lineage (Table 3.2). The Thy1.2+
tumor cell populations were heterogeneous with respect to the surface distribution
of CD4 and CD8 markers, and there was no significant difference between the two
groups. The tumors were not outgrowths of the originally injected cells since the
antibodies used for cell surface staining did not react with Jurkat cells (data not
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Figure 3.4. RT-PCR analysis of HYB-TBLV and HYB-TBLV sagDFS-induced lymphomas.
RT-PCR analysis of the number of enhancer elements (upper panel) in the U3 region of the
viral RNA expressed in the thymic lymphomas was performed using primers C3HLTR501(+) and
TBLVLTR786(-). The amplified products obtained from viral RNA U3 regions containing 1, 2, and
3 enhancer elements are indicated by arrows. Tumors 13, 14, 15, and 16 were induced by HYB-
TBLV while tumors 1, 2, 5, 6, 8, 9, 10, and 17 were induced by HYB-TBLVsagDFS. RT-PCR
amplification ofgapdmRNA (lower panel) was performed as a control for RNA integrity.
shown).
To analyze the clonality of thymic lymphomas induced by wild-type
and sag-frameshift TBLV, TCRβ and γ chain rearrangements were analyzed by
Southern blotting (Figure 3.5). Most of the tumors induced by either virus showed
rearrangement of both TCR chains, and many tumors had a significant clonal
population. These results combined with the cell surface analysis suggested that the
lymphomas induced by HYB-TBLV and HYB-TBLVsagDFS were phenotypically
similar and were of oligoclonal origin. The tumor phenotypes were also similar to
those of tumors induced by intrathymic injection of newborn mice with non-clonal
TBLV virions produced by the lymphoma line, 485-10 [309, 310].
Thus, a novel TBLV tumorigenicity assay in adult mice was developed using
a cloned hybrid TBLV provirus and used to evaluate the role of TBLV truncated Sag
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Table 3.2.Comparison of cell surface markers on lymphomas induced by HYB-
TBLV and HYB-TBLV sagDFS in adult BALB/cJ mice.
% %
Hybrid Tumor % % Thy1.2+ Thy1.2+
provirus number Thy1.2+ Thy1.2+ CD4- CD4+
CD4+ CD8+ CD8- CD8+
11 9 2.1 2 87
12 73 0.8 25 1.7
HYB-TBLV a 13 27 0.6 72 0.1
14 4.1 22 2.4 71
15 26 0.6 3 70
1 21 45 13 22
2 3.4 8.3 2.6 86
HYB-TBLV sagDFSa 3 19 3.8 5.5 72
4 5.7 11.4 4.4 79
5 74 0.24 24 1.5
Normal BALB/cJ thymusb 11 3.3 2.1 84
a Statistical analysis was performed usingt-tests with and without logarithm transformation to
stabilize the variance.
b The numbers represent average values obtained from 10 weanling BALB/cJ mice.
in determining lymphomagenicity. Our results demonstrated that the truncated Sag
is dispensable for TBLV tumorigenicity, suggesting that MMTV disease specificity
is determined by the activity ofcis-acting elements in the viral LTR.
3.1.4 TBLV enhancer masks the MMTV NRE activity.
To determine the contributions of the NRE and the T-cell enhancer on TBLV
lymphomagenicity, two mutant MMTV LTRs were engineered by inserting the
TBLV T-cell enhancer (E) either at theStuI site upstream of the NRE (MTVStuE
LTR) or at theAflII site downstream of the NRE (MTVAflE LTR) leaving the
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Figure 3.5. Analysis of TCR gene rearrangements in HYB-TBLV and HYB-TBLVsagDFS-
induced lymphomas.
(A) Southern blotting for TCRβ chain rearrangements. (B) Southern blotting for TCRγ chain
rearrangements. Tumors 12, 14, 15, and 16 were induced by HYB-TBLV, whereas tumors 4, 5, 9,
and 10 were induced by HYB-TBLVsagDFS. Digestion of liver DNA from uninfected animals was
used to demonstrate the DNA fragments derived from the unrearranged TCR genes. Genomic DNA
(15µg) was digested withHindIII, separated on 0.8% agarose gels, transferred to nitrocellulose and
hybridized with probes p86T5β (for TCRβ chain) [125] or Cγ1.2 (for TCRγ chain) [208].
NRE intact in both LTRs (Figure 3.6A). While thesagcoding sequence remained
unaffected in the MTVAflE LTR, enhancer insertion in the MTVStuE LTR truncated
the sag gene at a position similar to that in the TBLV LTR [27]. The third
recombinant LTR, MTV∆NRE, used in this study has been described previously
[286]. This recombinant lacks the entire NRE and the flanking T-cell enhancer
sequences (Figure 3.6A).
The MTV∆NRE LTR demonstrated a 3-fold elevated transcriptional
efficiency compared to the MMTV LTR in Jurkat T cells transiently transfected with
LTR-driven firefly luciferase (LUC) reporter plasmids [286, 444]. However, the
TBLV T-cell enhancer located upstream of the NRE partially relieved NRE activity,
resulting in a 250-fold increased LUC expression from the MTVStuE LTR relative
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to the MMTV LTR (Figure 3.6B). MTVAflE and TBLV LTRs demonstrated similar
transcriptional strengths, achieving 700-fold elevated LUC expression compared to
the MMTV LTR (Figure 3.6B). These data indicate that the T-cell enhancer placed
between the MMTV NRE and the LTR promoter completely masks NRE activity
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Figure 3.6. Construction and characterization of mutant MMTV LTRs.
(A) Diagram depicting the composition of MMTV, TBLV and mutant MMTV LTRs. The arrow on
the MMTV LTR denotes the transcription start site at the U3-R border. Thesagcoding region is
depicted as green lines above each LTR. However, Sag is not expressed in these assays. (B) Transient
transfection assay comparing the transcriptional efficiencies of wild-type MMTV and TBLV LTRs
and their recombinants in the Jurkat T-cell line. LUC activity is reported in light units normalized for
DNA uptake as measured by co-transfection with theRenilla luciferase expression plasmid, pRL-
TK. LUC activity from the TBLV and mutant MMTV LTRs is depicted relative to that from the
MMTV LTR (assigned a value of 1). Standard deviations from the means of triplicate assays are
shown.
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3.1.5 TBLV enhancer improves glucocorticoid induction of MMTV LTR.
In the absence of glucocorticoid [dexamethasone (DEX)] the MTVAflE,
MMTV, TBLV, and MTVStuE LTRs exhibited statistically similar transcriptional
efficiencies in transient transfections of the HC11 mouse mammary gland cell
line, indicating the lack of a significant transcriptional advantage from T-cell
enhancer addition [286] (Figure 3.7). Under the same conditions, the MTV∆NRE
LTR had a higher transcriptional activity compared to the MMTV LTR (P=0.03)
(Figure 3.7). In the presence of DEX, transcription from the MMTV LTR, which
harbors 6 HREs [141], increased five-fold (P=0.005). The MTV∆NRE LTR
with 3 HREs did not undergo a statistically significant DEX induction (P=0.2).
The T-cell enhancer (containing a triplicated HRE) provided a transcriptional
advantage in the presence of DEX since the transcriptional efficiencies of TBLV
and MTVAflE LTRs demonstrated ca. 30-fold DEX-induction compared to the
uninduced MMTV LTR (P=0.01 and<0.001, respectively) (Figure 3.7). However,
DEX responsiveness of the MTVStuE LTR was significantly lower than that of
the MTVAflE and TBLV LTRs (P=0.001 and 0.01, respectively), suggesting that
positioning the NRE between the enhancer and the promoter mitigates the DEX-
responsive transcriptional influence of the T-cell enhancer.
3.1.6 Lymphomagenic MMTVs require a T-cell enhancer and loss of the
NRE activity.
Recombinant MMTV LTRs were prepared by substitution ofAvrII to SstI
































Figure 3.7. Transient transfection assay comparing the transcriptional efficiencies of wild-
type and mutant MMTV and TBLV LTRs in HC11 cells.
Transfection assays were performed in HC11 mouse mammary gland cell line in the absence (orange
bars) or presence (blue bars) of dexamethasone (DEX). LUC activity is reported in light units
normalized for DNA uptake as measured by co-transfection with the pRL-TK reporter plasmid.
LUC activity from the TBLV and mutant MMTV LTRs is depicted relative to that from the MMTV
LTR in the absence of DEX (assigned a value of 1). Standard deviations from the means of triplicate
assays are shown. The results were analyzed by pair-wiset-te ts.
cells that stably express wild-type (HYB-MTV) or recombinant viruses (HYB-
MTVStuE, HYB-MTVAflE and HYB-MTV∆NRE) were derived. Comparable
viral Gag expression in all the stable cell lines was verified by Western blot analysis
of whole cell lysates (Figure 3.8) using MMTV CA-specific monoclonal antibody
[350]. Weanling BALB/cJ mice were intraperitoneally inoculated with 2×107
virus-expressing cells, and viral infection was followed by flow cytometry analysis
of peripheral Sag-reactive CD4+ T cells.
Of the peripheral, Sag-reactive CD4+Vβ14+ T cells, 37 to 59% were
deleted at 3 months post-inoculation with Jurkat/HYB-MTV and Jurkat/HYB-
MTVAflE, respectively (Figure 3.9), whereas non-reactive CD4+Vβ8+ T cells
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Figure 3.8. Characterization of mutant MMTV proviruses.
Western blot analysis comparing viral Gag expression in Jurkat T cells stably expressing wild
type (HYB-MTV) or mutant (HYB-MTVStuE, HYB-MTVAflE and HYB-MTV∆NRE) MMTV
proviruses. Three different amounts (100, 50 and 20µg) of whole cell lysates were analyzed on
8% SDS-PAGE gels. Whole cell lysates derived from untransfected Jurkat T cells were included as
a negative control. Viral Gag (upper panel) was detected with an MMTV CA-specific monoclonal
antibody [350]. The arrow indicates the precursor form of Gag, Pr77. The same amounts of cellular
lysates were incubated with antibodies specific for actin (lower panel) as a control for protein loading
on the gel.
in Jurkat/HYB-MTVStuE infected mice, confirming the inability of the truncated
Sag to mediate T-cell deletion.
HYB-MTV induced mammary tumors with a 100% incidence and average
latency of 7.3 ± 1.7 months (Figure 3.10). HYB-MTV∆NRE also induced only
mammary tumors in 20% of the inoculated female mice within 10 ± 2.8 months
indicating that LTR NRE deletion alone was insufficient for lymphomagenesis. In
contrast, 50% of the HYB-MTVStuE-infected mice developed mammary tumors
within 8.7 ± 2.1 months, while 30% developed thymic lymphomas within 8
± 2.6 months. One HYB-MTVStuE-infected mouse (mouse no. 4) developed
both tumor types. HYB-MTVAflE infection gave a 17% incidence of mammary
tumors and a 22% incidence of thymic lymphomas with average latencies of 6
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Figure 3.9. Peripheral Sag-reactive CD4+ T cells are deleted in BALB/cJ mice inoculated
with Jurkat T cells stably expressing full-length Sag-encoding proviruses.
Flow cytometric analysis of Sag-mediated peripheral T-cell deletion in mice at 3 months post-
injection with Jurkat T cells stably expressing wild-type or mutant MMTV proviruses. Sag-
reactive CD4+Vβ14+ and Sag-non-reactive CD4+Vβ8+ peripheral T cells were analyzed on the
FACSCalibur using CELLQuest software. The percentage of TCR Vβ+ cells in the gated CD4+
T-cell population was calculated. The number of animals (N) analyzed from each group is indicated
within each bar. The mean percentage (± standard deviation) of CD4+TCR Vβ+ T cells in each
group is shown. Results were analyzed by pair-wiset-t sts. The asterisks indicate a significant
difference (P<0.05) between the indicated pairs.
or log-rank tests indicated that the mammary tumor incidence of each of the
mutants was significantly different than that of wild-type HYB-MTV (Figure
3.10A). Mammary tumor incidence was not statistically different among the
various mutants. Lymphomas have never been observed after infection with HYB-
MTV (Figure 3.10B), even after inoculation of much larger numbers of animals
[466, 484].
The LTR structure of newly integrated proviruses was then determined
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incidence              (months)
17% (1/6)                      6
20% (2/10)                10 ± 2.8
50% (3/6) 8.7 ± 2.1
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Figure 3.10.Kaplan-Meier plots of mammary tumors and thymic lymphomas induced by
wild-type and mutant MMTV proviruses.
Females were caged to maintain continuous breeding and lactation. Mice that died from non-tumor
causes (e.g., birthing problems) before the average latency of tumor induction were censored from
the study. (A) Development of mammary tumors. Numbers in parentheses indicate the number
of animals with tumor/total number of injected females. The circles indicate one or more animals
that died without any detectable tumors. (B) Development of thymic lymphomas. Numbers in
parentheses indicate number of animals with tumor/total number of injected males and females. One
mouse injected with HYB-MTVStuE developed both a mammary tumor and a thymic lymphoma
after 11 months of latency.
and either MMTV LTR (Figure 3.12A) or NRE-specific probes (Figure 3.12B).
The LTRs of predominant newly integrated proviruses in HYB-MTVAflE-induced
lymphomas contained the NRE (Figure 3.12A-B, lanes 5 and 7). The majority
of these LTRs retained their original size suggesting an intact triplicate T-cell
enhancer, while smaller sized LTRs might harbor fewer enhancer copies or partial
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NRE deletion. TBLV-induced lymphomas reportedly select integrations with
suboptimal number of enhancer repeats to modulate c-my expression [59]. LTRs of
predominant newly integrated proviruses in HYB-MTVStuE-induced lymphomas
lacked the entire NRE and were detected only by the MMTV LTR probe (Figure
3.12A-B, lanes 10 and 11). The size reduction of these LTRs was consistent
with complete NRE deletion in the presence of the T-cell enhancer. NRE-minus
recombinants were not observed in HYB-MTVStuE-induced mammary tumors
(Figure 3.12A-B, lanes 8, 9 and 12). Interestingly, the LTRs of newly integrated
proviruses in the HYB-MTV∆NRE-induced mammary tumor had reacquired
the NRE, suggesting that the presence of this region might favor mammary
tumorigenesis (Figure 3.12A-B, lane 13).
MMTV provirus
5’ LTR  gag     dut/pro         pol     env/rem 3’ LTR
NRENRE
PstI PstI PstI PstI PstI
MMTV LTR probe
MMTV NRE probe
5’ LTR-gag fragment 3’ LTR-cellular DNA fragment
Figure 3.11.Strategy for analyzing the LTR structure of newly integrated MMTV
proviruses in the wild-type and mutant MMTV-induced tumors.
Tumor genomic DNA digested withPstI, separated on 0.8% agarose gels, and transferred onto
nitrocellulose membranes were hybridized to probes derived from the MMTV LTR or only from
the NRE region of the MMTV LTR.PstI yields four fragments from newly integrated exogenous
MMTV proviruses, only two of which are detectable by the MMTV LTR and NRE probes. (i) The
5’ LTR-gagfragment whose size is determined by the LTR length and, (ii) the 3’ LTR-cellular DNA
fragment whose size is dependent on the length of the LTR and the flanking cellular DNA. Since the
LTR probe will detect fragments originating from all MMTV proviruses, the MMTV NRE-specific
probe will only detect fragments from proviruses that contain the NRE in their LTRs.
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Figure 3.12.Analysis of the LTR structure of newly integrated proviruses in wild-type and
mutant MMTV-induced mammary tumors (MT) and thymic lymphomas (TL).
(A) Southern blotting using the whole MMTV LTR as the probe. (B) Southern blotting with MMTV
NRE probe (StuI to AflII fragment of the MMTV LTR). Southern blotting of genomic DNA from an
uninfected BALB/cJ mouse liver (LI) was used to distinguish the bands originating from the three
endogenousMtvs in the BALB/cJ strain. White asterisks placed in lanes 5, 7, 10, 11, and 13 indicate
the LTR fragments of predominant newly integrated proviruses in tumor DNA.
The tumors were also analyzed by RT-PCR and the products were gel-
purified and sequenced or, in some cases, cloned into pGEM®-T Easy vector
(Promega) prior to sequencing (Figure 3.13). Most of the U3 sequences amplified
from viral RNA expressed in HYB-MTVStuE-induced lymphomas retained two to
three copies of the T-cell enhancer, yet lacked the entire NRE. Some amplified
U3 sequences had lost the T-cell enhancer while retaining the NRE. However,
proviruses containing these LTR U3 regions were not predominant in the tumor
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genomic DNA as revealed by Southern blotting (Figure 3.12). LTRs of predominant
newly integrated proviruses in the HYB-MTVStuE-induced lymphomas were
undetectable by the NRE probe and their size was consistent with the loss of the
entire NRE and retention of the T-cell enhancer.
MTVStuE LTR
3          TL
5          TL
3, 5      TL NRE
NRE
Mouse Tumor Recombinant LTR
NREMTVAflE LTR
1          TL
2          MT
NRE
NRE
Mouse Tumor Recombinant LTR
A
B
Figure 3.13.RT-PCR analysis of the LTR composition of MMTV proviruses expressed in
mutant MMTV-induced tumors.
(A) LTR composition of MMTV proviruses expressed in HYB-MTVStuE-induced thymic
lymphomas (TL). (B) LTR composition of MMTV proviruses expressed in HYB-MTVAflE-induced
thymic lymphomas (TL) and mammary tumors (MT).
Similar RT-PCR analysis of HYB-MTVAflE-induced lymphomas (Figure
3.13) revealed the presence of both the NRE and the TBLV enhancer in the viral
U3 sequences. Some amplified U3 sequences had lost the NRE and retained only
the T-cell enhancer, but proviruses containing these LTR U3 regions were not
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predominant in the tumor genomic DNA as determined by Southern blotting (Figure
3.12). LTRs of the predominant newly integrated proviruses in the HYB-MTVAflE-
induced lymphomas were detected by the NRE probe, and their size was consistent
with the presence of the entire NRE and three (or fewer at a lower frequency)
copies of enhancer elements. In contrast, the predominantly expressed proviruses
in the HYB-MTVAflE and HYB-MTVStuE-induced mammary tumors had lost the
T-cell enhancer while retaining the NREs in their LTRs. This observation was
also reinforced by Southern blot analysis of mammary tumors that revealed the
predominance of proviruses with smaller LTRs detectable by the MMTV NRE
probe. The reduced size of these LTRs correlated with the length of the T-cell
enhancer.
These results demonstrated that conversion of the mammotropic MMTV to a
lymphomagenic virus requires T-cell enhancer acquisition and loss of NRE activity
achieved either by NRE deletion or by masking the NRE activity by a downstream
enhancer. These results also revealed that truncation of thesag-coding sequence is
not a pre-requisite for TBLV-induced lymphomagenesis since the HYB-MTVAflE
virus that retained full-length Sag coding potential was lymphomagenic.
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3.2 An Mtv-Free BALB/cJ Congenic Strain is Resistant to
MMTV, TBLV and Vibrio cholerae.
3.2.1 Overview
Most laboratory mouse strains harbor endogenous MMTV proviruses (Mtv )
in their germline. Previous data have suggested that endogenousMtvs may protect
against infection by milk-borne MMTVs with the same Sag specificity. An
endogenousMtv-free, BALB/cJ congenic mouse strain (BALB/Mtv-null), which
develops low-grade MMTV(C3H) infection and demonstrates only a 5 to 10%
incidence of mammary tumors was developed. Moreover, these mice fail to undergo
Sag-reactive T-cell deletion. In contrast, BALB/cJ mice develop a 90 to 100%
incidence of MMTV(C3H)-induced mammary tumors and also demonstrate robust
Sag-mediated T-cell deletion. BALB/Mtv-null mice are also totally resistant to
Sag-independent TBLV lymphomagenesis in contrast to BALB/cJ mice, which
develop a 50% incidence of TBLV-induced thymic lymphomas. Genetic studies
demonstrate that resistance to MMTV-induced tumors in BALB/Mtv-null mice is
a recessive trait linked to the absence of endogenousMtv . BALB/cJ congenic
strains (BALB/Mtv-SP) harboring any one of the three endogenousMtvs (Mtv6, 8
or 9) located on three separate chromosomes of the BALB/cJ strain are susceptible
to MMTV tumorigenesis and Sag-mediated T-cell deletion. Production of MMTV
neutralizing antibodies does not contribute to the resistance trait since only about
30% of the MMTV(C3H)-infected BALB/Mtv-null mice develop a low titer of
MMTV capsid-specific antibodies. The BALB/Mtv-null strain is also more resistant
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to disease induced by the bacterial pathogen,Vibrio cholerae, which exhibits an
LD50 of 2.3×106 CFU in this strain. In contrast,V. choleraeexhibits a 10-fold lower
LD50 (1.6×105 CFU) in the BALB/cJ strain. Interestingly, theV. choleraeLD50 for
all three BALB/Mtv-SP strains ranges between 1 to 3×105 CFU, suggesting that the
heightened susceptibility toV. choleraealso co-segregates with each of the three
endogenousMtvs of the BALB/cJ strain. The absence of endogenousMtvs might
allow an altered immune response that forms the basis of a novel mechanism of
resistance to both viral and bacterial pathogens.
3.2.2 BALB/cJ congenic BALB/Mtv-null mice lack endogenousMtvs.
BALB/cJ is highly susceptible to exogenous MMTV-induced mammary
tumorigenesis. Milk-borne infection by MMTV(C3H) culminates with a 100%
mammary tumor incidence, and a similar 90% mammary tumor incidence is
observed in adult BALB/cJ females inoculated intraperitoneally with a rat fibroblast
cell line stably expressing an infectious MMTV proviral clone [316] (Table
3.3). Adult BALB/cJ mice also demonstrate a 50% incidence of TBLV-induced
lymphomas (Table 3.3) following intraperitoneal inoculation of Jurkat T cells stably
expressing the molecular clone, HYB-TBLV [317].
BALB/cJ mice harbor three endogenousMtvs - Mtv6, Mtv8 andMtv9 on
chromosomes 16, 6 and 12, respectively [65, 372]. EndogenousMtvs have been
demonstrated to provide resistance to infection by exogenous strains of MMTV
bearing Sags of similar specificity [157, 184]. Such endogenous proviruses also
serve as substrates for retroviral recombination [159, 161, 162] and, hence, may also
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Table 3.3.BALB/cJ mice are highly susceptible to MMTV(C3H) and TBLV-induced
tumorigenesis.
Mode of infection
Foster nursing on Intraperitoneal inoculation
MMTV+ C3H/HeN
Tumor mice XC/HYB-MTV Jurkat/HYB-TBLV
type Average Average Average
Incidence latency Incidence latency Incidence latency
(months) (months) (months)
Mammary 100% 90% – –
tumor (6/6)a 5.8 ± 0.4b (9/10)a 8.9 ± 2.2b
Thymic – – – – 50%
lymphoma (9/18)c 5.7 ± 1.5b
a (Number of female mice with mammary tumors / total number of infected females). Mice that
died before 12 months of age were excluded from the study.
b Mean (± standard deviation).
c (Number of mice with thymic lymphomas / total number of infected male and female mice).
influence infection by exogenous MMTVs of disparate Sag reactivity. Therefore, an
endogenousMtv-free, BALB/cJ congenic mouse strain, designated as BALB/Mtv-
null (H-2d), was derived for studying clonal exogenous MMTVs. This strain was
selected from a cross between BALB/cJ mice (H-2d) and the recently inbred strain
PERA/Ei (H-2k) that lacks endogenousMtvs [446], followed by 10 backcrosses to
the BALB/cJ strain. Thus, BALB/Mtv-null are congenic to BALB/cJ mice.
The absence of endogenousMtvs in BALB/Mtv-null mice was verified by
PCR analysis of mouse genomic DNA using endogenousMtv-specific primers
(Figure 3.14A) as well as by Southern blotting of mouse genomic DNA using
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MMTV-specific probes (data not shown). We further confirmed the lack of
endogenousMtv Sag-mediated T-cell deletion in BALB/Mtv-null mice using flow
cytometry (Figure 3.14B). Significant populations of endogenousMtv Sag-reactive
T cells - CD4+Vβ3+ (Mtv6 Sag-specific), CD4+Vβ5+ (Mtv6 and Mtv9 Sag-
specific), CD4+Vβ7+ (Mtv8 Sag-specific) and CD4+Vβ12+ (Mtv8 andMtv9 Sag-
specific) - were detected in the peripheral blood lymphocytes (PBLs) of BALB/Mtv-
null mice, indicating the absence of the corresponding endogenousMtvs. These
four T-cell subsets were almost completely deleted in age-matched BALB/cJ mice
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Figure 3.14.BALB/ Mtv-null mice lack endogenousMtvs present in the BALB/cJ genome.
(A) PCR analysis of mouse genomic DNA using endogenousMtv-specific primers. Genomic DNA
from BALB/Mtv6 (lane 4), BALB/Mtv8 (lane 2), and BALB/Mtv9 (lane 3) mice (harboring a
single endogenousMtv locus) were used as positive controls for PCR amplification of individual
endogenous proviral loci. PCR with no added DNA template was the negative control (lane 8).
(B) Flow cytometry analysis of endogenousMtv Sag-reactive CD4+ T-cell subsets in peripheral
blood lymphocytes (PBLs). PBLs from 6-month old BALB/cJ and BALB/Mtv-null mice were
dually labeled with mouse-specific CD4-PE and mouse-specific TCR Vβ3-, -5-, -7-, or -12-FITC
antibodies followed by analysis on the FACSCalibur using CELLQuest software. Three individual
animals of each strain were tested, and the average proportion of T-cell subsets (± standard
deviation) is depicted.
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3.2.3 BALB/ Mtv-null strain is resistant to MMTV tumorigenesis and Sag.
BALB/Mtv-null and BALB/cJ mice were infected by the milk-borne route
following foster-nursing on MMTV(C3H)+ C3H/HeN mice or by intraperitoneal
inoculation of weanling mice with rat XC fibroblasts stably expressing HYB-MTV
(XC/HYB-MTV) [316, 403]. Only a 5 to 10% incidence of mammary carcinomas
was observed in the BALB/Mtv-null strain compared to a 90 to 100% tumor
incidence in BALB/cJ mice during the 15-month observation period (Table 3.4).
Table 3.4.BALB/ Mtv-null mice are resistant to MMTV(C3H) and TBLV-induced
tumorigenesis.
Mode of infection
Foster nursing on Intraperitoneal inoculation
MMTV+ C3H/HeN
Tumor mice XC/HYB-MTV Jurkat/HYB-TBLV
type Average Average Average
Incidence latency Incidence latency Incidence latency
(months) (months) (months)
Mammary 10% 5% – –
tumor (1/10)a 15 (1/20)a 9
Thymic – – – – 0%
lymphoma (0/8)b –
a (Number of female mice with mammary tumors / total number of infected females). Mice that
died before 12 months of age were excluded from the study.
b (Number of mice with thymic lymphomas / total number of infected male and female mice).
Interestingly, BALB/Mtv-null mice inoculated with MMTV-infected rat
XC cells failed to undergo MMTV(C3H) Sag-mediated peripheral deletion of
CD4+Vβ14+ T-cells (Figure 3.15A). In contrast, approximately 69% of Sag-
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reactive CD4+Vβ14+ T cells were deleted in MMTV-infected BALB/cJ mice
(Figure 3.15A). BALB/Mtv-null mice infected neonatally with the milk-borne
MMTV(C3H) demonstrated a very low-grade (18 to 20%) deletion of Sag-cognate
T cells, unlike BALB/cJ mice in which approximately 59% of the CD4+Vβ14+,
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Figure 3.15.MMTV(C3H) Sag-mediated T-cell deletion is impaired in BALB/Mtv-null mice
inoculated with XC/HYB-MTV cells.
PBLs isolated from MMTV-infected and control-uninfected mice were dually labeled with
mouse-specific CD4-PE and mouse-specific Vβ8, or -14-FITC antibodies followed by analysis
on the FACSCalibur using CELLQuest software. The percentages of MMTV(C3H) Sag-
reactive CD4+Vβ14+ (A) and non-reactive CD4+Vβ8+ (B) T cells among the PBLs isolated
from BALB/Mtv-null (circles) or BALB/cJ (squares) mice inoculated with XC/HYB-MTV cells
(pink) compared to uninjected mice (blue) are depicted. The number adjacent to the average
%CD4+Vβ14+ T-cell proportion at each time point denotes the number of mice analyzed for that
time point.
The MMTV(C3H) Sag-mediated T-cell deletion in the BALB/cJ mice
was specific for the Sag-reactive CD4+Vβ14+ T-cell compartment while the
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Figure 3.16.MMTV(C3H) Sag-mediated T-cell deletion is impaired in BALB/Mtv-null mice
infected by milk-borne MMTV.
PBLs isolated from mice were dually stained with mouse-specific CD4-PE and mouse-specific Vβ3,
-8-, or -14-FITC antibodies followed by analysis on the FACSCalibur using CELLQuest software.
Asterisks denote statistical significance determined by two-tailed Student’st-tests (P<0.05).
The percentages of MMTV(C3H) Sag-reactive (CD4+Vβ14+) and non-reactive (CD4+Vβ8+ or
CD4+Vβ3+) T cells among the PBLs isolated from infected BALB/Mtv-null (A, B) or BALB/cJ
(C) mice (pink bars) compared to uninfected mice (blue bars) are depicted. The numbers within the
bars denote the number of mice that were analyzed for that time point. Only one MMTV(C3H)-
infected BALB/cJ female (C) was analyzed at 6 months since five females had been sacrificed after
developing mammary tumors.
unaffected (Figure 3.15B, and Figure 3.16C, right panel). However, the CD4+
Vβ3+ T-cell subset, also not recognized by MMTV(C3H) Sag, underwent a low-
grade deletion in BALB/Mtv-null mice infected with milk-borne MMTV (Figure
3.16B, left panel).
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3.2.4 BALB/ Mtv-null mice are resistant to TBLV tumorigenesis.
Sag-mediated amplification of MMTV in lymphoid cells is required for
a robust infection by exogenous MMTV leading to mammary tumorigenesis
[157, 161, 184]. Therefore, resistance to MMTV tumorigenesis in BALB/Mtv-
null mice could be attributed to the lack of Sag-mediated viral amplification. To
test this possibility we assessed the tumorigenicity of TBLV, a Sag-independent
variant of MMTV [317], in BALB/Mtv-null mice. As described earlier, TBLV is a
thymotropic variant of MMTV that induces thymic lymphomas in mice [26, 317].
We previously determined that TBLV-induced lymphomagenesis in BALB/cJ mice
is independent of the truncated TBLV Sag [317]. Fifty percent of weanling
BALB/cJ mice inoculated intraperitoneally with Jurkat cells stably expressing a
hybrid proviral clone of TBLV develop lymphomas with an average latency of 5.7
months [317] (Table 3.1). In contrast, BALB/Mtv-null mice inoculated with the
same batch of Jurkat/HYB-TBLV cells failed to develop any lymphomas within
the 10-month observation period (Table 3.4). BALB/Mtv-null mice also were
completely resistant to thesag-frameshift TBLV mutant, HYB-TBLVsagDFS (data
not shown) that encodes only the first 17 amino acids of Sag.
Thus, BALB/Mtv-null mice are resistant to both MMTV-induced mammary
tumorigenesis and TBLV-induced lymphomagenesis, suggesting that the resistance
phenomenon is independent of the Sag response.
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3.2.5 BALB/ Mtv-null mice develop MMTV and TBLV infection.
To determine if the resistance to TBLV and MMTV-induced tumorigenesis
and impairment of MMTV Sag-mediated T-cell deletion response was due to lack
of infection, we performed several RT-PCR analyses. MMTV LTR,env and
gag-specific primers were used to detect MMTV transcripts in mouse organs,
including the mammary gland and spleen. Despite their resistance to MMTV-
induced tumorigenesis and lack of Sag-mediated T-cell deletion, BALB/Mtv-null
mice are susceptible to MMTV infection. MMTV RNA was detected in 8 to
15-month-old BALB/Mtv-null mice that were infected neonatally with milk-borne
MMTV(C3H) (Figure 3.17A) as well as in adult mice at 15 months post-injection
with MMTV-expressing XC cells (Figure 3.17B). BALB/Mtv-null mice inoculated
intraperitoneally with Jurkat/HYB-TBLV cells also were susceptible to infection.
TBLV transcripts were detected by RT-PCR using TBLV LTR-specific primers in
splenic RNA isolated from animals at 10 months post-injection (Figure 3.18A).
Although BALB/Mtv-null mice are susceptible to MMTV and TBLV infection,
viral RNA was not detected in all the BALB/Mtv-null mice tested. MMTV or
TBLV-infected BALB/cJ mice that have not developed virus-induced tumors also
do not demonstrate detectable viral RNA in their organs with a 100% frequency
(data not shown), suggesting that these mice have low-level and/or sporadic
infections.
MMTV-infected BALB/Mtv-null mice also transmitted milk-borne virus to
their progeny albeit at a very low frequency (Figure 3.18B). MMTV RNA was
detected by RT-PCR usinggag-specific primers at a low frequency in the progeny
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(4th to 6th litter) of BALB/Mtv-null mice that were foster-nursed on MMTV(C3H)+
C3H/HeN mice. However, as observed in the parental generation, the progeny mice
did not demonstrate MMTV Sag-mediated T-cell deletion (data not shown).
All RT-PCR products were sequenced to confirm the authenticity of viral
transcription products. Cellulargapd RNA was amplified by RT-PCR from all
samples to ascertain RNA integrity. RT-PCRs, in which the RT had been omitted,
were used to verify the absence of DNA contamination.
Thus, BALB/Mtv-null mice are susceptible to MMTV and TBLV infection,
yet they fail to develop symptoms of infection as determined by virus-induced
tumorigenesis and robust MMTV Sag-mediated T-cell deletion.
3.2.6 MMTV resistance of BALB/ Mtv-null mice is a recessive trait.
To determine the gene(s) that are involved in the MMTV resistance trait
of BALB/Mtv-null mice, a genetic analysis was initiated by breeding BALB/cJ x
BALB/Mtv-null F1 mice (Figure 3.19).
Weanling F1 mice were intraperitoneally inoculated with XC/HYB-MTV
cells and observed for mammary tumorigenesis and Sag-mediated peripheral T-cell
deletion. Approximately 62% of the MMTV(C3H) Sag-reactive (CD4+Vβ14+)
T cells were deleted in the MMTV-infected F1 mice, and the kinetics of deletion
was similar to that observed in BALB/cJ mice (Figure 3.20). The non-cognate
CD4+Vβ8+ T-cell population showed only compensatory changes.
The injected BALB/cJ x BALB/Mtv-null F1 mice also developed mammary
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Figure 3.17.BALB/ Mtv-null mice are susceptible to MMTV(C3H) infection.
(A) RT-PCR analysis of mammary gland (MG), spleen (SN), and salivary gland (SG) RNA from
mice infected with milk-borne MMTV(C3H). RNAs from 8 to 15-month-old female (F) and
male (M) BALB/Mtv-null mice were analyzed using LTR-specific primers C3HLTR501(+) and
C3HLTR1074(-) (top panel). SG RNA from a XC/HYB-MTV injected BALB/Mtv8 mouse was
used as a positive control. Template-minus PCR served as the negative control. Duplicate RT-
minus (-RT) RT-PCRs confirmed the absence of DNA contamination (middle panel). RNA integrity
was verified by PCR amplification ofgapd-specific cDNAs (bottom panel). (B) RT-PCR analysis
of MG RNA from BALB/Mtv-null females at 15 months post-injection with XC/HYB-MTV using
gag-specific primers gag79(+) and gag461(-) (top panel). HYB-MTV-induced BALB/cJ mammary
tumor (MT) RNA was used as a positive control. Controls for DNA contamination (middle panel)
and RNA integrity (bottom panel) also are shown.
3.5). MMTV(C3H) RNA expression was detected in the mammary tumors by RT-
PCR using the TBLVENV8509(+) and C3HLTR501(-) primers followed byClaI
RFLP analysis (Figure 3.21). These MMTV(C3H)-specific RT-PCR products give
two smaller fragments after cleavage at the singleClaI restriction site within the
amplified LTR sequence. EndogenousMtv-specific RT-PCR products remain uncut
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Figure 3.18.BALB/ Mtv-null mice are susceptible to TBLV infection and transmit milk-
borne MMTV(C3H) at a low frequency.
(A) RT-PCR analysis of spleen (SN) RNA from BALB/Mtv-null mice at 10 months post-infection
with HYB-TBLV. RNA was used for RT-PCR with LTR-specific primers C3HLTR501(+) and
TBLVLTR786(-) (top panel). Size variation in the TBLV-specific RT-PCR products (arrows) is
due to the number of T-cell enhancer repeats in the LTR. HYB-TBLV-induced BALB/cJ thymic
lymphoma (TL) RNA was used as the positive control. (B) RT-PCR analysis of mammary gland
(MG) RNA from MMTV-infected BALB/Mtv-null mice. Reactions were performed using RNA
from 4th to 6th litter female progeny of milk-borne MMTV(C3H)-infected mice andgag-specific
primers gag79(+) and gag461(-) (top panel). HYB-MTV-induced BALB/cJ MT RNA was used as a
positive control. Controls for DNA contamination (A and B, middle panels) and RNA integrity (A
and B, bottom panels) also are shown.
sequenced to verify the presence of the expected viral amplification products.
Thus, resistance to MMTV tumorigenesis in BALB/Mtv-null mice is a
recessive trait and the BALB/cJ x BALB/Mtv-null F1 mice are comparable to
























Figure 3.19.Breeding scheme of BALB/cJ x BALB/Mtv-null F1, BALB/ Mtv-SP, and
BALB/ Mtv-nullSP mice.
F1 mice (NE1) heterozygous for all three endogenousMtv loci were obtained by backcrossing the
BALB/Mtv-null strain to the BALB/cJ strain. BALB/cJ congenic strains (NE2) heterozygous for a
single endogenousMtv locus (Mtv6, Mtv8 or Mtv9) were selected from the F1 (NE1) x BALB/Mtv-
null backcross. Seventy-five percent of the mice in the NE3 generation were homozygous or
heterozygous for a single endogenousMtv locus. These animals were designated BALB/Mtv6,
BALB/Mtv8 and BALB/Mtv9 (collectively termed BALB/Mtv-SP). The remaining 25% of the mice
(designated BALB/Mtv-nullSP ) from the same cross were null for all three endogenousMtv .
3.2.7 Mtv loss correlates with MMTV resistance in BALB/Mtv-null mice.
The BALB/Mtv-null strain retained its resistance to MMTV tumorigenesis
after several backcrosses to the BALB/cJ strain of mice, yet BALB/cJ x BALB/Mtv-
null F1 mice were susceptible to MMTV-induced mammary tumors. This
observation suggested that the gene(s) responsible for the resistance phenotype


















Figure 3.20.BALB/cJ x BALB/ Mtv-null F1 mice demonstrate MMTV(C3H) Sag-mediated
T-cell deletion.
PBLs isolated from XC/HYB-MTV-injected (blue squares) and control, uninfected (pink circles)
BALB/cJ x BALB/Mtv-null F1 mice were dually stained with mouse-specific CD4-PE and Vβ8-
or -14-FITC antibodies followed by analysis on the FACSCalibur using CELLQuest software. The
percentages of MMTV(C3H) Sag-reactive (CD4+Vβ14+) and non-reactive (CD4+Vβ8+) T cells
among the PBLs is depicted. The number adjacent to the average %CD4+Vβ1 T-cell proportion
at each time point denotes the number of mice analyzed for that time point.
against during the derivation of the BALB/Mtv-null mice. To determine whether
the MMTV resistance trait of BALB/Mtv-null mice co-segregates with any of the
endogenousMtv loci in BALB/cJ mice, BALB/cJ congenic strains carrying a single
endogenousMtv locus were derived. BALB/Mtv6, BALB/Mtv8, and BALB/Mtv9
mice (collectively referred to as BALB/Mtv-SP) were derived from a BALB/cJ
x BALB/Mtv-null cross followed by backcrossing to the BALB/Mtv-null strain
(Figure 3.19). The same crosses also yielded siblings of BALB/Mtv-SP mice that
lacked all three endogenousMtvs. These endogenousMtv-free mice, designated
as BALB/Mtv-nullSP , have the same genetic background as the BALB/Mtv-SP
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Figure 3.21.Mammary tumors induced in the XC/HYB-MTV-injected BALB/cJ x
BALB/ Mtv-null F1 mice express MMTV(C3H) transcripts.
RT-PCR analysis of RNA from MMTV-induced mammary tumors (MT) from BALB/cJ x
BALB/Mtv-null F1 (lanes 3-10) females was followed by digestion withClaI. Endogenous and
exogenous MMTV-specific cDNAs were PCR amplified using MMTVenvand LTR-specific primers
TBLVENV8509(+) and C3HLTR501(-). Amplification of the endogenousMtv-specific cDNAs
served as an internal positive control for the PCR. PCR products were digested and used for agarose
gel electrophoresis. An internal plasmid control forClaI-mediated restriction digestion was included
in each reaction. The results are shown in the top panel, and the positions of fragments generated by
ClaI digestion of the internal plasmid control are marked (red asterisks). EndogenousMtv-specific
RT-PCR products that remain undigested byClaI (green asterisk), and the two fragments generated
by ClaI digestion of MMTV(C3H)-specific RT-PCR products (pink asterisk) are also indicated.
Controls for RNA integrity (bottom panel) and lack of DNA contamination (middle panel) also are
shown.
by PCR analysis of genomic DNA (Figure 3.14A) and by flow cytometric analysis
of endogenousMtv Sag-reactive T-cell subsets in the peripheral blood lymphocytes
(data not shown).
Weanling BALB/Mtv-SP and BALB/Mtv-nullSP mice were inoculated
intraperitoneally with XC/HYB-MTV cells and observed for MMTV(C3H) Sag-
mediated T-cell deletion and mammary tumorigenesis. Interestingly, all three
BALB/Mtv-SP strains - BALB/Mtv6, BALB/Mtv8, and BALB/Mtv9 - demonstrated
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equivalent MMTV(C3H) Sag-mediated deletion of peripheral CD4+Vβ14+ T cells
with similar kinetics (Figure 3.22A). Approximately 38% of the CD4+Vβ14+ T
cells were deleted within 9 months post-infection in BALB/Mtv6 mice, whereas
48% and 45% of the CD4+Vβ14+ T cells were deleted in BALB/Mtv8 and
BALB/Mtv9 mice, respectively. However, the BALB/Mtv-nullSP siblings lacked
Sag-mediated T-cell deletion, a phenotype similar to the original BALB/Mtv-
null mice. The CD4+Vβ8+ T-cell subset, not recognized by MMTV(C3H)
Sag, remained unaffected in all mouse strains under investigation (Figure 3.22B),
validating the specificity of the Sag-mediated T-cell deletion response observed in
BALB/Mtv-SP mice.
BALB/Mtv-SP mice were also susceptible to MMTV induced mammary
tumorigenesis. The incidence of mammary carcinomas was highest within the
BALB/Mtv8 strain since 75% of the females developed tumors with an average
latency of 9.1 ± 3.6 months (Table 3.5). Thirty eight percent of the BALB/Mtv6
females and 67% of the BALB/Mtv9 females developed mammary tumors with an
average latency of 12.8 ± 1.8 and 11.5 ± 3.5 months, respectively. Two out of the
9 BALB/Mtv-nullSP females (22%) also developed mammary tumors at 14.5 ± 0.7
months post-infection.
Statistical analysis revealed that the BALB/Mtv6 and BALB/Mtv8 strains
of mice had a significantly higher susceptibility to MMTV-induced tumorigenesis
compared to the BALB/Mtv-null strain (Figure 3.23). BALB/Mtv9 mice
also demonstrated an increased susceptibility to MMTV-induced tumorigenesis
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Figure 3.22.BALB/ Mtv-SP mice demonstrate MMTV(C3H) Sag-mediated T-cell deletion.
The percentages of Sag-reactive (A-D) CD4+Vβ14+ and non-reactive (E-H) CD4+Vβ8+ T cells
among the PBLs isolated from MMTV-infected (blue) and control uninfected (pink) BALB/Mtv6
(panels A and E), BALB/Mtv8 (panels B and F), BALB/Mtv9 (panels C and G), and BALB/Mtv-
nullSP (panels D and H) mice are depicted. Asterisks indicate statistical significance determined
by two-tailed Student’st-test (P<0.05). The numbers within each bar denote the number of mice
analyzed for that time point.
marginally significant due to an unusually high attrition of BALB/Mtv9 females
owing to reproductive complications. MMTV(C3H) RNA expression was detected
in the mammary tumors by RT-PCR using TBLVENV8509(+) and C3HLTR501(-)
primers. Products also were verified byClaI RFLP analysis followed by sequencing
of theClaI-digested RT-PCR products (Figure 3.24).
Therefore, the phenomenon of susceptibility to MMTV tumorigenesis and
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BALB/cJ x BALB/Mtv-null F1 86% (12/14) 7.3 ± 2.4c
BALB/Mtv6 38% (5/13) 12.8 ± 1.8
BALB/Mtv8 75% (6/8) 9.1 ± 3.6
BALB/Mtv9 67% (2/3) 11.5 ± 3.5
BALB/Mtv-nullSP 22% (2/9) 14.5 ± 0.7
a Weanling mice were inoculated intraperitoneally with 2×107 XC/HYB-MTV cells and observed
for 15 months.
b (Number of female mice with mammary tumors / total number of infected females). Mice that
died before 12 months of age, generally due to birthing problems, were excluded from the study.
c Mean (± standard deviation).
Sag-mediated T-cell deletion appears to co-segregate with all three endogenousMtv
loci in BALB/cJ mice. This observation suggests that the resistance of BALB/Mtv-
null mice to MMTV infection correlates with their lack of endogenousMtvs,
rather than linkage of three recessive genes with each provirus on three separate
chromosomes.
3.2.8 BALB/ Mtv-null mice lack MMTV-neutralizing antibodies.
Since the presence of any one of the endogenousMtvs of BALB/cJ
mice was sufficient to render the BALB/Mtv-null mice susceptible to MMTV
tumorigenesis, we hypothesized that BALB/cJ, but not BALB/Mtv-null mice, have
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Weeks post-injection





































Figure 3.23.Statistical analysis of MMTV-induced mammary tumorigenesis in the
BALB/ Mtv-SP mice.
Kaplan-Meier survival analysis of the susceptibility of BALB/Mtv6, BALB/Mtv8, BALB/Mtv9, and
BALB/Mtv-null mice to MMTV tumorigenesis. The LIFETEST procedure in SAS 8.2 was used to
compute nonparametric estimates of the survivor function by the product-limit method (also called
the Kaplan-Meier method). The homogeneity of survival functions across groups was tested using
the log-rank test and the Wilcoxon test. The P values for the pair-wise comparisons were as follows
- BALB/Mtv-null versus BALB/Mtv6: PLog−rank =0.0264; PWilcoxon=0.0445; BALB/Mtv-null
versus BALB/Mtv8: PLog−rank<0.0001; PWilcoxon<0.0001; BALB/Mtv-null versus BALB/Mtv9:
PLog−rank =0.0094; PWilcoxon=0.0674.
immune tolerance to MMTV. Therefore, following MMTV infection, BALB/Mtv-
null mice may develop a strong MMTV-specific neutralizing antibody response that
would curtail a robust infection required for tumorigenesis. To assess the anti-
MMTV humoral response, BALB/cJ and BALB/Mtv-null mice were foster-nursed
on MMTV+ C3H/HeN mice followed by analysis of MMTV-specific antibodies
in sera obtained weekly (Figure 3.25A). BALB/cJ mice sporadically developed
virus-specific antibodies during the first 3 to 5 weeks of age as reported previously
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Figure 3.24.Mammary tumors induced in the XC/HYB-MTV-injected BALB/ Mtv-SP mice
express MMTV(C3H) transcripts.
RT-PCR was performed using RNA from MMTV-induced mammary tumors from four BALB/Mtv8
(lanes 3-6), 1 BALB/Mtv9 (lane 7), and 1 BALB/Mtv6 (lane 8) females. Endogenous and
exogenous MMTV-specific cDNAs were amplified by PCR using MMTVenv and LTR-specific
primers TBLVENV8509(+) and C3HLTR501(-). Amplification of the endogenousMtv-specific
cDNAs served as an internal positive control for the PCR. PCR products were then digested
with ClaI followed by agarose gel electrophoresis. An internal plasmid control forClaI-mediated
restriction digestion was included in each reaction. The results are shown in the top panel, and
the positions of fragments generated byClaI digestion of the internal plasmid control are marked
(red asterisks). EndogenousMtv-specific RT-PCR products that remain undigested byClaI (green
asterisk), and the two fragments generated byClaI digestion of MMTV(C3H)-specific RT-PCR
products (pink asterisks) are also indicated. Controls for RNA integrity (bottom panel) and lack of
DNA contamination (middle panel) also are shown.
undetectable in older (6 to 9 week-old) mice. Serum antibodies against MMTV
were also detected in about 30% of the BALB/Mtv-null mice infected by milk-
borne MMTV, and some individuals demonstrated a higher antibody titer than that
obtained in infected BALB/cJ mice. The anti-MMTV response was also maintained
for a longer duration in these BALB/Mtv-null mice compared to the BALB/cJ mice.
The serum antibodies from BALB/Mtv-null mice were specific for MMTV capsid
as determined by Western blotting against purified MMTV virions (Figure 3.25B).
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BALB/Mtv-null serum antibodies did not demonstrate any reactivity with MMTV
Env proteins, suggesting their inability to function in virus neutralization.
Thus, the resistance of BALB/Mtv-null mice towards MMTV tumorigenesis























































Figure 3.25.BALB/ Mtv-null mice infected by milk-borne MMTV develop MMTV CA-
specific serum antibodies.
(A) Sera from milk-borne MMTV(C3H)-infected (blue) or age-matched uninfected (pink) BALB/cJ
(squares) and BALB/Mtv-null (circles) mice were analyzed weekly by ELISA to detect MMTV
virion-specific antibodies. Each symbol represents an individual mouse. The serum antibody titer
was calculated as the reciprocal of the highest serum dilution that reacted specifically with MMTV
virions. (B) Western blot against MMTV virion proteins using a 1:20 dilution of sera (titer =
320) from MMTV(C3H)-infected BALB/Mtv-null mice at 4 to 5 weeks of age. MMTV CA or
SU-specific monoclonal antibodies were used as positive controls. Sera from two age-matched
uninfected BALB/Mtv-null mice were used as negative controls.
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3.2.9 BALB/ Mtv-null mice reject MMTV-expressing BALB/cJ B-cells.
The resistance of BALB/Mtv-null mice towards MMTV tumorigenesis also
may result from a cell-mediated immune response against virus-infected cells.
To evaluate this hypothesis, weanling BALB/Mtv-null and BALB/cJ mice were
inoculated with 5×106 A20 (BALB/c B-cell lymphoma line) cells [221]. A second
set of mice were inoculated with 5×106 A20 cells stably expressing HYB-MTV
(A20/HYB-MTV) (Figure 3.26). The proliferation of A20 cells resulted in solid,
peritoneal tumors in 25% of the inoculated BALB/cJ mice with an average latency
of 7.5 ± 1.5 weeks (Table 3.6). BALB/Mtv-null mice had a similar tolerance
towards A20 cells since 29% of these mice developed peritoneal A20 tumors within
6.8 ± 2.3 weeks. Thirty eight percent of the BALB/cJ mice also developed
large, peritoneal outgrowths within 5.2 ± 0.5 weeks of inoculation with MMTV-
expressing A20 cells (Table 3.6). In contrast, the BALB/Mtv-null mice completely
rejected the same dosage of A20/HYB-MTV cells and failed to develop any tumors.
This experiment provides preliminary evidence that the resistance towards
MMTV tumorigenesis in the BALB/Mtv-null strain might be influenced by the cell-
mediated cytotoxic immune response of these mice towards MMTV-infected cells.
3.2.10 BALB/ Mtv-null mice are resistant toVibrio cholerae.
Since the resistance of BALB/Mtv-null mice towards MMTV and TBLV-
induced tumorigenesis might be an immunological phenomenon, it is possible that
this mouse strain has an altered response to other pathogens. The susceptibilities
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Figure 3.26.Characterization of A20/HYB-MTV cells.
(A) HYB-MTV RNA expression in A20/HYB-MTV cells was verified by RT-PCR andClaI
RFLP analysis. MMTV-specific cDNAs were PCR-amplified usingenvand LTR-specific primers
TBLVENV8509(+) and C3HLTR501(-). Amplification of the endogenousMtv-specific cDNAs
served as an internal positive control. PCR products were digested withClaI followed by agarose gel
electrophoresis (top panel). An internal plasmid control forClaI-mediated restriction digestion was
included in each reaction (red asterisks). EndogenousMtv-specific RT-PCR products that remain
undigested byClaI (green asterisk) and the two fragments generated byClaI digestion of HYB-
MTV-specific RT-PCR products (pink asterisks) are also indicated. RT-PCR amplification ofgapd
mRNA served as a control for RNA integrity and quantitation (B) Western blot analysis of MMTV
Gag expression in A20/HYB-MTV cells. Gag precursors (indicated by arrows) were detected in
100µg of whole cell lysates (WCL) with MMTV CA-specific monoclonal antibody [350]. WCL
from untransfected A20 cells was used as a control to determine the level of Gag expression from
endogenousMtvs.
expresses cholera toxin, were compared by intragastric inoculation of 5 to 6-day-
old pups with 50µl of bacterial suspensions containing 105, 106 or 107 CFU of
mid-log phase bacteria. The average LD50 of V. cholerae0395 in BALB/cJ mice
was calculated to be 1.6×105 CFU (Table 3.8). In contrast, the average LD50 of V.
choleraein BALB/Mtv-null mice was 10-fold higher (2.3×106 CFU) (Table 3.7).
To evaluate whether the increased resistance toV. cholerae in the
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Table 3.6.BALB/ Mtv-null mice reject BALB/c B-cell lymphoma stably expressing
HYB-MTV.
A20 A20/HYB-MTV
Mouse Tumor Average Tumor Average
strain incidencea latency incidencea latency
(weeks)b (weeks)b
BALB/cJ 25% (3/12) 7.5 ± 1.5 38% (5/13) 5.2 ± 0.5
BALB/Mtv-null 29% (4/14) 6.8 ± 2.3 (0/14) –
a A20 and A20/HYB-MTV cells formed solid tumors in the peritoneum. The incidence is calculated
as a percentage, and the number of mice with tumors versus the number of inoculated mice is shown
within brackets.
b Mean (± standard deviation).
BALB/Mtv-null strain was linked to the absence of endogenousMtvs, the
susceptibilities of the BALB/Mtv6, BALB/Mtv8 and BALB/Mtv9 strains of mice
to V. choleraeinfection were determined. The average LD50 of V. choleraein
these three strains was 2.25×105, <1.2×105, and 2×105, respectively (Tables 3.9,
3.10, and 3.11) indicating that the susceptibilities of BALB/Mtv6, BALB/Mtv8, and
BALB/Mtv9 mice toV. choleraeinfection were comparable to that of the BALB/cJ
strain. The results were analyzed by single-factor ANOVA followed by Tukey’s
post-hoc test using SPSS 12.0. A significant difference (P<0.05) was observed
between the average LD50 of BALB/Mtv-null mice compared to the BALB/cJ strain,
while the BALB/Mtv-SP mice were statistically similar to the BALB/cJ strain in
their susceptibilities toV. cholerae. Thus, susceptibility toV. choleraeco-segregates
with endogenousMtv loci located on separate chromosomes. These data indicate
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Table 3.7.LD50 of Vibrio cholerae0395 in BALB/Mtv-null mice.
Experiment Dose Dead/Live pups LD50
9×107 4/0
1 8×106 4/0 1.3×106
4×105 0/4
8.5×106 2/1
2 9×105 2/2 1.6×106
6.5×104 0/4
7.5×106 2/1
3 9×105 0/2 5×106
9×104 0/3
1.5×107 3/0
4 5×105 0/4 1.5×106
2×105 0/4
Average LD50 2.3×106
that the lower mortality rate followingV. choleraeinfection in the BALB/Mtv-null
strain is also due to the absence of endogenousMtv .
These results elucidate a generic resistance mechanism in the BALB/Mtv-
null mice that provides a heightened resistance to disparate pathogens, MMTV and
V. cholerae. The resistance to both pathogens is linked to the absence of endogenous
Mtvs in the BALB/Mtv-null mice.
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Table 3.8.LD50 of Vibrio cholerae0395 in BALB/cJ mice.
Experiment Dose Dead/Live pups LD50
2×107 3/1
1 6×105 3/1 2.2×105
5×104 1/2
3.5×107 4/0
2 4×106 4/0 1×105
1×105 2/2
3×107 2/0
3 4.5×106 3/0 <8.5×104
8.5×104 2/1
Average LD50 1.6×105
Table 3.9.LD50 of Vibrio cholerae0395 in BALB/Mtv6 mice.
Experiment Dose Dead/Live pups LD50
7.5×106 3/0
1 9×105 3/1 2×105
9×104 1/1
8.5×106 2/1
2 9×105 3/1 4×105
6.5×104 0/3
4×107 3/0
3 3.5×106 4/0 2×105
1×105 1/3
2×106 2/0




Table 3.10.LD50 of Vibrio cholerae0395 in BALB/Mtv8 mice.
Experiment Dose Dead/Live pups LD50
2×107 4/0
1 1×106 4/1 8×104
5×104 2/2
2×107 3/0
2 2.7×106 4/1 < 1.2× 105
1.2×105 2/0
2.4×107 3/0
3 7.5×106 2/0 < 1.6× 105
1.6×105 2/1
Average LD50 < 1.2× 105
Table 3.11.LD50 of Vibrio cholerae0395 in BALB/Mtv9 mice.
Experiment Dose Dead/Live pups LD50
1.25×107 4/0
1 9×105 4/0 8.4×104
4×104 1/3
1.5×107 3/0
2 1.5×106 3/0 2.2× 105
7.5×104 0/3
4.3×107 3/0
3 2.3×106 5/0 2× 105
9×104 1/3
1×107 2/0





4.1 Conversion of MMTV to a Lymphomagenic Virus
4.1.1 A novel TBLV tumorigenicity assay
A molecular clone of TBLV (HYB-TBLV) was constructed to study the
life cycle and tumorigenicity of a previously heterogeneous virus. HYB-TBLV
was engineered by substituting theClaI to SstI region of the TBLV LTR into
the corresponding region of the 3’ LTR of HYB-MTV [403]. Adult BALB/cJ
mice inoculated intraperitoneally with Jurkat T cells stably expressing HYB-TBLV
consistently developed a 50% incidence of T-cell lymphomas with a latency of 5.7
± 1.5 months. A similar change in the tumor target tissue, from mammary gland
to thymus, was reported for recombinant viruses obtained by substitution of the
3’ LTR of HYB-MTV with the entire LTR of thymotropic MMTV variants MA
and DL-8 [475]. Lymphomagenicity of HYB-TBLV allowed the definition of a
smaller (438 bp) region (encompassing the LTR deletion and substitution) of the
thymotropic LTR that is sufficient for altering the tumorigenicity of the recombinant
provirus.
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Rat XC fibroblasts [418] have been widely used for introducing the MMTV
molecular clone, HYB-MTV, into mice [403]. However, XC-cell transfectants
of HYB-TBLV were highly inconsistent in transmitting infection resulting in
tumorigenesis in mice [Mustafa, F.et. al., unpublished observations). This
inefficiency might be due to the low infectious titer of virus produced by XC cells.
Additionally, XC cells do not release extracellular virions, which might have a
significant influence on the infection efficiency. Jurkat T cells were selected as
carriers of HYB-TBLV with the assumption that the T-cell-specific enhancer in
the TBLV LTR would allow elevated viral transcription in T cells, leading to the
production of higher viral titers. Jurkat T cells also release extracellular virions
[317] that might facilitate a greater efficiency of infection and hence tumorigenesis.
Inherent properties of the cell lines might also influence the infectiousness of the
stable transfectants. The different nature of the immune response and cell-cell
interactions induced by XC cells and Jurkat T cells may have a significant influence
on the ability of these cells to transfer the virus to host cells. It has been suggested
that dissemination of MMTV infection is mediated mainly by cell-cell contact
rather than free viral particles [379]. Neither XC nor Jurkat cells induce tumors
in mice due to the host immune reaction against the xenogeneic cell lines [410].
Previous studies on TBLV were performed by intrathymic inoculation
of newborn pups with heterogeneous virus-containing cultured lymphoma-cell
supernatants [21, 22, 23, 375]. Thymic lymphomas developed in 90% of these
animals within 42 to 60 days of inoculation [21, 22, 23, 309, 375]. Several
factors might have contributed to the lower incidence and longer latency of HYB-
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TBLV-induced lymphomas. First, since the thymus starts to regress in adult mice
[148, 193], fewer proliferating thymocytes would be available for infection and
random insertional mutagenesis by TBLV [59, 358]. The ages of the thymic and
bone marrow microenvironments were demonstrated to influence the induction of
radiation-induced thymic lymphomas in mice [437]. The tumor incidence was
much higher in younger microenvironments as compared to tissues from older
mice, perhaps due to secreted growth factors. Second, the route of infection
might influence the efficiency of tumorigenesis. Lymphoma cell supernatants
were introduced into newborn mice intrathymically, thus directly inoculating TBLV
into the target for oncogenesis, whereas HYB-TBLV-expressing Jurkat cells were
introduced into the mouse peritoneum, requiring virus transmission by an unknown
mechanism to thymocytes or their progenitors. Third, the infectious viral titer
introduced into mice by injecting 485-10 lymphoma cell supernatants might have
been much higher compared to the infectious titer obtained from Jurkat cells
expressing HYB-TBLV. Fourth, it is possible that the culture supernatants from 485-
10 cells contained a mixture of TBLV strains, which contributed to the transforming
activity compared to the clonal HYB-TBLV produced by Jurkat T cells.
Thymic lymphomas induced by HYB-TBLV were phenotypically similar
to the lymphomas induced by uncloned virus-containing culture supernatants
from 485-10 lymphoma cells [309, 310]. In each case, the lymphomas were
oligoclonal as determined by Southern blot analysis of TCRβ and γ chain
rearrangements. Tumor cell populations were Thy1.2+ and heterogeneous for
CD4 and CD8 surface markers. Most tumors had an abnormal proportion of
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CD4/CD8 double-positive, double-negative and single-positive cells compared to
the ratio of these compartments in a normal thymus. Oligoclonal tumors might
arise by proliferation and differentiation, involving TCR gene rearrangements and
co-receptor expression, of a single transformed pluripotent precursor cell [50].
Abnormal proportions of thymocyte compartments could also result from abnormal
differentiation of transformed progenitor cells. Oligoclonality might also arise from
transformation of multiple thymocytes that have undergone independent TCR gene
rearrangements and selection for co-receptor usage [50]. However, the finding that
TBLV-induced tumors have multiple integrations near c-myc and Rorγ [59, 60]
and the detection of distinct TCR rearrangements suggest that multiple cells are
transformed by TBLV followed by differential growth selection of these cells.
Thus, the T-cell lymphomas induced by the TBLV hybrid proviral clone in
adult mice are comparable to those induced by inoculation of newborn mice with the
culture supernatant from 485-10 lymphoma cells. Development of a cloned TBLV
provirus-based tumorigenicity assay provides a valuable tool for the molecular
dissection of viral elements required for determining MMTV disease specificity.
4.1.2 Sag-independent TBLV lymphomagenesis
A sag-frameshift provirus (HYB-TBLVsagDFS), encoding only the first
17 amino acids of Sag, was engineered to determine the role of the truncated
Sag in TBLV-induced lymphomagenesis. The incidence (60%) and latency (4.8
± 0.6 months) of lymphoma induction by HYB-TBLVsagDFS was not significantly
different from the wild-type HYB-TBLV. The frameshift virus induced lymphomas
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that were oligoclonal as determined by Southern blotting analysis of TCRβ and
γ chain rearrangements. These tumors also were not significantly different
from HYB-TBLV-induced lymphomas with respect to the cell surface markers:
CD4, CD8 and Thy1.2. Thus, truncated Sag is not required for TBLV-induced
tumorigenesis in BALB/cJ mice and might be specific for the intraperitoneal route
of infection. Alternatively, the Sag proteins expressed from the endogenousMtvs
in the BALB/cJ mice may complement thesag-null TBLV provirus. However, it is
likely that the truncated Sag has no role in TBLV-induced tumorigenesis and that
cis-acting LTR transcriptional elements are critical for TBLV tumorigenicity.
4.1.3 Similarity of MMTV NRE with insulators
T-cell enhancer position with respect to the NRE within the MMTV
LTR influences its contribution toward transcriptional efficiency. When placed
downstream of the NRE adjacent to the promoter, the enhancer gives 700-fold
increased transcription from the MMTV LTR in Jurkat T cells. However, when
the NRE is situated between the enhancer and the promoter, the transcriptional
influence of the enhancer is greatly mitigated. Thus, the MMTV NRE, which
binds CDP and SATB1, represses the TBLV enhancer in mutant MMTV LTRs in a
position-dependent manner.
Binding of SATB1 and CDP to matrix attachment regions (MARs) is known
to repress transcriptional enhancers by – (i) antagonizing transcriptional activators,
e.g., CDP binding to flanking MAR elements interferes with Bright (B-cell
regulator of IgH transcription) at the immunoglobulin heavy chain intronic enhancer
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(Eµ) [453] and (ii) modulating the chromatin structure, e.g., at MARβ located
upstream of the TCRβ enhancer (Eβ) [74, 220]. However, the position sensitivity of
the NRE-mediated repression is reminiscent of the action of insulator elements. A
defining property of insulators is their interference with the activity of silencers
and enhancers when placed between the regulatory element and the promoter,
whereas such regulatory elements are not inhibited in a promoter-proximal location
[142]. Insulator sequences appear to function by several different mechanisms,
including – insulator-insulator interactions that form chromatin loop domains;
recruitment of chromatin-modifying/remodelling complexes, either directly or via
general regulatory factors (GRFs), which act as landing platforms; enhancer
capture involving decoy promoters; association with nuclear pore complexes; and
interaction with the nuclear matrix via MAR/SAR (scaffold attachment region)
domains [142, 235, 319]. Interestingly, SATB1 has been proposed to function as a
GRF at insulators [142]. Moreover, its negative regulatory activity for the MMTV
promoter requires interaction with the nuclear matrix [401].
4.1.4 Increased glucocorticoid induction of MMTV by the TBLV enhancer
The MMTV LTR demonstrated a 5-fold glucocorticoid induction of its
transcriptional activity in HC11 cells. The TBLV and MMTV LTRs both have six
HREs due to triplication of an HRE half-site within the T-cell enhancer and removal
of the two HREs located within the NREs [27, 141, 338]. However, compared
to MMTV, the TBLV LTR demonstrated an enhanced glucocorticoid response
that may result from absence of NRE-mediated repression of hormone-induced
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transcription [483]. Also, the HREs embedded within the MMTV NREs [141]
may not function effectively in the glucocorticoid induction of MMTV LTR-driven
transcription. Sequences surrounding MMTV HREs are known to influence the
activity of the HREs by determining the recruitment of co-factors, which destabilize
GR binding to the HREs in a cell-type specific manner [203]. Furthermore, a region
(between -163 to -147 bp from the transcription start site) within the MMTV HRE
has been implicated in binding nuclear factors that negatively regulate the hormone
responsiveness of the LTR in certain cell lines [420]. The distance between the
MMTV TATA box and the HREs also influences the transcriptional activation since
altering the distance beyond the optimum decreases transcriptional activation [180].
The MMTV mutant MTVAflE LTR harbors nine HREs yet its glucocorticoid
responsiveness is similar to that of the TBLV LTR. This might result from inefficient
GR binding to the HREs located within the NRE. The MTVStuE LTR also
harbors nine HREs, but demonstrates a significantly lower glucocorticoid induction
compared to both TBLV and MTVAflE LTRs. Thus, as discussed in Section
4.1.3, the position of the NRE with respect to the enhancer influences its activity,
including the glucocorticoid response of the MMTV LTR.
The NREs repress both hormone-induced and basal transcription from the
MMTV LTR [483]. Thus, the MTV∆NRE LTR lacking the entire NRE shows
an increased basal transcription in HC11 cells. However, the TBLV LTR also
lacks the NRE but does not demonstrate a significantly higher basal transcription
compared to the MMTV LTR, suggesting that the T-cell enhancer might have a
negative influence on the basal MMTV transcription in HC11 mammary cells. The
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MTV∆NRE LTR harbors three HREs but does not show a significantly higher
induction by glucocorticoids. Since hormone receptor-binding sites in the MMTV
LTR act synergistically [20] a reduction in the number of HREs in the LTR would
reduce the efficiency of glucocorticoid induction.
4.1.5 Requirement of a T-cell enhancer and loss of NRE activity in
lymphomagenic MMTVs
Unlike wild-type HYB-MTV, which exclusively induces mammary tumors
in BALB/cJ mice, HYB-MTVAflE and HYB-MTVStuE induced both mammary
tumors and thymic lymphomas in the infected mice. The lower incidence of
tumor induction by the HYB-MTVStuE and HYB-MTVAflE viruses might be
within experimental variation; however, the lower transcriptional efficiency of the
MTVStuE LTR compared to the TBLV LTR in T cells may result in a slower
viral amplification and a decreased rate of oncogenesis. Additionally, the time
required for the selection of HYB-MTVStuE recombinants might also contribute
towards the lower incidence of lymphomagenesis. The transcriptional strength
of the MTVAflE LTR is comparable to that of the TBLV LTR; however, unlike
TBLV, the MTVAflE virus induced Sag-mediated T-cell deletion. This deletion
is also statistically faster than the T-cell deletion observed in HYB-MTV infected
mice. The low tumor incidence of the HYB-MTVAflE virus might be a by-product
of the rapid deletion of T cells that might serve as oncogenesis targets and also
function in viral amplification and spread. Rapid Sag-mediated T-cell depletion
has been correlated with a low mammary tumor incidence in adult mice infected
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with MMTV(SW) [335]. The significantly faster Sag-mediated T-cell deletion in
mice infected by HYB-MTVAflE might result from the higher viral loads generated
by enhanced viral replication in T cells. However, faster kinetics of Sag-mediated
T-cell depletion may be due to experimental variation.
RT-PCR and Southern blot analysis of lymphoma RNA and DNA revealed
that both the T-cell enhancer and the NREs were retained in the predominant
HYB-MTV AflE proviruses. In contrast, proviruses containing only the T-cell
enhancer and lacking the NREs were selected in all the HYB-MTVStuE-induced
thymic lymphomas. Selection of NRE-minus proviruses was not observed in
HYB-MTV StuE-induced mammary tumors, even in an animal that developed
both a mammary tumor and a thymic lymphoma. These results suggest that
the development of lymphomagenic MMTV requires two alterations in the
LTR transcriptional regulatory elements, loss of NRE-mediated transcriptional
repression and, T-cell enhancer acquisition. Besides TBLV, the LTR transcriptional
strengths of two other naturally occuring thymotropic MMTV variants (MA and
DL-8) have been tested in T-cell lines. Both of these LTRs were also shown to
harbor T-cell enhancers along with deletions within the NRE.
The selection of NRE-minus recombinants in HYB-MTVStuE-induced
lymphomas may be driven by the incomplete suppression of NRE activity by
the upstream T-cell enhancer as observed in transient transfection assays in T
cells. HYB-MTVAflE is not subject to this selection pressure since the T-cell
enhancer located downstream of the NRE completely masks its repressive activity.
Loss of NRE activity and T-cell enhancer acquisition would allow increased viral
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expression in T cells resulting in a higher probability of oncogenic insertional
mutagenesis. The viral T-cell enhancer also may be critical for transcriptional
upregulation of appropriate cellular oncogenes resulting in lymphomagenesis. The
composition of viral enhancers has been correlated with altered patterns of proviral
integrations near cellular oncogenes [321]. Furthermore, the lymphomagenic
ability of HYB-MTV AflE confirms that Sag truncation is dispensable for MMTV-
induced lymphomagenesis, although T-cell tumor incidence may be increased.
4.1.6 Presence of NREs and T-cell enhancer loss in mammotropic MMTVs
The predominant proviruses expressed in HYB-MTVAflE and HYB-
MTVStuE-induced mammary tumors lacked the T-cell enhancer while harboring
the NREs. Selection of such variants indicates the incompatibility of the T-cell
enhancer in the context of MMTV-induced mammary tumorigenesis and might
also explain the lower incidence of mammary tumor induction by HYB-MTVStuE
and HYB-MTVAflE viruses. The T-cell enhancer might negatively affect MMTV
LTR-driven transcription in mammary cells (as suggested by transient transfection
assays), thus slowing viral replication and oncogenic insertional mutagenesis.
The T-cell enhancer could also antagonize MMTV-induced mammary cell-specific
oncogene activation required for mammary tumorigenesis.
Interestingly, the predominant proviruses detected in HYB-MTV∆NRE-
induced mammary tumor were recombinants that had acquired the NRE sequences.
This observation suggests that the NREs play a positive role in MMTV-
induced mammary tumorigenesis by enhancing viral transcription in differentiated
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mammary cells or through oncogene activation. The low tumor incidence of the
HYB-MTV ∆NRE virus might be due to the requirement for such recombinants.
4.1.7 Summary and conclusions
In conclusion, these studies demonstrated that LTRcis-acting transcriptional
elements are the critical determinants of MMTV-induced tumorigenesis. Viral
transcriptional elements determine the level of viral expression in specific cell types
and their potential to activate the appropriate cellular oncogenes. Altered patterns of
tumorigenesis resulting from changes in the composition of transcriptional elements
in viral LTRs has been extensively reported for murine and feline leukemia viruses,
e.g., SL3-3 and FeLV [322, 411]. However, these studies are unique in altering
disease specificity between epithelial and lymphoid cell types.
4.1.8 Scope of further studies
The contribution of individual transcription factors in determining MMTV-
induced disease remains unclear. However, in view of the rapid selection of
recombinants that occurs duringin vivoexperiments, unambiguous results would be
difficult to achieve. Future experiments could attempt to target MMTV oncogenesis
using tissue-specific enhancers in a promoter-proximal location within the viral
LTR. For example, insertion of the immunoglobulin B-cell enhancer upstream
of the MMTV promoter may result in recombinant viruses that induce B-cell
lymphomas. Such recombinant viruses may be useful in determining novel tissue-
specific oncogenes and tumor suppressors.
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4.2 An EndogenousMtv-Free BALB/cJ Congenic Mouse Strain
is Resistant to MMTV, TBLV and Vibrio cholerae.
4.2.1 A novel mode of resistance to MMTV
These studies describe a novel mechanism of resistance to exogenous
MMTV(C3H)-induced mammary tumorigenesis in a BALB/cJ congenic mouse
strain (BALB/Mtv-null) that lacks the three endogenousMtvs resident in the
BALB/cJ germline [65, 372]. An immune response to MMTV(C3H) Sag was
also negligible in the BALB/Mtv-null mice. Deletion of Sag-reactive T cells
was not detectable in adult BALB/Mtv-null mice inoculated intraperitoneally with
XC/HYB-MTV cells, whereas a very low-grade deletion of Sag-reactive cells was
observed in mice infected by milk-borne MMTV. The low-grade T-cell deletion in
neonatally infected BALB/Mtv-null mice might be due to maternal Sag-presenting
B cells introduced via milk [16] since non-self MHC class II molecules can also
induce an immune response to MMTV Sag [416]. This explanation is consistent
with the low-grade deletion observed in the CD4+Vβ3+ T-cell subset that is reactive
to the endogenousMtv6, but not to the MMTV(C3H) Sag, present in the C3H/HeN
strain (Figure 3.16B, left panel).
4.2.2 Role of MMTV Sag in the viral life cycle
Despite impaired Sag-mediated viral amplification, the BALB/Mtv-null
mice were susceptible to MMTV infection. Viral transcripts were detected by
RT-PCR analysis in various mouse organs, including the mammary glands and
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spleen. A number of studies have suggested that Sag-induced interaction of T
and B cells is critical for a robust infection by exogenous MMTV, leading to
oncogenesis. Transgenic mice expressing high levels of MMTV(C3H) Sag delete
their Sag-cognate Vβ14+ T cells and fail to be infected by exogenous, milk-borne
MMTV(C3H) due to the absence of Sag-reactive T cells [157]. A similar phenotype
has been reported in TCR Vβ8.2 transgenic mice that are resistant to MMTV(SW)
whose Sag does not recognize TCR Vβ8.2 [184]. Milk-borne MMTV also fails to
infect B-cell-deficient mice as determined by the absence of Sag-mediated T-cell
deletion and proviral integrations in the spleen and mammary glands [40].
Knock-out mice deficient in cell surface molecules involved in T-B cellular
interaction also fail to efficiently propagate milk-borne MMTV. CD40L-/- mice
infected by milk-borne MMTV show rare proviral integrations in their spleen and
lack Sag-mediated T-cell deletion [76]. Similarly, mice deficient in CD28/CTLA4-
B7 interactions show minimal Sag-mediated peripheral T-cell deletion and limited
viral dissemination [73], whereas MHC class II deficient mice infected by milk-
borne MMTV(C3H) show drastically reduced viral spread from the gut to the
mammary gland [41].
4.2.3 Resistance of BALB/Mtv-null mice to TBLV
The resistance of BALB/Mtv-null mice to MMTV-induced tumorigenesis
may be due to the lack of Sag-mediated immune response and poor viral
amplification in the lymphoid compartment. However, BALB/Mtv-null mice were
also resistant to Sag-independent, TBLV-induced lymphomagenesis. TBLV is a
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T-cell tropic variant of MMTV that encodes a truncated Sag protein lacking the
C-terminal region required for TCR recognition [27, 466]. Lack of TBLV-induced
tumorigenesis suggests that the resistance phenomenon of BALB/Mtv-null mice is
linked to the host immune system at a step that is upstream of the Sag response
and common to both MMTV and TBLV infections. The lack of Sag-mediated
T-cell deletion appears to be a downstream effect of the limiting step because a
direct correlation was observed between the presence/absence of Sag-mediated T-
cell deletion and susceptibility/resistance, respectively, to MMTV-induced tumors.
These results also demonstrate that resistance of BALB/Mtv-null mice to tumor
induction is independent of the target organs and tissues.
4.2.4 Correlation of Mtv loss with MMTV resistance in BALB/Mtv-null mice
Genetic mapping linked the resistance phenomenon of BALB/Mtv-null
mice to the absence of endogenousMtvs in this strain. BALB/cJ congenic
strains containing any one of the three endogenous proviruses (Mtv6, 8 or 9)
were susceptible to MMTV(C3H) Sag-mediated T-cell deletion and mammary
tumorigenesis. The endogenousMtv-free siblings of mice carrying singleMtvs,
did not undergo MMTV(C3H) Sag-mediated T-cell deletion and also demonstrated
a lower mammary tumor incidence. The extent of deletion as well as the tumor
incidence in XC/HYB-MTV injected BALB/Mtv-positive mice was lower than that
of injected BALB/cJ mice; this result may be due to a gene dosage effect since
BALB/cJ mice contain two copies each ofMtv6, 8, and 9 while the BALB/Mtv-SP
mice contain one or two copies of a single endogenous provirus.
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A combination of two or more endogenousMtv strains may be required to
achieve the level of susceptibility observed in BALB/cJ mice. In agreement with
this idea, BALB/cJ x BALB/Mtv-null F1 mice, which harbor a single copy each
of Mtv6, 8, and 9, were very similar to BALB/cJ mice in their susceptibility to
MMTV-induced tumorigenesis and kinetics of Sag-mediated T-cell deletion. Thus,
the presence of endogenousMtvs in BALB/cJ mice renders them susceptible to
exogenous MMTV(C3H)-induced tumorigenesis. These observations demonstrate
that although endogenousMtvs were proposed to protect against infection by
exogenous MMTV strains of similar Sag specificity [157, 184], they can also
facilitate tumorigenesis by exogenous MMTVs encoding Sags of alternate TCR
Vβ specificity.
4.2.5 Lack of MMTV-neutralizing antibodies in BALB/ Mtv-null mice
Another endogenousMtv-free mouse strain derived from a BALB.D2
(inbred, Mtv6, 7, 8, 9) x 38CH (wild-derived inbred,Mtv-free) cross has been
described to be relatively resistant to MMTV infection and cancer development
[139]. The resistance phenomenon was attributed to the lack of immune tolerance
to MMTV since the neonatal immune system ofMtv-free mice develops in the
absence of endogenousMtv-encoded proteins [139]. Compared toMtv-expressing
mice, higher levels of MMTV-specific antibodies were detected in theseMtv-free
mice in response to exogenous MMTV infection. Increased neutralizing antibodies
were implicated in providing partial protection against chronic MMTV infection,
resulting in viral clearance within a few generations [139]. Low titer, MMTV-
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specific antibodies also were detected in the sera of about 30% of the BALB/Mtv-
null mice infected by milk-borne MMTV. These antibodies were specific for
MMTV capsid protein and did not react with MMTV Env proteins thus, precluding
their role in virus neutralization. The remaining 70% of the MMTV-infected
BALB/Mtv-null mice did not develop any antibodies against MMTV. Lack of Sag-
mediated T-cell deletion in BALB/Mtv-null mice also distinguishes them from the
BALB.D2-congenicMtv-free strain [139]. Therefore, the resistance of BALB/Mtv-
null mice to MMTV-induced tumorigenesis is linked to the absence of endogenous
Mtvs and cannot be attributed to antibody-mediated viral clearance and lack of
tolerance to virus infection.
4.2.6 Susceptibility to MMTV in other Mtv-free mouse strains
Resistance to tumorigenesis by exogenous MMTV has not been described
in other known strains ofMtv-free mice. The wild-derived inbred strain Czech II is
free of endogenousMtvs but harbors a milk-transmitted exogenous MMTV(Czech
II) virus [144]. Czech II mouse colonies display an average mammary tumor
incidence of 12% with a latency of 9 to 28 months [144]. The low tumor
incidence has been interpreted to be a result of the low virulence of MMTV(Czech
II). Infection studies using highly tumorigenic strains of MMTV have not been
performed in these mice. An inbred, endogenousMtv-free mouse strain derived
from a cross between C58/J and CBA/CaJ strains also has been described [388].
This strain was shown to be susceptible to infection by a newly described exogenous
MMTV strain, JYG-MMTV [471]. Viral RNA was detected in the mammary
148
glands of infected female mice and also in the milk collected from 2-day old pups,
tumorigenicity was not assessed.
4.2.7 Cell-mediated immunity and MMTV resistance of BALB/Mtv-null
mice
The resistance to exogenous MMTV in BALB/Mtv-null mice might be
mediated by an enhanced cytotoxic T lymphocyte (CTL) response directed at
MMTV-infected cells due to the lack of immunologic tolerance provided by
endogenousMtvs in BALB/cJ mice. MMTV Env-derived peptides have been
demonstrated to activate peptide-specific CTLs that result in reduced tumor growth
[455]. A heightened MMTV-specific immune response mediated by CTLs in the
BALB/Mtv-null mice might also be the basis for complete rejection of the BALB/cJ
B-cell lymphoma line, A20, stably expressing HYB-MTV. However, BALB/Mtv-
null mice develop A20 tumors, which express endogenousMtvs, with a 29%
incidence, perhaps reflecting the greater immunogenicity of HYB-MTV encoded
proteins. However, BALB/Mtv6 mice were susceptible to MMTV-induced tumors,
despite the incomplete nature of theMtv6 provirus. Mtv6 has a 6241 bp deletion
encompassing most of thegagandenvgenes and the entirepol gene [78] and this
deletion removes most of the immunodominant CTL epitopes of both Gag and Env
[153]. Therefore, BALB/Mtv6 mice would not be tolerant to these epitopes on
exogenous MMTV proteins. Preliminary experiments comparing the anti-MMTV
CTL responses of BALB/cJ and BALB/Mtv-null mice inex-vivoandin-vivoassays
failed to detect>2% specific lysis in either case (data not shown).
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4.2.8 Effect of MMTV Sag on immune response against pathogens
Sags encoded by endogenousMtvs alter the immune repertoire of mice
by influencing both positive and negative selection of T cells [388]. Unlike
BALB/Mtv-null mice, BALB/cJ mice demonstrate almost complete deletion of
Vβ3, 5, 7 and 12+ T cells from their periphery while harboring a compensatory
increase in other TCR Vβ subsets like Vβ14+ T cells [the subset recognized
by MMTV(C3H) Sag]. This alteration of T-cell subsets might influence the
tumorigenesis of exogenous MMTVs, even for those encoding Sags with different
TCR specificities than endogenousMtv Sags.
The Sag-mediated alteration of the T-cell repertoire has been shown to
influence the susceptibility or resistance to various infections. In inbred mouse
strains bearing the H-2k MHC haplotype, susceptibility to polyomavirus-induced
tumors has been linked to the presence of endogenousMtv7 [255]. TheMtv7-
encoded Sag mediates the deletion of Vβ6+ T cells that are essential for mounting
a robust anti-tumor CTL response on an H-2k background. Similarly,Mtv7 Sag-
mediated deletion of TCR Vβ8.1+ T cells has been shown to confer resistance to
cerebral malaria induced byPlasmodium berghei[167]. Sag-mediated deletion of
TCR Vβ4+ T cells by MMTV(SIM) renders BALB/cJ mice resistant toLeishmania
major infection [240]. Vβ4+ and Vβ8+ CD4+ T cells produce an early burst of IL4
in response toL. major that induces a Th2 response and susceptibility to infection
in BALB/cJ mice. Lastly, resistance toPlasmodium yoeliiin the BALB/c strain has
been linked to the presence of the endogenousMtv7 locus [419].
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4.2.9 Role of endogenousMtvs during exogenous MMTV infection
EndogenousMtv-encoded protein(s) might cooperate with exogenous
MMTV in facilitating (i) efficient infection of specific cell types, for instance
DCs and B cells, and/or (ii) appropriate cellular interactions and/or activation and
proliferation, e.g., DC-mediated T-cell priming. This cooperation would allow
a Sag-mediated immune response, leading to viral spread and tumor induction.
However, the role of DCs and B cells in TBLV-induced tumors is unknown.Ex-
vivo bromodeoxyuridine (BrdU) incorporation assays did not reveal differences in
the percentage of cycling cells in the draining lymph nodes following foot-pad
inoculation of MMTV (data not shown). Interestingly, milk-borne MMTV(C3H)
infection has been demonstrated to induce endogenousMtv aggene expression in
BALB/cJ and C3H/HeN mice [469]. Ten to 30 fold induction of endogenousMtv
sagmRNA was observed in the gut-associated lymphoid cells, spleen and thymus
of these mice within 24 hr post-infection. This induction was specific for the spliced
sagtranscript since no increase was observed in the total endogenousMtv RNA.
EndogenousMtv Sags might have an additional function in the pathogenesis
of an exogenous MMTV. Sag also is the only viral protein that is known to be
expressed by the defectiveMtv6 provirus [78] and, in the absence of Rem coding
potential, the export of the truncatedgag mRNA would be very inefficient in
BALB/Mtv6 mice. Mtv6 also lacks the Penv promoter and, hence, the major
transcript produced fromMtv6 is thesagmRNA from the standard LTR promoter.
This transcript could potentially encode novel proteins by the use of alternate
start codons GUG and CUG. The possibility that these novel protein(s) influence
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exogenous MMTV pathogenicity remains to be exhaustively tested. RT-PCR
analyses of a BALB/c derived cell line (A20) as well as tissue RNA obtained
from BALB/Mtv6 spleen, lymph nodes, and thymus did not detect any novel
mRNAs being expressed from the endogenousMtv6 locus (data not shown). This
observation does not rule out a cell-type specific or infection-triggered expression of
novel mRNAs from endogenousMtvs. TheMtv6 locus was chosen for this analysis
because BALB/Mtv6 mice are susceptible to both MMTV andV. cholerae. The
truncated endogenousMtv6 locus also would facilitate detection of novel mRNAs
due to the absence ofgag, pol, env, andremmRNAs.
4.2.10 Resistance of BALB/Mtv-null mice to V. cholerae
Besides MMTV and TBLV, the BALB/Mtv-null mice show decreased
mortality following infection with V. cholerae. Interestingly, the increased
resistance toV. choleraecorrelates with the absence of endogenousMtvs despite
a vast difference in the pathogenicity and life cycles of MMTV andV. cholerae. A
potential connection between the presence of endogenousMtvs and susceptibility
to V. choleraemight be provided by Sag. The T-cell repertoire of BALB/Mtv-null
mice, generated in the absence of endogenousMtv-encoded Sag, might present an
altered immune response, perhaps involving heightened inflammation or enhanced
humoral immunity, which might play a role in clearing theV. choleraeinfection
more effectively. However, adaptive immune responses would not be significantly
activated during the 48 hr assay for LD50 determination following a primary
bacterial infection.
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The innate immune responses would form the primary defense againstV.
choleraefor the duration of the LD50 assay. An increased inflammatory innate
immune response againstV. choleraein the BALB/Mtv-null mice compared to
the BALB/cJ and BALB/Mtv-SP mice might provide a greater resistance to the
bacterial infection, thus resulting in a higher LD50. The influence of endogenous
Mtvs andMtv-encoded Sags on the mouse innate immune response remains to be
elucidated. However, exogenous MMTVs and MuLVs have been shown to activate
TLR4 [64, 359]. An endogenousMtv-encoded product may enhance CT activity,
thus aggravating the cholera symptoms.
4.2.11 Summary and conclusions
In conclusion, a novel mode of resistance to MMTV- and TBLV-induced
tumorigenesis andV. cholerae-induced mortality in a BALB/cJ congenic mouse
strain (BALB/Mtv-null) lacking endogenousMtvs has been described. Both
resistance traits genetically correlate with the absence of endogenousMtvs in
the BALB/Mtv-null mice and occur during early pathogen interaction with the
immune system. EndogenousMtv-encoded Sag is a primary candidate in mediating
susceptibility to pathogens because Sag is the only protein known to be expressed
from the endogenousMtv6 locus, which provides susceptibility to MMTV andV.
cholerae. Sag might function by modulating the response or interaction of the
mouse immune system towards pathogens, resulting in the manifestation of the
multi-pathogen resistance phenomenon. However, a critical role of a novelMt -
encoded protein in providing pathogen susceptibility cannot be excluded.
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4.2.12 Scope of further studies
Future experiments would address the role of CD8+ cytotoxic T cells in
determining MMTV resistance by infection of BALB/Mtv-null mice on a CD8-null
background. Transgenic mice expressing single MMTV cDNAs would be used
for direct assessment of the contribution of endogenousMtv-encoded proteins in
determining the pathogen resistance of BALB/Mtv-null mice. Comparison of Th1
(IFNγ) versus Th2 (IL10) cytokine profiles of lymphocytes harvested from MMTV-
infected BALB/cJ, BALB/Mtv-null, and BALB/Mtv-SP mice would determine the
relation between endogenousMtvs, the type of immune response and susceptibility
to pathogens. The response of the BALB/Mtv-null mice to purified cholera toxin
also would be compared to the responses of the BALB/cJ and the BALB/Mtv-single
positive mice. Assessment of the susceptibility of BALB/Mtv-null mice to other
pathogens, in particularSalmonella typhimuriumand ectromelia virus, would help
characterize the resistance phenomenon and also determine if this mouse strain is
resistant to a wider spectrum of mouse pathogens.
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Appendix
List of abbreviations used:
ALV avian leukemia virus
APC antigen presenting cell
APE1 apurinic/apyramidinic endonuclease 1
APOBEC apolipoprotein B mRNA editing catalytic subunit
ARM arginine-rich motif




Bright B-cell regulator of IgH transcription
CA capsid
cAMP cyclic adenosine monophosphate
CDP CCAAT displacement protein
CDR1 complementarity determining region 1
CFU colony forming units
CIIPBM class II peptide binding motif
CIS common integration site
CT cholera toxin
CTF CCAAT transcription factor
CTL cytotoxic T lymphocyte




DLS dimer linkage sequence
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DMBA 7,12-dimethylbenz (α)-anthracene






ELISA enzyme-linked immunosorbent assay
Eµ immunoglobulin heavy chain intronic enhancer
Env envelope
ER endoplasmic reticulum
FACS fluorescence-activating cell sorting
Fgf fibroblast growth factor
FITC fluorescein isothiocyanate
FoxA forkhead box A
Fv1,4 Friend virus susceptibility genes







GRF general regulatory factor
HERV-K human endogenous retrovirus-K
HIV human immunodeficiency virus
HMG high mobility group
HRE hormone-responsive element
HRP horseradish peroxidase
HSV herpes simplex virus
HTLV-1 human T-cell leukemia virus-1
HV4 hypervariable region 4





IL2R interleukin 2 receptor
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IN integrase
ISBP initiation site-binding protein
ITAM immunoreceptor tyrosine-based activation motif
LD50 lethal dose 50
LDV lactate dehydrogenase elevating virus
LI liver
LTR long terminal repeat
LUC luciferase
Lv1 lentivirus restriction factor 1
MA matrix
MAb monoclonal antibody
MAF mammary cell activating factor
MAR matrix attachment region
MEM mammary-specific enhancer of MMTV
META MMTV envtranscriptional activator
MG mammary gland
MGE mammary gland enhancer
MGF mammary gland factor
MHC major histocompatibility
Mls mixed-lymphocyte stimulating
MLV murine leukemia virus
M-MLV Moloney murine leukemia virus





NES nuclear export signal
NF1 nuclear factor 1
NLS nuclear localization signal
NO nitric oxide
NRE negative regulatory element
Oct-1/OTF-1 octamer transcription factor
ORF open reading frame
PAGE polyacrylamide gel electrophoresis
PBL peripheral blood lymphocyte
PBS primer binding site










RCS reticulum cell sarcoma
Rec regulator of expression encoded by corf
Ref1 restriction factor 1
Rem regulator of export of MMTV mRNAs
Rev regulator of virion expression
RFLP restriction fragment length polymorphism
RNA ribonucleic acid
RT reverse transcriptase
RT-PCR reverse transcription-polymerase chain reaction
Sag superantigen
SAR scaffold attachment region
SATB1 special AT-rich-sequence binding protein 1
SDS sodium dodecyl sulphate
SG salivary gland
SN spleen
SPSS Statistical Package for Social Sciences
-sssDNA minus-strand strong stop DNA
+sssDNA plus-strand strong stop DNA
STAT5 signal transducer and activator of transcription 5
SU surface envelope protein
TBLV type B leukemogenic virus
TBP TATA-binding protein
TCR T-cell receptor
TEF-1 transcriptional enhancer factor 1
Tfr1 transferrin receptor 1
TGFβ transforming growth factorβ
TK thymidine kinase
TL thymic lymphoma
TLR4 toll-like receptor 4
TM transmembrane envelope protein
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TNFα tumor necrosis factorα
U3 3’ unique region
U5 5’ unique region
WCL whole cell lysate
Wnt wingless-related MMTV integration site
ZAP zinc finger antiviral protein
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